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Tumour-selective, non-cytotoxic chemotherapeutics are much sought after in oncology. 
Two cancer-selective drug types are angiogenesis inhibitors, drugs which halt the 
growth of new blood vessels in tumours, and hypoxia-activated prodrugs, which are 
non-toxic agents that are activated into cytotoxins selectively within tumours. It is 
possible to conceive a dual-action prodrug (a.k.a. codrug) which releases both an 
angiogenesis inhibitor and a cytotoxin selectively within a tumour after bio-reductive 
activation. Specifically, prodrugs designed to release nitrogen mustard cytotoxins along 
with SU5416 from a 2-nitrophenylacetamide precursor were of particular interest.  
A synthesis of the prototype hypoxia-activated anti-tumour codrug (Z)-1 was 
successfully achieved with an overall yield of 12% over 7 steps. A synthetically more 
convenient route through carboxylic acid intermediate (Z)-5 was unsuccessful, as 
ester/amide coupling conditions produced the cyclisation product 5,7-dimethyl-2-(2-
nitrophenyl)-3H-pyrrolizin-3-one 14 in high yield. Instead, it was necessary to optimise 
a step-wise synthesis through N-(4-(bis(O-tert-butyldimethylsilyl-2-
hydoxyethyl)amino)phenyl)-2-(2-nitrophenyl)acetamide 8, then perform a Knoevenagel 
condensation with N-protected pyrrole aldehyde 9 to form (Z)-7. After deprotection and 
chlorination of (Z)-7, prototype codrug (Z)-1 was obtained as an air-stable solid.  
In order to demonstrate that reduction of (Z)-1 spontaneously produced SU5416 as 
necessary for in vivo activity, chemical NO2 reductions were performed. (Z)-1 was 
demonstrated to spontaneously produce SU5416 and the N-hydroxy SU5416 analogue 
2-OH in good yields after reduction. Similar results were observed for the ethyl ester 
(Z)-10 and anilide (Z)-29. These results represented a crucial proof-of-concept for the 




Several side reactions from the synthesis of (Z)-1 were also explored in depth. Indoline-
N-oxides 15 and 16 were the result of attempted amide couplings of 5 and HBTU or 
HATU with N,N-dimethyl-p-phenylenediamine (15) or p-phenylenediamine (16). 
Significant efforts were made to delineate the reaction mechanism. Through NMR 
studies, it was shown that (Z)-5 spontaneously decarboxylated in chloroform to form 
(E)-alkene 18. It was also shown that p-phenylenediamine reacted with HBTU or 
HATU in solution to form 2-(4-aminophenyl)-1,1,3,3-tetramethylguanidine 19. A 
reaction mechanism combining these two transformations to form 15 was proposed, 
supported by mass spectral data. 16 was also shown to spontaneously form indolinone-
N-oxide 17, a novel analogue of a known antimalarial series, which showed IC50 = 381 
nM against the K1 strain of P. falciparum. 
Alkene intermediates synthesised during optimisation of the Knoevenagel condensation 
necessary for (Z)-1 were tested for activity in a rat aortic ring angiogenesis assay. This 
assay showed that small ester derivatives such as (E)-10 and (Z)-10 represented a novel 
class of angiogenesis inhibitors, however all amide analogues tested (such as anilide 
(Z)-29) were inactive. The structurally similar 3H-pyrrolizin-3-one 14 was also shown 
to be a potent angiogenesis inhibitor. A facile one-step synthesis of substituted 2-aryl 
derivatives of 14 was developed, using pyrrole carboxaldehyde 4 and commercially 
available phenylacetic acid derivatives. 18 derivatives were synthesised through this 
reaction and tested for angiogenesis inhibition in a semi-quantitative HUVEC tube 
formation assay. Compound 14 was shown to be the most potent compound, with 
unsubstituted phenyl derivative 51 and o-fluoro derivative 69 also producing significant 
inhibition of HUVEC tube formation. Compounds 14 and 51 were then tested in a rat 
aortic ring angiogenesis assay which confirmed their inhibitive capacity, with 





ADMET Absorption, distribution, metabolism, excretion, toxicity 
ANU  Australian National University 
AR  Androgen receptor 
ATP  Adenosine triphosphate 
CML  Chronic myelogenous leukaemia 
DCC  N,N’-Dicyclohexylcarbodiimide 
DIPEA Diisopropylethylamine 
DMAP  4-Dimethylaminopyridine 
DMF  Dimethylformamide 
DMPD  N,N-dimethyl-p-phenylenediamine 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
EDCI  1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EGF(R) Epidermal growth factor (receptor) 
Et  Ethyl 
ESI-MS Electrospray ionisation mass spectrometry 
FDA  U.S. Food and Drug Administraiton 
F.O.V.  Field of view 
(FT)IR  (Fourier transform) Infrared spectroscopy 
5-FU  5-fluorouracil 
FVP  Flash vacuum pyrolysis 





HBTU  2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate 
HER2  Human epidermal growth factor receptor 2 
HIF-1  Hypoxia-inducible factor-1 
hLM  Human liver microsomes 
HOAt  1-Hydroxy-7-azabenzotriazole 
HOBt  N-Hydroxybenzotriazole 
HRMS  High resolution mass spectrometry 
HUVEC Human umbilical vein endothelial cells 
hTERT Human telomerase reverse transcriptase 
KHMDS Potassium hexamethyldisilazide 
LDA  Lithium diisopropylamide 
mAb  Monoclonal antibody 
MAPK  Mitogen-activated protein kinase 
Me  Methyl 
mLM  Mouse liver microsomes 
MMP  Matrix metalloproteinase 
MMAE Monomethyl auristatin-E 
mRNA  Messenger RNA 
Ms  Mesyl 
mTOR  Mammalian target of rapamycin 
NADPH Nicotinamide adenine dinucleotide phosphate 
NMR  Nuclear magnetic resonance 
PDGF(R) Platelet-derived growth factor (receptor) 




Ph  Phenyl 
PI3K  Phosphoinositide 3-kinase 
PPD  p-phenylenediamine 
RBC  Red blood cell 
RNA  Ribonucleic acid 
RTK(i) Receptor tyrosine kinase (inhibitor) 
SAR  Structure-activity relationship 
siRNA  Small interfering RNA 
TAV  Tumour-associated vasculature 
TBAF  Tetrabutylammonium fluoride 
TBDMS Tert-butyl dimethylsilyl 
t
Bu  Tert-butyl 
TEA  Triethylamine 
TGF-β  Transforming growth factor-β 
THF  Tetrahydrofuran 
TLC  Thin layer chromatography 
TMS  Trimethylsilyl 
TMU  Tetramethylurea 
TNF  Tumour necrosis factor 
uPA  Urokinase plasminogen activator 
UV-Vis Ultraviolet-Visible light spectroscopy 
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1.1 Cancer Statistics 
Cancer is a highly complex group of diseases characterised by uncontrolled 
proliferation of cells. In 2011, cancer accounted for about 3 in every 10 deaths in 
Australia, with lung and gastrointestinal tumours the leading contributors.
1,2
 Cancer is 
also responsible for the greatest health-care economic burden in Australia, costing 
upwards of $3.8 billion per year (7.2% of all direct health expenditure).
1
 Domestic 
research efforts in cancer attract $358 million in funding annually, representing 22% of 
the health and medical research budget.
1
 Improvements in early detection, diagnosis and 
treatment have drastically improved prognoses for cancer patients over the years.
3
 In 
Australia, 5-year survival rates have improved over 25 years from 45.1% to 66.1%.
1,2
 
The mortality-to-incidence ratio for all cancer types in Australia has declined at a 













1.2 Molecular Mechanisms of Cancer 
Cell division is an intricately controlled process where an array of positive and negative 
feedback mechanisms finely balance DNA replication, mitosis and apoptosis 
(programmed cell death) to maintain healthy tissues. This balance is managed by layers 
of signalling pathways that modulate a plethora of cellular processes involved in tissue 
homeostasis.
4,5
 Cancer occurs when a population of cells is no longer subject to the 
entirety of these control processes and cell proliferation proceeds to the detriment of the 
host organism. The simplistic historical notion that cancer is a disease of proliferation 
has been replaced in recent times by an evolutionary model.
5
 According to this model, 
cancer occurs when a population of cells accumulates a variety of mutations that gives 
them a survival advantage over neighbouring healthy cells.
5
 While cancer actually 
represents a myriad of different diseases, a number of commonalities are observed 
amongst most malignant tumours.
5
 These include: 
 an ability to signal their own growth and bypass anti-growth signals. 
 insensitivity to apoptotic messages. 
 an ability to overcome internal cell division limits.  
 consistent promotion of angiogenesis (growth of new blood vessels). 
 superior invasive and metastatic capabilities 
With some or all of these characteristics, a population of mutated cells (the cancer) is 
able to grow unchecked, extravasate into the bloodstream and metastasise to distant 






1.3 Traditional Cancer Treatment Protocols 
Surgical resection and radiation therapy remain the primary methods of treatment for 
solid tumours as they allow direct, targeted action on cancerous tissues. Modern cancer 
treatments combine these with chemotherapy in order to improve outcomes and increase 
the likelihood of remission.
6
  
There are many methods of applying chemotherapy in modern cancer treatments. For 
instance, drugs are often used as ‘adjuvant’ therapy to kill circulating cancerous or pre-
cancerous cells remaining after surgery and/or radiation.
7–9
 Conversely, ‘neoadjuvant’ 
therapy uses chemotherapy before other treatments in order to reduce the tumour mass 
and consequently the extent, complexity and risks of surgery, or the effects of 
radiotherapy on surrounding tissues.
10,11
 Anti-cancer drugs can also be used as palliative 
agents (i.e. to reduce pain and improve quality of life) in terminal patients.
12–15
 
Non-solid cancers are treated primarily with chemotherapy. Treatment of leukaemia 
(cancer of leukocytes or white blood cells), for instance, is typically layered into 
multiple chemotherapy protocols. The first aims to kill cancerous cells such that they 
are undetectable in a patient’s blood. This is known as ‘remission induction’ and 
involves aggressive treatment with combinations of cytotoxins.
15–18
 A second regimen, 
termed ‘consolidation’, is then cycled for months or even years to reduce the risk of 
relapse.
16,19,20
 These protocols can also be combined with radiation and bone marrow 
transplants depending on the nature and severity of a patient’s disease. Chemotherapy is 
also a primary treatment for many lymphomas (cancers derived from lymphocytes).
21
  
The availability of biochemical and genetic methods for analysis of cancers has allowed 
the molecular mechanisms behind many cancer sub-types to be determined. This has 




target the mechanism(s) identified, reducing the need for cytotoxic agents. These 
modern drugs tend to be less harmful to patients.
22
 Indeed, most FDA-approved 
chemotherapeutics these days tend to be targeted agents, which are often fast-tracked 
for approval.
23
 Aggressive combination chemotherapy treatments continue to be used, 





1.4 Types of chemotherapeutics 
Traditional cytotoxic chemotherapeutics target DNA replication and cell division under 
the premise that cancer cells are selectively killed over healthy cells due to their higher 
proliferation rates. Classes of cytotoxic agents include the DNA alkylators, DNA 
intercalators, anti-metabolites and tubulin-binders. Chemotherapy treatments have 




DNA-alkylators, such as melphalan, chlorambucil and carmustine (Figure 1.2(a)), 
function by alkylating DNA (usually via the nucleophilic guanine N7) and cross-linking 
strands (Figure 1.2(b)).
27,28
 These lesions can disrupt DNA replication directly by 
causing strand-breakages and preventing the binding of proteins, or indirectly by 
promoting apoptosis through formation of unnatural DNA complexes.
28
 Cisplatin and 
the related carboplatin are traditional DNA alkylators that continue to be used due to 
their effectiveness in treating testicular cancer. Use of these agents has seen 5-year 
survival rates in Australia increase to nearly 98%.
1
 In contrast, chlorambucil and 













Figure 1.2. (a) Structures of FDA-approved DNA-alkylators. (b) Mechanism of DNA 
alkylation by nitrogen mustards. 
 
Anti-metabolites like 5-fluorouracil (5-FU), cytarabine, gemcitabine and methotrexate 
(Figure 1.3) compete with endogenous metabolites during genetic replication cycles. 
These agents are close structural analogues of nucleosides or vitamins, where small 
changes have been introduced to ablate their function whilst maintaining their binding 
to endogenous targets. 5-Fluorouracil is an unnatural analogue of uracil, a nucleobase 
found in RNA and used in the synthesis of thymine for incorporation into DNA. 
Metabolites of 5-FU are misincorporated into RNA resulting in a general loss of cellular 
protein function.
31
 5-Fluorouracil is also a ‘suicide inhibitor’ of thymidylate 
synthase.
31,32
 The drug is a mainstay of many treatment protocols for head and neck 
cancers, lymphomas, skin cancers and gastrointestinal tumours.
33




nucleoside mimic that contains a modified arabinose sugar (a stereoisomer of 
deoxyribose) conjugated to cytosine. It is misincorporated into DNA and causes cell 
cycle seizure and DNA polymerase inhibition.
34,35
  
Methotrexate functions by blocking the activity of dihydrofolate reductase, thus 
inhibiting production of folic acid (vitamin B9), which is required for DNA and RNA 
synthesis.
36
 Methotrexate is used in a wide variety of indications, including lung and 
breast cancers and advanced non-Hodgkin’s lymphoma.
17
 A more recent anti-
metabolite, gemcitabine, has become an important addition to chemotherapy. This drug 
is an analogue of deoxycytidine, where the 2’-position of the deoxyribose has been 
difluorinated. The compound is misincorporated into DNA and causes apoptosis, 
although like many anti-metabolites, other targets are affected, e.g. ribonucleotide 
reductase. 
37–40
 Unlike other anti-metabolites, however, gemcitabine is effective against 
solid tumours and is used as a first-line treatment for pancreatic adenocarcinoma. It is 
also used in combination with other agents for advanced or metastatic non-small cell 




Figure 1.3. Structures of FDA-approved anti-metabolites. 
 
DNA intercalators are planar, aromatic compounds that insert into double-stranded 
DNA, distorting the tertiary structure and promoting apoptosis (Figure 1.4).
44
 These 
distorted complexes are stabilised by polar interactions with the phosphate backbone.
44
 




to their toxicity and mutagenicity, doxorubicin continues to be used as a frontline 
treatment for many cancer types.
45
  




Figure 1.4. Insertion of DNA-intercalators like doxorubicin into double-stranded DNA 
(i.e. intercalation) distorts DNA tertiary structure.
44,46
 (a) Normal double-helical and (b) 
distorted DNA structure with intercalated doxorubicin. 
 
Paclitaxel and vinblastine are examples of anti-mitotic agents, which target cell division 
rather than DNA replication.
47
 Specifically, anti-mitotic agents impair the function of 
tubulin, a key protein constituent of the microtubules required for physical budding and 
division of cells.
47,48
 Paclitaxel binding to microtubules leads to their structural 
stabilisation, preventing disassembly and separation. Vinca alkaloids like vinblastine, 
on the other hand, inhibit tubulin polymerisation (Figure 1.5).
49,50
 Paclitaxel was the 
first ‘blockbuster’ oncology drug and continues to be used in ovarian, breast and non-
small cell lung cancers, along with several other indications.
51
 Vinca alkaloids continue 
to be widely used for childhood and adult acute lymphocytic leukemias, Hodgkin and 











Figure 1.5. (a) Anti-mitotic agents vinblastine and paclitaxel inhibit cell division by 
targeting tubulin. (b) Structures of vinblastine and paclitaxel. 
 
Drugs targeting DNA-replication and cell-division can affect healthy cells leading to 
unpleasant side effects. Rapidly dividing cells tend to be the worst affected, including 
hair follicles (leading to alopecia), blood and immune cells (anaemia, fatigue and 
immunosuppression) and gastrointestinal cells (nausea, vomiting and diarrhoea).
28,44,53,54
 
Other side effects commonly experienced with cytotoxins are neutropenia and skin 
rashes. While the side effects can be somewhat mitigated with other drugs, toxicity to 
organs (particularly the kidneys and liver) is dose-limiting and often severe. It is well 




In the past two decades there has been a push to develop more selective agents that 
target the underlying molecular mechanisms of uncontrolled proliferation in cancer 
rather than directly targeting replication and cell division. 
 
1.5 Targets for Non-Cytotoxic Chemotherapy 
1.5.1 Apoptosis 
Millions of mutations occur daily in healthy human DNA due to the sheer volume of 
replication and mutation rates are increased by various risk factors. Nucleotides can be 
added, removed or mis-matched during DNA polymerisation, while mutagenic 
chemicals, UV or ionising radiation and oxidative stress can contribute to base 
modification, bonding between bases, cross-linkage or other DNA lesions.
55,56
  
Several protective mechanisms exist in cells to detect mutations, repair the damage, 
control cells that contain the mutations and signal apoptosis, where necessary. Genes 
that code proteins involved in these processes are called tumour-suppressor genes. One 
key example is p53. The p53 protein is a nuclear transcription factor that responds to 
DNA damage by influencing cell cycle regulation, DNA repair, apoptosis and cell 
homeostasis.
57
 Mutations or deletions in p53 are found in over 50% of all human 
tumours.
58
 Unfortunately, the complexity of p53’s actions and its function as a nuclear 
transcription factor make it a difficult drug target.
59,60
 Efforts to replace dysfunctional 
p53 in tumour cells using gene therapy techniques have shown considerable promise 
and there is now an approved adenovirus vector in China (Gendicine).
61
 Advexin is a 








1.5.2 Internal Cell Division Limits 
 All chromosomes are terminated by telomeres; endcaps of repeating DNA sequences 
that serve to protect the DNA. Telomeres contain a guanine-rich overhang that promotes 
formation of a protein complex called shelterin. This complex prevents inappropriate 
cellular processing and chromosomal fusion.
63,64
 During DNA replication, a portion of 
genetic material is lost from the telomere and, as this process repeats, the telomeres 
continue to shorten, eventually affecting genetic coding sequences.
65
 Without telomeres, 
chromosomal fusion can also occur leading to apoptosis.
65
 Telomere shortening limits 
the number of times a diploid cell can divide (the ‘Hayflick limit’), which suppresses 
cell line immortalisation and excessive proliferation.
66
 The ribonucleoprotein reverse 
transcriptase enzyme telomerase (transcribed from the hTERT gene) functions to 
maintain the protective endcaps in immortal stem cells.
65
 Telomerase activation is 
central to the survival and proliferation of cancer cells. Over 90% of cancers express 




Telomerase is currently being explored as a new drug target for cancer.
69
 Drugs in 
clinical development include inhibitors of its reverse transcriptase activity,
70,71
 small 








An increase in invasiveness and motility is typically observed during later stages of 
tumour maturation.
5
 To grow and eventually metastasise, a tumour needs to be able to 




into a distant tissue.
75
 Tumours can use a number of different chemical and enzymatic 
processes to achieve this. One hallmark of advanced tumours is that they switch from 
oxidative phosphorylation for energy production to glycolysis, even when the supply of 
oxygen is not limited (known as the Warburg effect – Figure 1.6).
76
 This process 
consumes high levels of glucose and produces increased lactic acid, which is expelled 
into the extracellular matrix.
77,78
 The associated decrease in pH can promote 
extracellular protease activity and matrix degradation.
79
  Lactate production and 




Figure 1.6. The ‘Warburg effect’ in tumour cells. Oxidative glycolysis is promoted in 
tumour cells even with a normal oxygen supply, increasing production (and efflux) of 





Tumours can also directly promote pro-metastatic enzymatic activity. For example, the 
broad spectrum serine protease plasmin, which is important in tissue breakdown and 
clotting, has been shown to be upregulated in metastatic tumours.
81




upregulated proteolytic enzymes include matrix metalloproteinases, cathepsins and the 
urokinase plasminogen activator (uPa), which are all involved in various stages of 
detachment and motility pathways.
81–84
 Inhibitors of MMPs have generally been 
disappointing in clinical trials, a feature attributed to the complexity and redundancy of 
extracellular proteolytic signalling.
85
 The uPA system has shown promise as an anti-





1.5.4 Growth Signalling 
Cell proliferation and differentiation in healthy tissues is promoted by cytokines, growth 
factors and hormones. These signalling molecules affect cells by modulating 
intracellular reaction cascades. Growth factors promote growth and differentiation and 
their activity is controlled by endogenous inhibitors and transcription factors. Cancer 
cells can co-opt growth factor signalling through direct or upstream mutations, leading 
to constitutive expression and uncontrolled growth.
88
 In recent times, targeted cancer 
drugs have focused sharply on intercepting growth factors and hormones that activate 
receptor tyrosine kinases (RTKs). These enzymes catalyse the transfer of phosphate 
groups from ATP to downstream proteins, affecting cell growth, proliferation and cell 
survival in response to extracellular signals.
89
 
The epidermal growth factor (EGF) family of receptors plays a role in the normal 
growth and development of various tissues
90
 and it has been estimated that 50-70% of 
lung, colon and breast carcinomas (the most common solid tumours) overexpress EGF 
receptors (e.g. EGFR or ErbB-3).
90
 Several RTK inhibitors that block EGFR function 
have been developed as anti-cancer drugs.
22









Figure 1.7. Inhibition of EGFR signalling pathways with small molecule RTK 
inhibitors and mAbs. EGF = epidermal growth factor, EGFR = epidermal growth factor 
receptor, RTKi = receptor tyrosine kinase inhibitor, mAb = monoclonal antibody. 
 
Another tumour-promoting growth factor is transforming growth factor-β (TGF-β). 
TGF-β regulates proliferation and differentiation of cells, embryonic development, 
wound healing and angiogenesis by acting on epithelial, endothelial and haematopoietic 
cells.
92
 Cell motility and invasiveness is enhanced by TGF-β.
92
 Mutations causing 
resistance to TGF-β are observed in over 85% of epithelium-derived human cancers.
93
 
In these cases, TGF-β primes the surrounding matrix and promotes invasiveness of 
TGF-β insensitive cancer cells.
93







While growth factors control the progression of most cancers, some tissues are 
susceptible to highly aggressive tumours because of tissue-specific hormones. Blocking 
these hormones can greatly improve efficacy of treatments for sub-types of gonadial, 
prostate and breast cancers. Trastuzumab (Herceptin) is a monoclonal antibody used in 
breast cancer that targets HER2, an EGF RTK that promotes cell proliferation.
91,95
 
Lapatinib is a small-molecule dual HER2/EGFR inhibitor that is used to treat “triple 
positive” breast cancers.
96
 Tamoxifen is a particularly effective small molecule 
oestrogen receptor antagonist that is used as an adjuvant to surgery when treating 
oestrogen-dependent breast cancers.
11,97
 Early and late-stage prostate cancers are often 
treated with bicalutamide (Casodex), which antagonises the nuclear androgen receptor 
(AR).
98
 Figure 1.8 shows the structures for these hormone receptor-targeting agents.  
 
Figure 1.8. Examples of hormone receptor-targeting anti-cancer drugs. 
 
1.5.5 Angiogenesis  
Angiogenesis is the growth of new blood vessels from pre-existing vasculature. It is a 
complex process and is carefully regulated in healthy tissues by families of growth 
factors and their corresponding nuclear, cytosolic and membrane-bound receptors.
99–101
 
As localised tumours grow, sections of the tumour become hypoxic (i.e. low oxygen 
concentration) because of the increased distance of cells from blood vessels due to the 
aberrant vasculature and their increased metabolic needs (Figure 1.9).
102
 Hypoxia is 




production of reactive oxygen species) and is considered a marker of poor prognosis.
103–
105
 Tumours respond to hypoxia by entering latent phases, modifying their metabolism 




Figure 1.9. Hypoxic and necrotic cells arise in solid tumours due to their increased 




A major pro-angiogenic response to hypoxia is initiated by hypoxia-inducible factor-1 
(HIF-1). HIF-1 is a nuclear signalling protein that binds to hypoxia responsive elements 
on DNA in response to hypoxia, increasing transcription of proteins that restore normal 
oxygen supply.
107,109
 HIF-1 is a heterodimeric protein consisting of two subunits; 
oxygen-sensitive HIF-1α and constitutively expressed HIF-1β.
110
 When oxygen is 
present, cytosolic HIF-1α is hydroxylated and ubiquitinated by the von Hippel-Lindau 
tumour suppressor protein and targeted to the proteasome for removal.
111
 When a cell 
becomes hypoxic, the hydroxylation process is slowed and dimerisation of HIF-1αβ 
occurs, resulting in signal activation.
112
 
HIF-1 is often overexpressed in human cancers and its expression is correlated with 
poor prognosis.
103,104,113,114






 For example, some drugs bind to targets in the phosphatidylinositol 3-
kinase (PI3K), mammalian target of rapamycin (mTOR) and extracellular-signal-related 
mitogen-activated protein kinase (MAPK) pathways, reducing the transcription of HIF-
1α mRNA.
116–119
 Several drugs that inhibit mTOR have been approved, including the 
rapamycin derivative Temsirolimus (Figure 1.10), which is used for renal cell 




Figure 1.10. Temsirolimus targets mTOR to reduce transcription of HIF-1α. 
 
Important downstream pro-angiogenic signalling proteins include platelet-derived 
growth factors (PDGFs), vascular endothelial growth factors (VEGFs) and epidermal 
growth factors (EGFs).
122,123
 These RTKs activate a wide variety of downstream targets 
that promote angiogenesis, cell motility, differentiation, matrix degradation and 
survival.
91,124
 Transcription of these proteins is often upregulated in cancers and their 
function is poorly controlled, leading to formation of a disorganised, highly permeable 
vasculature (tumour-associated vasculature, TAV).
99,100,107,124-126
 
Two main strategies have been developed to target these processes: (1) sequestration of 
the signalling proteins using mAbs and (2) inhibition of RTKs using small molecules 
(Figure 1.11).
123,126,127
 Bevacizumab (Avastin®) is a monoclonal antibody that binds to 




cancer in 2004 and was the first FDA-approved angiogenesis inhibitor.
128
 It has since 
been approved for a variety of advanced lung, renal, ovarian and brain tumours.
128
 
Imatinib (Gleevec®, Figure 1.12) is a small molecule RTK inhibitor that shows high 
specificity for the bcr-abl RTK (also known as the “Philadelphia chromosome” or Ph+), 
a constitutively “on” mutant RTK found in 95% of chronic myelogenous leukaemia 
(CML) patients.
129
 It has since been approved for gastrointestinal stromal tumours and 
several mutant kinase-related leukaemias.
130
 A related analogue dasatinib (Sprycel®) is 
approved as a first line treatment for CML and Ph+ acute lymphoblastic leukaemia.
131
  
Sunitinib (Sutent®) is an FDA-approved angiogenesis inhibitor that was originally 
indicated for use in imatinib-resistant gastrointestinal stromal tumours.
132
 The 
compound is a multi-target RTK inhibitor that binds to several related PDGF family 
receptors.
133
 Sunitinib was developed in favour of its predecessor semaxinib (SU5416), 
a VEGFR-2 selective RTK inhibitor that reached Phase II clinical trials.
134
 Sunitinib 
shows a broader inhibition profile across RTKs than SU5416, which is attributed to the 
F-substituent at the 5-position of the oxindole moiety. A hydrophilic N,N-
diethylethylenediamine carboxamide moiety at the 3-position of the pyrrole improved 
the compound’s ADMET properties. Sunitinib later received approval as a first-line 
therapy in advanced renal cell carcinoma and against metastatic or unresectable 
pancreatic neuroendocrine tumours.
135
 Both sunitinib and semaxinib are compounds of 





Figure 1.11. Inhibition of angiogenesis and tumour growth by VEGF-A-targeting mAbs 
and small molecule RTK inhibitors. 
 
Other angiogenesis inhibitors approved for use in cancer include sorafenib (Nexavar®) 
and erlotinib (Tarceva®), which show similar RTK selectivity profiles to sunitinib. 
Another drug pazopanib (Votrient®) targets EGFR selectively (Figure 1.12).
127
 These 
targeted RTK inhibitors are often used in combination with traditional cytotoxic drugs 
as they show mostly cytostatic action.
136
 Compared to traditional cytotoxins, however 
angiogenesis inhibitors tend to be well-tolerated, although it is clear that they are not the 







Figure 1.12. Small molecule RTK angiogenesis inhibitors approved for use in cancer 
treatment. Semaxinib and Sutent (sunitinib) are compounds relevant to the PhD project 
(red).  
 
1.6 Anti-Cancer Prodrugs 
1.6.1 Prodrugs - General 
Prodrugs are biologically inert or only weakly active compounds that are modified to 
active forms by metabolic reactions in vivo. Prodrug forms have been investigated for 
many cytotoxic agents as a means of improving their efficacy and safety profiles.
138,139
 
Masking the cytotoxic moieties can improve bioavailability, reduce systemic toxicity 
and modulate first-pass metabolism and plasma half-life. Prodrugs of anti-cancer agents 
often aim to reduce the gastrointestinal toxicity of their active components and improve 
selectivity for tumours over healthy tissues.
139,140
 
Examples of approved anti-cancer prodrugs are capecitabine and tegafur; both prodrugs 
of 5-fluorouracil (5-FU).
138
 Capecitabine is a hydrophobic carbamate derivative of 5-






 Tegafur is a tetrahydrofuran-linked aminal derivative of 5-fluorouracil used 
primarily in the treatment of gastric and colorectal cancers.
142
 Capecitabine and tegafur 
are enzymatically converted in vivo to 5-fluorouridine, the activate metabolite of 5-FU 
(Figure 1.13). The prodrugs reduce gastrointestinal toxicity and show improved oral 
bioavailability over the parent 5-FU.
138,141,142
 Cyclophosphamide is an inert prodrug 
activated by a mixed function microsomal oxidase system in the liver to produce 
multiple active forms, many of which are DNA-alkylators.
143
 It is used to treat several 







Figure 1.13. (a) Capecitabine and tegafur are FDA-approved prodrug forms of 5-FU 
that generate the active metabolite 5-fluorouridine in vivo. (b) Mechanism of activation 







1.6.2 Tumour-Targeted Prodrugs 
Tumour-targeted prodrugs are designed to make use of a variety of activation processes 
unique to or introduced into cancers. These prodrugs reduce the side effects of highly 
toxic agents by localised activation in the immediate tumour environment.
145,146
 Two 
major classes of tumour-targeted prodrugs are antibody-drug conjugates and hypoxia-
activated prodrugs. 
 
1.6.2.1 Antibody-Drug Conjugates 
Antibody-drug conjugates are biologics that use selective recognition of tumour-
associated antigens and receptors to deliver an extremely potent cytotoxin selectively to 
tumours.
147,148
 This approach uses the exquisite selectivity of monoclonal antibodies 
(mAbs) to provide highly specific cancer cell killing. The mAbs are typically linked via 
a plasma-stable, enzyme-cleavable tether and chemical spacer to the cytotoxin. The 
conjugates are localised to tumours through antigen recognition and, following 
internalisation, are cleaved by intracellular enzymes, e.g. cathepsins (Figure 1.14).
149
 
Fewer than 10 cytotoxin molecules are usually linked to the mAbs to maintain avidity, 
thus necessitating the use of extremely potent toxins.
148–150
  
Two FDA-approved examples are brentuximab-vedotin (Adcetris®) and trastuzumab-
emtansine (Kadcyla®).
151
  Brentuximab targets CD30, a membrane protein associated 
with tumour necrosis factor (TNF) signal transduction that is expressed on active T- and 
B-cells in malignant lymphomas.
152,153
 The vedotin portion of the conjugate is 
comprised of the potent cytotoxin monomethyl auristatin E (MMAE), a p-aminobenzoic 
acid spacer and a cathepsin-cleavable citrulline-valine linker.
151
 MMAE is a tubulin 






vedotin was approved in 2011 for use in relapsed or refractory Hodgkin’s lymphoma 
and systemic anaplastic large cell lymphomas.
155
  
Trastuzumab-emtansine combines trastuzumab’s avidity for HER2 with mertansine, a 
maytansine alkaloid that inhibits microtubule assembly at subnanomolar 
concentrations.
150,156
 These two agents are linked with a succinimidyl-trans-4-
(maleimidylmethyl)cyclohexane-1-carboxylate moiety. Trastuzumab-emtansine was 
approved in 2013 for use in HER2+ breast cancers that have progressed following 
standard treatments.
157
 Many other antibody-drug conjugates are likely to enter the 




Figure 1.14. Cell killing mechanism of tumour-targeted antibody-drug conjugates. 
 
1.6.2.2 Hypoxia-Activated Prodrugs 
Another approach for targeting prodrugs to tumours is to invoke hypoxia-activation. As 




triggers angiogenesis and other cellular mechanisms to restore oxygen levels.
107,158–161
 
In comparison, virtually all solid tumours over 1 mm
3
 contain regions that are at least 
transiently hypoxic.
102,103,162–164
 Many tumours remain viable in spite of hypoxia due to 




The low concentration of oxygen and low pH in hypoxic tumour microenvironments 
can promote tumour-selective reduction reactions.
115
 Several oxidative enzymes exist 
ubiquitously across tissues and are responsible for many aspects of catabolism, 
recycling of important species (e.g. nucleobases) and energy generation. Examples 
include xanthine oxidases, NADPH-cytochrome reductases, lipoxygenases, DT-
diaphorase and cytochrome P450. Each of these enzymes catalyse redox reactions that 
use water and O2 to oxidise organic substrates.
165–167
 This process results in reduced 
oxygen products, including peroxide and other reactive oxygen species like superoxide, 
which can be further scavenged by enzymes such as superoxide dismutase and catalase 
to prevent damage to the cell.
168
  
In hypoxic and anoxic tumour cells, oxygen is not present in sufficient quantities to 
counter the reduction reactions, meaning that when reduced species are formed they are 
susceptible to further reduction reactions. This tumour-specific feature can be exploited 
with prodrugs that are activated to produce cytotoxins only after multiple-electron 
reduction reactions.
108,169
 Under normoxic conditions in healthy tissues, the initial 
reduction products are reversibly reoxidised by systems coupled to molecular oxygen. 
In hypoxic and anoxic cells in solid tumours, where molecular oxygen supply is limited, 
the initial reduction products are not back-oxidised and can undergo further reduction 




hypoxic tissues, unmasking of the active cytotoxin is localised to the immediate tumour 
vicinity, minimising its detrimental effects on normal tissues. 
A number of requirements need to be met for a hypoxia-activated prodrug to be 
functional. Firstly, it should be inert in plasma and not be activated by hepatic 
cytochrome P450s as this can lead to unacceptable liver toxicity. It should accumulate 
in hypoxic tumours and undergo selective activation, with the active species then 









The most studied class of hypoxia-activated prodrugs are the nitroaromatics.
169
 These 
compounds use reduction of an aryl nitro group to an aryl hydroxylamine or amine 
moiety to trigger activation of a cytotoxin.
108
 For example, cytotoxins such as nitrogen 
or phosphoramide mustards can be conjugated to nitro aromatic moieties to reduce their 
intrinsic reactivity towards DNA.
170,171
 The strongly electron withdrawing nitro group 
reduces electron density and consequently nucleophilicity of the reactive functional 
group in the prodrug. When hydroxylamine or amine groups are revealed following 
bioreduction, these nucleophilic and/or electron donating groups trigger spontaneous 
reactions that lead to formation of a cytotoxin.  
The first hypoxia-selective prodrug developed for use in cancer was misonidazole 






Misonidazole was observed to accumulate in cancer cells after hypoxia-selective 
reduction, producing species that bind cellular nucleophiles at the 4- or 5-positions of 
the imidazole ring (Figure 1.16).
173
 The compound was originally conceived as a 
radiosensitiser that could confer radiation sensitivity to hypoxic tumours.
174,175
 
Unfortunately, clinical evaluation of misonidazole in cancer did not show sufficient 
efficacy. Nevertheless, 
18
F-labelled misonidazole has proven to be an effective PET 
agent for imaging hypoxia in tumours.
165
  
TH-302 (evofosfamide) is a related prodrug that uses the nitro-imidazole scaffold as a 
hypoxia-selective trigger for release of a bromoisophosphoramide alkylating mustard 
(Figure 1.16).
167,171
 It is currently being investigated in Phase III trials in combination 
with doxorubicin for use in soft-tissue sarcomas. A separate Phase III trial is 








Figure 1.16. Hypoxia-selective activation mechanism of the nitroaromatic prodrugs (a) 
Misonidazole, and (b) TH-302 (evofosfamide). 
 
In 1994, Denny et al. described nitroaromatic prodrug chemistry for hypoxia-selective 






electron-withdrawing amide bond para to a phenylenediamine mustard nitrogen served 
to reduce its nucleophilic character, preventing aziridinium ion formation and 
subsequent DNA alkylation. Upon reduction to the hydroxylamine or aniline, a 
spontaneous 5-membered intramolecular cyclisation occurred to release the active 
phenylenediamine nitrogen mustard (Figure 1.17). A molecule of oxindole (or N-
hydroxyoxindole) was released from the prodrug as a waste fragment. 
 
Figure 1.17. Hypoxia-activated 2-nitrophenylacetate-based prodrug chemistry 




Similar chemistry was later deployed with the angiogenesis inhibitor SU5416 (Figure 
1.18), where the 2-nitrophenylacetate group was appended to the oxindole nitrogen of 




Figure 1.18. Hypoxia-triggered activation of a 2-nitrophenylacetate prodrug derivative 







1.7 Mutual Prodrugs (Codrugs) 
 1.7.1 General 
Mutual prodrugs (or codrugs) are compounds that combine two active agents into a 
single prodrug molecule. A number of codrugs are currently in development, as 
reviewed by Das et al.
178
 Examples are being assessed for use in alcohol and tobacco 
withdrawal, ocular disorders, neurodegenerative disorders, HIV therapy, cardiovascular 
disease and as anti-cancer and antibacterial agents.
178
 
Benorylate (Figure 1.19) is an FDA-approved codrug that combines paracetamol and 
aspirin via an ester linkage to produce a single, orally active dual-action analgesic.
179
 
Sulfasalazine is a codrug of the anti-inflammatory agent 5-aminosalicylic acid and the 
sulfa antibacterial sulfapyridine, which is used to treat rheumatoid arthritis and the 
inflammatory bowel disorder Crohn’s disease.
180,181
 The codrug links the two agents via 
an azo bond. Sultamicillin is an antibiotic codrug that links the two antibacterials 
ampicillin and sulbactam via an acetal-type linkage. The codrug form shows excellent 










1.7.2 Rational Design of a Hypoxia-Activated Anti-Tumour Codrug 
Inspired by the 2-nitrophenylacetate prodrug chemistry described earlier, we conceived 
a codrug structure 1, containing the components of angiogenesis inhibitor SU5416 and a 
phenylenediamine-based nitrogen mustard (Figure 1.20). In this codrug, the benzylic 
position of the 2-nitrophenylacetate triggering moiety is substituted by the alkenyl 
pyrrole portion of SU5416. Attachment of the phenylenediamine mustard via an amide 
bond should lower the nucleophilic character of the mustard nitrogen, thus preventing 
aziridinium ion formation and non-selective DNA alkylation. The phenylenediamine 
mustard proportion should also provide steric bulk that prevents angiogenesis inhibition 
by the SU5416-like portion (i.e. prevents binding to RTK targets). Hypoxia-selective 
bioreduction of the aryl nitro moiety to the aniline derivative should trigger a 
spontaneous 5-membered cyclisation that simultaneously releases the angiogenesis 
inhibitor SU5416 2 (as opposed to an oxindole “waste” fragment, see Figure 1.20) and 
the phenylenediamine mustard. No longer deactivated by the amide bond, the p-amino 
group of the mustard would feed electron density onto the mustard nitrogen to increase 
its nucleophilicity and promote aziridinium ion formation and DNA alkylation. 
 
Figure 1.20. Putative hypoxia-selective activation mechanism of SU5416-




The advantages of such an agent as an anticancer therapeutic are potentially striking. 
Due to tumour-selective activation of the codrug, the gastrointestinal and other 
toxicities of both the cytotoxin and angiogenesis inhibitor components could be 
mitigated, allowing for higher and more efficacious dosages, imitating combination 
therapy but without the associated side effects. 
 
1.8 Thesis Aims 
The central aim of the PhD thesis was to develop and optimise a synthetic route towards 
codrug 1 and demonstrate chemical proof-of-concept showing that chemical reduction 
of the NO2 group leads to formation of SU5416 and release of the cytotoxin. As detailed 
in the following chapters, these aims were achieved and in the process several novel 
































2.1 Retrosynthetic Analysis 
The concept of a self-immolative codrug like 1 raised a number of questions about its 
chemical properties and synthesis. The compound is intended to be stable under 
physiological conditions and to become reactive in vivo after triggering. Several issues 
were envisioned around when and how to introduce the reactive phenylenediamine 
mustard during the synthesis. As outlined in Chapter 1.4, mustards function via 
intramolecular nucleophilic activation to form aziridinium ions, which alkylate DNA. 
Preventing aziridinium formation was considered essential for the stability and 
functioning of the prodrug and for personal safety during the synthesis. The presence of 
an amide group para to the mustard nitrogen was expected to suppress activation by 
reducing its nucleophilicity through electron withdrawal.
170
 
Two synthetic routes were conceived towards 1 (Figure 2.1). The first (Route 1) 
involved an early stage Knoevenagel condensation between ethyl-2-(2-nitrophenyl) 
acetate 3 and pyrrole-2-carboxaldehyde 4 (or a protected derivative). Related 
condensation chemistry is used in the synthesis of SU5416 and sunitinib from 
oxindoles.
183,184
 Ester hydrolysis would yield the key acid intermediate (Z)-5, which 
could be coupled to a suitably protected phenylenediamine mustard precursor 6 to 
produce amide 7. Advancing 7 to 1 would proceed via alcohol deprotection and 
chlorination (Route 1, Figure 2.1(a)). Alternatively, the amide linkage could be 
installed earlier by coupling 2-nitrophenylacetic acid to the protected phenylenediamine 
mustard precursor 6 to afford advanced amide intermediate 8. The alkene 7 would 
subsequently be generated using a Knoevenagel condensation with 8 and pyrrole 4 (or a 
protected derivative). Final alcohol deprotection and chlorination would deliver 1 




Route 1 was the preferred strategy as it was potentially more general, allowing a 
multitude of anticancer cytotoxins to be easily appended to the late-stage acid 
intermediate (Z)-5 via simple amide (or ester) couplings. 
(a) Route 1 
 
(b) Route 2 
 
Figure 2.1. Retrosynthetic analysis for codrug 1.  
 
2.2 Discovery of a Novel Knoevenagel Condensation 
Prior to commencing my PhD studies, preliminary synthetic explorations in the Kelso 
Lab had determined that a Knoevenagel condensation did not proceed directly between 
ethyl-2-(2-nitrophenyl) acetate 3 and unprotected 3,5-dimethyl-1H-pyrrole-2-
carbaldehyde 4 under a variety of conditions. Failure of this reaction was attributed to 
low reactivity of the aldehyde in 4. In order to increase electrophilicity of the aldehyde, 






Bu, Et and Me carbamates of 4 were synthesised (by other students) from the 
requisite chloroformates and the potassium salt of 4 (generated via reaction of 4 with 
KH in THF at 0 
o
C) in good yields. The N-Me carbamate 9 (Scheme 2.1) proved to be 
effective in promoting the desired Knoevenagel condensation with ester 3. Use of 
K2CO3 and 18-crown-6 as base in the presence of aldehyde 9 afforded the desired cis 
(Z)-10 and trans (E)-10 isomers in 46% and 30% yields, respectively (Scheme 2.1). 
Neither the Et nor 
t
Bu-protected pyrroles afforded the alkenes under these conditions. 
The pyrrole N-carbamoyl group was fortuitously lost during the course of the reaction, 
meaning that the product did not require a separate N-deprotection step.  
This preliminary finding suggested Route 1 (Figure 2.1(a)) would be feasible, as ester 
hydrolysis of (Z)-10 could provide the key carboxylic acid intermediate (Z)-5. The 
result suggested that an analogous Knoevenagel condensation using an amide instead of 
ester 3 might also be feasible, supporting exploration of Route 2 (if needed). 
 
Scheme 2.1. Knoevenagel condensation developed earlier in the Kelso Lab. 
 
Work by PhD student Pichit Sudta in the Kelso Lab showed that the carboxylic acid (Z)-
5 could be prepared using a 3-step sequence proceeding via allyl ester 12. Previous 
efforts to produce (Z)-5 via ester hydrolysis of (Z)-10 (or the methyl ester) under acidic 
and basic conditions had failed, with only isomerisation between (Z)-10 and (E)-10 




nitrophenylacetic acid 11 with allyl bromide and K2CO3 in acetone (74%), or via 
H2SO4-catalysed esterification of 11 with allyl alcohol (88%).  
The newly discovered Knoevenagel condensation was found to work well between allyl 
ester 12, providing (Z)-13 and (E)-13 in 41% and 33% yields, respectively. 
Deprotection of (Z)-13 with 10 mol% Pd(PPh3)4 in the presence of morpholine (allyl 
cation scavenger) in THF provided (Z)-5 in 84% yield, with no alkene isomerisation. An 
identical yield of (E)-5 was obtained via deallylation of (E)-12 under the same 
conditions. 
 
Scheme 2.2. Synthesis of key carboxylic acid intermediate (Z)-5. Reagents and 
conditions: a. K2CO3, allyl bromide, acetone, rt, 74%. b. allyl alcohol, cat. H2SO4, rt, 
88%. c. 9 (1.0 mol eq.), K2CO3, 18-crown-6, THF, 65 
o
C, 14 h; (Z)-13 41%, (E)-13 
33%. d. 10 mol% Pd(PPh3)4, morpholine, THF; (Z)-5 84% from (Z)-13, (E)-5 84% from 
(E)-13. 
 
2.3 Conformation and Reactivity of Acid Intermediate 5 
My attempts (during Honours) and attempts by other students in the Kelso Lab to 
perform alcohol and amine couplings with carboxylic acid intermediates (Z)-5 and (E)-5 
all failed to give the desired cis- and trans-ester/amide products. The reactions instead 




arising through intramolecular cyclisation of the pyrrole nitrogen onto the activated 
carbonyl group (Figure 2.2(a)). It was suspected that cyclisation was being promoted by 
an intramolecular hydrogen bond between the pyrrole N-H of (Z)-5 and the carbonyl 
oxygen. This H-bond could increase acidity of the pyrrole N-H and weaken the carbonyl 
C=O bond and stabilise the tetrahedral transition state leading to intramolecular ring 
closure under ester and amide coupling conditions.  
As part of my PhD work, I repeated Pichit Sudta’s synthesis of (Z)-5 and was able to 
grow a crystal of the compound suitable for X-ray analysis. I also converted a sample of 
(Z)-5 to 5,7-dimethyl-2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14 and obtained a crystal 
of from Et2O. The X-ray structure of 14 was solved by Tony Willis (ANU) and is 
shown in Figure 2.2(b). The structure showed that the 2-nitrophenyl ring was tilted 
35.5
o
 relative to the plane of the 3H-pyrrolizin-3-one ring and that the NO2 group was 
positioned close to the carbonyl oxygen. The distance between the carbonyl oxygen and 
the NO2 nitrogen was 2.8 Å. This close proximity suggests a favourable interaction 
















           (Z)-5               14 
Figure 2.2. (a) Attempted syntheses of amide and ester derivatives of (Z)-5 using 
standard coupling procedures resulted in formation of 3H-pyrrolizin-3-one 14 in good 
yields (70-88%). (b) X-ray crystal structures of (Z)-5 and 14. Anisotropic displacement 
ellipsoids show 30% probability levels. Hydrogen atoms are drawn as circles with small 
radii. Crystallographic data are provided in Chapter 6.1.1. Appendices 1(a) and 1(b).  
 
The X-ray structure of (Z)-5 confirmed the presence of the proposed H-bond stabilising 
a pseudo 7-membered ring. Evidence for the H-bond was also observed in the 
compound’s 
1
H NMR spectrum, where the pyrrole N-H signal for (Z)-5 appeared far 
downfield at 11.87 ppm, whereas for (E)-5 it was observed at 6.78 ppm (in CDCl3). 
These characteristic chemical shifts were also observed in the 
1
H NMR spectra of 
derivatives of 5, as exemplified by allyl esters (Z)-13 and (E)-13, where the pyrrole N-H 
appeared at 11.81 ppm and 6.75 ppm, respectively (Figure 2.3(a)). Single crystal X-ray 
structures of (Z)-13 (previously obtained in the Kelso Lab) and (E)-13 (obtained during 
my Honours) were solved by Tony Willis (ANU). These structures clearly showed the 





     
(b) 
      (Z)-13            (E)-13 
Figure 2.3. (a) 
1
H NMR spectra highlighting the downfield chemical shifts of the 
pyrrole N-H signal in (Z)-13 relative to (E)-13. (b) X-ray crystal structures of (Z)-13 and 
(E)-13 (solved by Tony Willis, ANU). Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 
Crystallographic data for (Z)-13 and (E)-13 are provided in Chapter 6.1.1. Appendices 




Ester and amide couplings were also explored (by me, during Honours) with the trans-
acid (E)-5. It was rationalised that (E)-5 might not be susceptible to intramolecular 
cyclisation due to the unfavourable positioning of the pyrrole N-H trans to the 
carboxylic acid moiety and because it lacked the activating H-bond. If the desired 
couplings were found to proceed, it was envisaged that the trans products could be 
converted to the requisite cis isomers through alkene isomerisation. Under most of the 
couplings examined, however, the 3H-pyrrolizin-3-one 14 was again observed as the 
major product, suggesting that isomerisation of (E)-5 to (Z)-5 was facile under the 
reaction conditions investigated. 
 
2.4 Indole-N-oxides 15 and 16 
2.4.1 Discovery of 15 and 16 
A notable change in the reactivity of trans acid (E)-5 was observed during attempted 
couplings with HBTU and N,N-dimethyl-p-phenylenediamine (DMPD) in the absence 
of bases (Figure 2.4(a)). Bases were deliberately excluded from reactions to reduce 
base-promoted isomerisation of (E)-5 to (Z)-5 and subsequent 3H-pyrrolizin-3-one 
formation. The reactions did not produce the expected trans-amide product or 3H-
pyrrolizin-3-one 14, however, but instead formed a deep purple solid as the major 
product. A crystal of the compound was obtained from Et2O/pet. spirit and submitted to 
Tony Willis (ANU) for X-ray analysis. The structure was solved as (E)-2-(3,5-dimethyl-





C NMR spectra (Chapter 6.2 Appendix 2) for 15 were consistent with 




The reaction proceeded further to completion when p-phenylenediamine (PPD) was 
used in place of DMPD, providing a higher isolated yield (56%) of the dark purple solid 





Figure 2.4. (a) Synthesis of 15 and 16 from (E)-5, (b) X-ray crystal structure of 15 
(solved by Tony Willis, ANU). Anisotropic displacement ellipsoids show 30% 
probability levels. Hydrogen atoms are drawn as circles with small radii. 







2.4.2 Further Explorations with 15 and 16 
Compound 16 was found to be unstable, producing two decomposition products soon 
after purification by silica gel column chromatography. The two products were (1) an 
intensely coloured violet solid and (2) PPD, suggesting that hydrolysis of 16 to the 
novel violet ketone derivative 2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-oxo-3H-indole 1-
oxide 17 (Figure 2.6(a)) had occurred. Acids (E)-5 and (Z)-5 were similarly observed to 
decompose over time, forming the same violet solid 17 and a second red amorphous 
solid which was characterised as the trans-alkene 18. The reaction was apparently 
proceeding through a spontaneous decarboxylation followed by an electrocyclic 
reaction of an intermediate allene ( Figure 2.5(a)).  
NMR studies to monitor the spontaneous decompositions were performed by leaving 
(Z)-5 in an NMR tube in CDCl3 over a period of two weeks (Figure 2.5(b)). The 
1
H 
NMR spectra shown in Figure 2.5(b) showed that 18 forms spontaneously from (Z)-5. 









Figure 2.5. (a) Proposed mechanism for decomposition of (Z)-5 to form 18 via allene 
18a. (b) Aromatic region of 
1
H NMR spectra showing signals from the spontaneous 
decarboxylation of (Z)-5 in CDCl3 (Top). 
1
H NMR spectra showing the equivalent 
chemical shift regions for pure samples of (Z)-5, 17 and 18. 
 
Attempts to deliberately hydrolyse 15 and 16 under acidic conditions (H2SO4 (cat.), 
THF) led to quantitative formation of ketone 17 (Figure 2.6(a)). A single crystal X-ray 





C NMR, IR and HRMS were consistent with this structure. The imine 
15 and ketone 17 shared similar UV-Vis spectra, with both showing absorption maxima 




The strong red-absorptions and intense violet colours were consistent with the extensive 










Figure 2.6. (a) Synthesis of the ketone 17. Reagents and conditions: 1:1 1M HCl:THF, 
quant. (b) X-ray crystal structure of 17 (solved by Tony Willis, ANU). Anisotropic 
displacement ellipsoids show 30% probability levels. Hydrogen atoms are drawn as 
circles with small radii. Crystallographic data for 15 are provided in Chapter 6.1.1. 




2.4.3 Proposed Mechanism for Formation of 15 and 16. 
Further synthetic studies were undertaken to probe the reaction mechanisms leading to 
formation of 15 and 16. Firstly, it was found that cis- and trans-carboxylic acids (Z)-5 
and (E)-5 both worked equally well in the reaction. Facile cis to trans isomerisation 
promoted by electron donation from the pyrrole nitrogen into the carboxylic acid 
carbonyl and NO2 groups would give the alkenic double bond significant single bond 
character, allowing facile rotation and isomerisation. 
Introduction of TEMPO into the reaction at 10% or 100% by weight (relative to 5) had 
no effect on the yield of 15 or 16, suggesting that radicals were not involved in the 
mechanisms. Compounds 15 and 16 were not observed when replacing (Z)-5 with 
pyrrolizin-3-one 14 or amides such as (Z)-29 (see Table 2.1), eliminating these as 
intermediates. Addition of catalytic diisopropylethylamine (DIPEA) to reactions with 
HBTU, (Z)-5 and p-phenylenediamines DMPD or PPD resulted in formation of 3H-
pyrrolizin-3-one 14 as the major product. Use of the carbodiimide coupling reagent 
dicyclohexycarbodiimide (DCC) in base-free conditions yielded 14 as the only product. 
The reaction proceeded more rapidly with additional mol eq. of HBTU or PPD. The 
reaction also proceeded well with the closely related coupling reagent 1-
[Bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide 
hexafluorophosphate) (HATU) and was indeed faster, completing in 30 min (c.f. 4 h 
with HBTU). No reaction was observed between the acids (Z)-5 or (E)-5 and HBTU or 
HATU in the absence of PPD or when PPD and the acids were combined in the absence 
of HBTU or HATU. In CH2Cl2, a very slow reaction was observed when HATU and 
PPD were added together, however. This reaction resulted in two new peaks at m/z 136 
and 207 in the ESI
+
 mass spectrum. Monitoring this reaction by 
1




indicated formation of 2-(4-aminophenyl)-1,1,3,3-tetramethylguanidine 19 (Figure 
2.7(a), MW = 206.29 g/mol). Its structure was subsequently confirmed by 2D NMR 
analysis and HRMS. 3H-[1,2,3]triazolo[4,5-b]pyridin-3-ol (HOAt, MW = 136.11 
g/mol) was also formed in a 1:1 stoichiometric ratio in the reaction. Reactions of this 
type are supported by a literature precedent.
185
 Peaks at m/z 207 and 136 were also 
observed in the ESI
+
 mass spectrum of the crude reaction mixtures that formed 15 or 16 
using HBTU or HATU, suggesting that the guanidinium species 19 was being formed in 
the reaction.  
From a structural perspective, to form 16 from (E)-5, HATU and PPD, the alkenic β-
carbon of (E)-5 must attach to the NO2 group’s nitrogen atom and PPD must attach one 
of its nitrogen atoms to the α-carbon of (E)-5. This suggested that a pre-transformation 
to a resonance-stabilised nitrenium ion of PPD might be occurring. One possible 
mechanism for the formation of a nitrenium ion is shown in Figure 2.7(a). The oxygen 
atom of a second molecule of HATU could act as a nucleophile that attacks the 
guanidine carbon of protonated 19. Elimination of tetramethylurea (TMU) would give 
the nitrenium derivative of PPD and reduced HATU. Peaks at 116 m/z (TMU) and 313 
m/z (PPD-19 adduct) were suggestive of this transformation.  
A mechanism for the formation of 16 from (E)-5, PPD and HATU is proposed in Figure 
2.7 (b). Formation of 19 from reaction of HATU with PPD occurs in step 1, which is 
followed by deprotonation of (E)-5 to form the carboxylate anion and the protonated 
guanidininium form of 19 (step 2). Formation of the PPD+ nitrenium ion from 19 then 
occurs. An allene species 18a is formed by decarboxylation of (E)-5 (See Chapter 2.4.2, 
step 3). The nascent benzylic anion then attacks PPD+ (step 4). The resulting enamine 




followed by dehydration yield the final 16 (steps 6 and 7). While the mechanism is 




Figure 2.7. Proposed mechanism of formation of (a) nitrenium ion PPD+ from reaction 





2.5 Antiplasmodial Activity of 17 
 A literature search revealed that ketone 17 was a novel analogue of indolone-N-oxides 
that have previously been shown to possess in vitro antibacterial, antifungal and 
antiplasmodial activity.
186–188
 The broad antimicrobial properties of the class are 
attributed to generation of reactive oxygen species, although antiplasmodial activity was 
also attributed to a redox process in infected red blood cells (RBCs) that causes 
destabilisation of cells and parasite death.
186,187
  
Reported analogues contained various aryl and alkyl groups at the position occupied by 
the 3,5-dimethylpyrrole in 17, along with substituents on 6-membered ring of the 
indolone-N-oxide (Figure 2.8), synthesised using Sonogashira couplings between aryl 
alkynes and 2-nitrophenyl halides to form 2-nitrophenylalkyne derivatives that cyclised 
in situ.
186,187
 The most potent antiplasmodial was 2-(4-(dimethylamino)phenyl)-5-
methoxy-3-oxo-3H-indole 1-oxide 20.
186,187
 Compound 20 showed an IC50 of 1.7 nM 
against the 3D7 strain of P. falciparum (African, chloroquine-sensitive strain) and IC50 
< 3 nM against the FcB1 (chloroquine-resistant) strain. It also had good selectivity, 
showing > 14,600-fold higher activity against the parasite than MCF-7 breast cancer 
cells.  
 




Compound 17 was tested using the microdilution radioisotope technique against the K1 




Genetic Engineering and Biotechnology (BIOTEC) Thailand, where it returned an IC50 
= 381 nM.
189,190
 Cytotoxicity of 17 against Vero cells was also determined using an 
Alamar blue viability assay,
191
 where it showed CC50 = 58.4 μM, giving it a selectivity 
index of 153. As it was less potent and selective than compound 20, and with literature 
already published on the indolone-N-oxide series, further biological investigations with 
17 were not undertaken. 
 
2.6 Substrate Scope of the Knoevenagel Condensation 
With the divergent approach (Route 1) towards codrug 1 (i.e. via the carboxylic acid 
(Z)-5) no longer appearing feasible, attention was turned to Route 2, where the amide 
bond is formed first followed by the Knoevenagel condensation. Pursuing Route 2 
required confirmation that the Knoevenagel condensation could also be carried out with 
amides as well as esters. Model amides 23 and 24 were prepared by coupling 2-
nitrophenylacetic acid to aniline and benzylamine in 95% and 94% yields, respectively, 
using HBTU as the coupling reagent. Both amides underwent the desired condensation 
with pyrrole aldehyde 9 to form the cis-alkenes (Z)-29 and (Z)-30 in 22% and 16% 
yields, respectively, using the standard conditions that had been developed. The 
analogous ethyl amide 22 and Knoevenagel product (Z)-28 were prepared in 2012 by a 
Kelso Lab Honours student (Rhys Mitchell) in 21% yield.  
It was noted that while the ester derivatives tended to form similar proportions of cis 
and trans-alkene products, the amides formed mostly the cis isomer. For example, use 
of ethyl ester 3 produced (Z)-10 and (E)-10 in 42% and 35% yields, respectively (Table 
2.1, Entry 1). The methyl ester 21 produced (Z)-27 and (E)-27 in 36% and 40% yields 




yields, respectively (Table 2.1, Entry 3). In comparison, the ethylamide derivative 22 
produced 21% of the cis product (Z)-28 and none of the trans isomer (E)-28 (Table 2.1, 
Entry 4). Similarly, the aniline and benzylamine derivatives 23 and 24 produced (Z)-29 
and (Z)-30 in 22% and 16% yields, respectively, and less than 5% of (E)-29 and (E)-30 
were produced and neither could be isolated in pure form (Table 2.1, Entries 5 and 6). 
Rhys was also successful in synthesising ethyl ester derivatives where the 2-nitrophenyl 
moiety was replaced with phenyl or 2-chlorophenyl groups. The Knoevenagel 
condensation in these cases required use of the much stronger base LDA. Interestingly, 
the phenyl derivative 25 produced a 32% yield of the trans-phenyl analogue (E)-31 and 
no cis-product (Z)-31 (Table 2.1, Entry 7). A 41% yield of the trans 2-chlorophenyl 
product (E)-32 was obtained from 26 with only 5% of (Z)-32 being isolated (Table 2.1, 
Entry 8). A summary of all compounds prepared via the Knoevenagel condensation is 
provided in Table 2.1. Compounds re-synthesised by me during my PhD studies are 
indicated with an *. Compounds I synthesised for the first time during my PhD studies 
are indicated with a #. Full characterisation and experimental procedures are provided 














Table 2.1. Summary of Knoevenagel condensations. Reagents and conditions: a. 
K2CO3, 18-crown-6, THF, reflux, 16 h; b. LDA, THF, -78 
o















1 3 NO2 OEt a (Z)-10, 42* (E)-10, 35* 
2 21 NO2 OMe a (Z)-27, 36* (E)-27, 40* 
3 12 NO2 OAll a (Z)-13, 41* (E)-13, 33* 
4 22 NO2 NHEt a (Z)-28, 21 (E)-28, 0
A
 










7 25 H OEt b (Z)-31, 0 (E)-31, 32 
8 26 Cl OEt b (Z)-32, 5 (E)-32, 41 
A
Compound could not be isolated in pure form 
B
Esters 3, 21, 25-26 were synthesised by refluxing the phenylacetic acids in the requisite alcohol (as 
solvent) with catalytic H2SO4. 
C
Amides 22-24 were synthesised by coupling 2-nitrophenylacetic acid to the requisite amines using 




2.7 Anti-Angiogenic Properties of Alkene Products 
When designing codrug 1, it was reasoned that the presence of the attached cytotoxin 
should render the pro-angiogenesis inhibitor moiety (based on SU5416 2) inactive due 




ablate angiogenesis inhibition as all published SAR studies with SU5416, sunitinib and 
related analogues retained this key moiety.
134
 These hypotheses were examined by 
testing the antiangiogenic activity of the model cis and trans derivatives of 10, 13 and 
27-32 obtained from the Knoevenagel condensations. The Et and Me esters (Z)-10 and 
(Z)-27 had been shown to be angiogenesis inhibitors in preliminary experiments at the 
start of my PhD studies but none of the other derivatives had been tested.  
Compounds were examined using a rat aortic ring angiogenesis assay in the lab of Prof. 
Chris Parish at the John Curtin School of Medicine (ANU) by a research assistant Anna 
Bezos.
192
 In this model, 1 mm sections from female rat aortas are suspended in a fibrin 
gel matrix and exposed to growth media. The aortic sections form new blood vessel 
sprouts over 5 days, which are scored manually as the % field of view (F.O.V.) 
occupied under a light microscope. Inhibitors of angiogenesis produce a quantifiable 
reduction in the F.O.V. occupied by the sprouting blood vessels. Figure 2.9 provides a 





Figure 2.9. Summary of rat aortic ring angiogenesis inhibition assay performed by 
Anna Bezos at the John Curtin School of Medicine (ANU). 
Two positive controls PI-88 and SU5416 were included in the assays. PI-88 is a highly 
sulfated oligosaccharide-based angiogenesis inhibitor that underwent Phase III clinical 
trials as a treatment following cancer resection in patients with hepatitis virus-related 
hepatocellular carcinoma.
193
 At 100 µg/mL, PI-88 reduced F.O.V. occupancy to 39.2%. 
SU5416 (synthesised by me using the literature method)
184
 produced significantly 
higher inhibition of angiogenesis at 10 µg/mL (F.O.V. occupancy 9.7%) than at 100 
µg/mL (F.O.V. occupancy 30.6%), while 61.4% F.O.V. occupancy was observed at 1 
µg/mL. Small crystals observed in wells containing 100 µg/mL SU5416 2 suggested 
that the poor dose dependency may have been due to low solubility of the compound in 
the assay medium. 
Et and Me esters (Z)-10, (E)-10, (Z)-27, and (E)-27 were found to completely inhibit 
angiogenesis at 100 µg/mL. At 10 µg/mL, (E)-10 continued to show complete 
inhibition, whereas the other three esters all showed significantly diminished effects at 
this concentration. At 1 µg/mL the four esters showed either minimal effects (< 20% 
difference relative to negative control) or no activity. Surprisingly, the cis-allyl ester 
(Z)-13 showed the same level of inhibition at both 100 and 10 µg/mL (F.O.V. 
occupancy 28.3 and 29.3%, respectively) but no activity at 1 µg/mL. For the trans-allyl 
ester (E)-13, strong activity was observed at 100 µg/mL (F.O.V. occupancy 8.3 %), but 
this activity was completely ablated at 10 µg/mL. It was concluded that (E)-10 was the 
most active angiogenesis inhibitor of the 2-nitrophenylacetic ester series. 
The cis-ethylamide (Z)-28 showed reduced effects (F.O.V. occupancy 51.7% at 100 




ester group for an amide is detrimental to activity. Observing that phenyl and benzyl 
amides (Z)-29 and (Z)-30 were inactive at 100 µg/mL supported this conclusion. These 
results also implied that 1 should be a poor angiogenesis inhibitor because it also 
incorporated an amide linkage.  
Removal of the NO2 group from the phenyl ring was found to completely abolish 
activity (i.e. (E)-31 v. (E)-10). Interestingly, replacing the NO2 group with Cl had no 
effect on activity at 100 µg/mL, with both (E)-32 and (E)-32 completely inhibiting 
angiogenesis. At 10 µg/mL, however, (E)-32 showed no activity. Results are 
summarised in Figure 2.10. 
 
 
Figure 2.10. Rat aortic ring angiogenesis inhibition assay. Inhibition of angiogenesis by 
compounds 10, 13 and 27-32 relative to negative control (no compound) and positive 
controls PI-88 (100 µg/mL) and SU5416 2. Negative control (no compound) showed 
85.7% F.O.V. occupancy. Data represent the mean F.O.V. occupancy (%) generated 
from at least six replicate cultures of each test compound at each concentration. 
 




The Knoevenagel condensation conditions used in the preparation of esters 10, 13 and 
27 employed 1.0 mol eq. of 2-nitrophenylacetate ester, 1.5 mol eq. of K2CO3, 0.5 mol 
eq. of 18-crown-6 and 1.0 mol eq. of pyrrole aldehyde 9. These reactions were typically 
stirred for 12-16 hours at 65-75 
o
C in dry THF. Initial attempts using these conditions to 
synthesise amides 29 and 30 revealed the need for scrupulously anhydrous conditions 
and the importance of reaction times. Knoevenagel condensations to produce esters 10, 
13 and 27 could be left heating beyond completion of the reaction and were not affected 
by small changes in the reaction protocol. On the other hand, the amides produced 
intractable mixtures without freshly prepared, scrupulously dried reactants, reagents and 
solvents, and required strict adherence to the protocol with careful monitoring. The 
reactions were low yielding and the trans products were generally unable to be isolated 
in pure form (by column chromatography). Several coloured side products were also 
formed that were not observed in the ester-based reactions, making purification by 
column chromatography difficult. A study was undertaken to examine the side products 
formed during the Knoevenagel condensation between pyrrole aldehyde 9 and anilide 
23 to form (Z)-29. Importantly, this study aimed to identify conditions that could be 
transferred to the synthesis of codrug 1 via Route 2 (Figure 2.1). 
Parameters varied during the optimisation study included the solvent, base and reaction 
times (Table 2.2). All reactions were carried out using 1.5 mol eq. of the indicated oven-
dried potassium salts (as base), 1.0 mol eq. of 2-(2-nitrophenyl)-N-phenylacetamide 23 
and 1.0 mol eq. of 18-crown-6. Reactions were stirred at 65 
o
C in freshly distilled dry 
solvent under a N2 atmosphere. After 1.0 hour, a solution containing 1.0 mol eq. of 
aldehyde 9 in the same solvent was added dropwise to the stirred mixture under N2. The 
reactions were monitored by TLC (8:2 pet. spirit:acetone) until complete consumption 




solvent removed under reduced pressure. The remaining aqueous mixture was extracted 
with 50 mL of Et2O and washed with saturated NaHCO3 solution and brine. The organic 
layers were combined and dried over MgSO4 and evaporated to dryness. The crude 
residues were purified by column chromatography and the products isolated and 
identified (where possible). 
When performing column chromatography, a slow gradient from 100% pet. spirit to 8:2 
pet. spirit:acetone (without pressure) yielded a fast eluting non-polar product 33. 
Compound 33 was a yellow oil that showed m/z 315 by ESI-MS. After 7 h only trace 33 
was isolated by column chromatography but its yield increased to 3% after 10 h and 
15% after 14 h (Table 2.2, Entries 1-3).  
The non-polar compound was characterised and unambiguously identified as the N-
phenyl analogue of SU5416 33, apparently formed via intramolecular cyclisation of the 
amide nitrogen onto the phenyl ring carbon bearing the nitro group and loss of HNO2 
(Figure 2.11). While uncommon, intramolecular cyclisation of amides onto aryl nitro 
groups has been reported in the literature.
194,195
 This was an interesting result as N-
aryloxindoles are typically made by transition-metal catalysed reactions between aryl 
halides and the oxindole NH. While not examined here, exploration of this chemistry 
might reveal a general method for preparing N-aryloxindoles. Based on this observation, 
a corresponding product was predicted to form (confirmed, see Chapter 3.2.4) during 
Knoevenagel condensations between 8 and 9 to produce 7 enroute to 1 via Route 2. 
 





A second product identified in the reactions was the N-deprotected pyrrole aldehyde 4, 
which was isolated in 9% yield after 7 h, 11% after 10 h and 28% after 14 h (Table 2.2, 
Entries 1-3). Compound 4 presented problems during purification as it streaked on silica 
gel columns and contaminated fractions containing the cis-product (Z)-29. Compound 
(Z)-29 was obtained in 28% yield after 7 h and 38% after 10 h (Table 2.2, Entries 1-2). 
After 14 h, (Z)-31 was difficult to separate from compound 4, providing only 22% of 
pure material (Table 2.2, Entry 3). Remaining starting materials (i.e. pyrrole aldehyde 9 
and amide 23) co-eluted from the column. The trans product (E)-29 eluted very slowly 
from the column and it was difficult to separate from the streaking amide 23. The best 
column chromatography protocol for purification of (Z)-29 and (E)-29 involved use of a 
slow gradient from 100% pet.spirit to 8:2 pet. spirit:acetone without application of 
pressure and over a period of 5 h. 
Conditions for the synthesis of (Z)-29 and (E)-29 that enabled acceptable purification by 
column chromatography involved using 1.0 mol eq. of 23 and 9, 1.5 mol eq. of K2CO3 
and 1.0 mol eq. of 18-crown-6, with THF as solvent and a reaction time of 10 h at 65 
o
C 
(Table 2.2, Entry 2). Use of K3PO4 and KO
t
Bu as bases  (Table 2.2, Entries 9 and 11) 
increased the rate of decarbamoylation of 9 to 4 (39% and 48% with K3PO4 and KO
t
Bu, 
respectively). Yields of (Z)-29 and (E)-29 were also reduced to 18% and 7%, 
respectively, with K3PO4. No yield of (Z)-29 or (E)-29 was obtained with KO
t
Bu. 
Yields of N-phenyl SU5416 33 increased from 3% with K2CO3 to 5% with K3PO4 and 
31% with KO
t
Bu, suggesting that stronger bases assist its formation.  
Alternative solvents were examined. Et2O (Table 2.2, Entry 5) produced similar yields 




20% yield of N-deprotected pyrrole aldehyde 4 was also produced (c.f. 3% in THF). 
CH2Cl2 (Table 2.2, Entry 4) resulted in lower yields of the products (18% yield of (Z)-
29 and 10% of (E)-29) as did 
i
Pr2O (25% (Z)-29, 19% (E)-29. Table 2.2, Entry 8).
 
t
BuOMe produced slightly lower yields compared to THF, (37% and 20% yields of (Z)-
29 and (E)-29, respectively), although the yield of 33 was increased to 40% (Table 2.2, 
Entry 7). Surprisingly, use of 1,4-dioxane failed to produce any (Z)-29 or (E)-29 (Table 
2.2, Entry 6). 
 
Table 2.2. Optimisation of Knoevenagel condensation to produce (Z)-29, (E)-29 and 33. 
Reagents and conditions: a. base, 18-crown-6, solvent, reflux.  
 
  Yield % 
Entry Base Solvent Time (h) (Z)-29 (E)-29 4 33 
1 K2CO3 THF 7 28 14 9 < 1 
2 K2CO3 THF 10 38 26 11 3 
3 K2CO3 THF 14 22 < 5* 28 15 
4 K2CO3 CH2Cl2 10 18 10 32 5 
5 K2CO3 Et2O 10 34 29 20 3 
6 K2CO3 1,4-Dioxane 10 NO REACTION 
7 K2CO3 
t
BuOMe 10 37 20 2 40 
8 K2CO3 
i
Pr2O 10 25 19 26 10 
9 K3PO4 THF 10 18 7 39 5 
10 K3PO4 
t




11 KOtBu THF 10 0 0 48 31 
*Could not be isolated in pure form. 
# Reactions were carried out by dissolving 0.2 g of 23 in 10 mL of dry solvent in a three-neck 
roundbottom flask along with 1.5 mol eq. of base and 1.0 mol eq. of 18-crown-6. Reactions were stirred 
at reflux for 1 h before adding 1.0 mol eq. of 9 in 3 mL of dry solvent dropwise under N2 and stirring at 
reflux. 
 
2.9 Summary and Future Directions 
Work in this chapter showed that Route 2 (Figure 2.1) showed promise as a way of 
accessing codrug 1 due to the successful Knoevenagel condensation between 2-(2-
nitrophenyl)acetanilide 23 and pyrrole aldehyde 9. Failure of the key acid intermediate 
(Z)-5 to undergo ester and amide couplings ruled out further investigation of Route 1. A 
new class of angiogenesis inhibitors was produced using the novel Knoevenagel 
chemistry and several highly coloured reaction products were isolated and structurally 
characterised. These products had characteristic colours and it was thought that this 
feature might facilitate identification of more complicated byproducts produced when 
the reaction was attempted during the synthesis of 1 (Figure 2.12).  
 





Indole-N-oxides 15-18 were deep purple to violet in colour, whereas oxindoles 2 and 33 
were yellow solids. Cyclisation to the 3H-pyrrolizin-3-one 14 produced a deep red 
crystalline solid, while the target α,β-unsaturated amide (Z)-29 and ester (Z)-10 were 
bright orange-red solids. Placing a hydrogen or chloride atom at the ortho position in 
place of the NO2 group (i.e. (E)-32 and (Z)-32), led to solids with a pale yellow colour. 
These transformations were all accompanied by characteristic shifts in polarity by TLC 




C NMR spectra.  
The scope and utility of these reactions could be explored in the future. For example, if 
successfully translated into a more general scheme, the synthesis of oxindoles such as 
33 from 2-nitrophenylacetate derivatives would appear to be a more substituent-neutral 
reaction compared to the typical Fischer indole synthesis with late-stage decoration. 
This reaction would allow early substitution at the usually unreactive 5- and 6-positions 
as well as alkyl or aryl substituents at the nitrogen which would typically require strong 
base and unfavourable N-alkylation or transition-metal catalysis. 
Exploration of the indole-N-oxide forming reactions (Chapter 2.4) to produce other 
intensely coloured products like 15 and 16 could be quite interesting. While 17 proved 
to be only a moderate antiplasmodial, the synthetic pathway to this indolone-N-oxide 
was novel. A three-step sequence from 2-nitrophenylacetic acid using a Perkin reaction 
followed by decarboxylative cyclisation (Chapter 2.4) and hydrolysis of the imine might 
provide indolone-N-oxides that are difficult to synthesise by other methods (Figure 
2.13).  
 





The reaction mechanism described in Chapter 2.4.3 presented much novel chemistry, 
although the mechanism was not unambiguously confirmed in this Thesis. Further 
confirmation of the mechanism could be obtained by trapping the nitrenium ion PPD+ 
or guanidine 19 with nucleophiles. Trapping of the 2-(2-nitrophenyl)-allene species with 
other electrophiles might also be informative. The trans-alkene 18 resulting from 
spontaneous decarboxylation of 5 may also provide similar reactivity in the presence of 
strong base. The utility of the novel 3H-pyrrolizin-3-one class of compounds, 



















Synthesis of Codrug 1  











3.1 Strategy (a) 
Work in Chapter 2 identified Route 2 as a promising way to access codrug 1 following 
confirmation of a successful Knoevenagel reaction between 2-(2-nitrophenyl)acetanilide 
23 and N-protected pyrrole aldehyde 9 to produce (Z)-29. Route 2 required preparation 
of a suitably O-protected amide intermediate 8, which could undergo the Knoevenagel 
reaction with pyrrole aldehyde 9. Two strategies towards 8 were considered (Scheme 
3.1). In Strategy (a), the diethanolamine 35 (or its acid salt) could be prepared and then 
coupled with 2-nitrophenylacetic acid to give 34. Protection of the alcohols could be 
performed before or after amide formation giving 8. Strategy (b) would start by 
coupling p-phenylenediamine to 2-nitrophenylacetic acid to give amide 36. Bis-N-
alkylation of 36 with a 2-haloethanol would give 34 and after o-protection intermediate 
8. 
 
Scheme 3.1. Retrosynthetic analysis for key amide intermediate 8. 
 
Strategy (a) was preferred for several reasons. Firstly, synthesis of intermediate 35 had 
been previously described in the literature.
196
 Secondly, the diethanolamine moiety 
could be introduced using reliable nucleophilic aromatic substitution chemistry (i.e. 
using 1-fluoro-4-nitrobenzene, thus avoiding the aryl amine bis-alkylation reaction 




of mixtures of primary, secondary and tertiary amines as well as quaternary ammonium 
salts which are difficult to separate. 
In pursuing strategy (a), the first step involved forming the p-nitro-bis-ethanolamine 
derivative 37 (Scheme 3.2). 1-Fluoro-4-nitrobenzene was reacted with freshly distilled 
diethanolamine in DMSO at reflux, as per Ferlin et al.
196
 The high aqueous solubility of 
the product 37 made isolation from DMSO very difficult. The reaction was 
subsequently repeated neat to avoid this complication, which resulted in a 77% yield of 
the desired yellow solid after recrystallisation from MeOH/H2O (Lit. 96%).
196
  
According to Ferlin et al., the free base form of N,N-bis-ethanolamino-p-
phenylenediamine 35 can be isolated in EtOAc after SnCl2.2H2O-mediated NO2 
reduction with careful pH control.
196
 While conversion of 37 to 35 appeared to be 
complete (monitored by TLC, 100% EtOAc), only a small amount of 35 was obtained 
in the EtOAc extract, even with careful pH monitoring. The small quantity of free base 
35 obtained quickly decomposed into a black tar. The same article suggested that the 
more stable HCl salt could be obtained by addition of methanolic HCl to the free base, 
followed by evaporation. It was found, however, that the acid salt of 35 also degraded 
quickly and could not be obtained in useful quantities. 
These challenges triggered investigations into an alternative procedure, where the NO2 
to NH2 reduction was performed with H2/Pd/C in order to simplify the workup. The 
reduction of 37 was carried out in methanol until TLC showed consumption of starting 
material. The mixture was then filtered through celite and concentrated in vacuo. The 
residue was redissolved in CH2Cl2 and immediately added to a solution of 2-
nitrophenylacetic acid in CH2Cl2, which had been pre-activated to the HOBt ester with 




The H2/Pd reduction was repeated in DMF and again went to completion. The mixture 
was filtered through celite directly into a pre-activated solution of the 2-
nitrophenylacetic acid HOBt ester in DMF. This reaction also failed to yield any of the 
amide, suggesting that the phenylenediamine derivative was either insufficiently 
nucleophilic or was decomposing too rapidly to undergo amide coupling.  
In an attempt to increase stability, 37 was bis-O-TBDMS-protected using standard 
literature conditions to produce derivative 38 in 72% yield (Lit. 95%).
197
 The reduction 
reactions described above were each repeated with 38 in attempts to synthesise the 
TBDMS-protected amide 8 via amine 39. While the reduction reactions with 38 
appeared by TLC to produce 39, subsequent coupling reactions using HBTU as the 
coupling reagent failed to yield any 8. Additional attempts with 2-nitrophenylacyl 
chloride were similarly unsuccessful. At this point Strategy (a) was abandoned. 
 
Scheme 3.2. Unsuccessful synthesis of key amide intermediate 8 using Strategy (a). 
Reagents and conditions: a. neat, reflux, 77%;
196





3.2 Strategy (b) 
3.2.1 Formation of amide 36 
Difficulties encountered with Strategy (a) shifted the focus towards Strategy (b). The 
first step of this approach involved coupling 2-nitrophenylacetic acid to p-




HBTU/DIPEA coupling conditions at room temperature in CH2Cl2. Several gram scale 
reactions were completed where the mol eq. of various reactants/reagents were modified 
(Table 3.1). The highest yield of 36 (75%) was obtained with 1.0 mol eq. 2-
nitrophenylacetic acid, 1.1 mole eq. of freshly recrystallised (EtOH) p-
phenylenediamine, 1.1 mol eq. HBTU and 2.2 mol eq. DIPEA (Table 3.1, Entry 1). 
Increased equivalents of p-phenylenediamine reduced the yield of 36. 
 
Table 3.1. Optimisation of 2-nitrophenylacetic acid couplings with PPD to form 36. 
 
Entry acid, g 
PPD 
g, mol eq. 
HBTU 
g, mol eq. 
DIPEA 
mL, mol eq. 
36, % 
1 5.07 3.33, 1.1 11.69, 1.1 10.7, 2.2 75 
2 5.01 4.07, 1.4 10.60, 1.0 15.1, 3.1 67 
3 3.97 5.11, 2.1 8.75, 1.1 9.2, 2.4 43 
4 0.90 1.63, 3.0 2.11, 1.1 2.8, 3.2 40 
5 0.20 0.48, 4.0 0.46, 1.1 0.5, 2.6 39 
 
3.2.2 Bis-N-alkylation of 36  
The next step in Strategy (b) involved formation of the diethanolamine derivative 34, 
which required bis-N-alkylation of 36 with 2 eq. of a 2-haloethanol. K2CO3 was used as 
the base and 2-bromoethanol as both reagent and solvent. Test reactions were performed 
on a 20 mg scale under a variety of conditions (Table 3.2) with the highest yield being 
67%. The reaction conditions were then increased to multigram scale where similar 




days at 50 
o
C to consume the starting material. Temperatures above 50 
o
C resulted in 
intractable mixtures. Addition of 2-butanone as a co-solvent reduced the yield to 25% 
and resulted in the formation of a black sludge. Switching to 2-chloroethanol and 
addition of catalytic NaI (in situ iodination, i.e. Finkelstein reaction) failed to improve 
the yield (Table 3.2, Entries 3,4 and 7).  
 
Table 3.2. Optimisation of bis-alkylation reaction conditions to produce 34. 
 
Entry 36, g 
2-haloethanol 
X, mL Base, g Additive Solvent 
34 
yield, % 
1 0.02 Br, 1.0 - - Neat NR 
2 0.02 Br, 1.0 K2CO3, 0.03 - Neat 67 
2a 1.90 Br, 15 K2CO3, 1.75 - Neat 67 
3 0.02 Br, 1.0 K2CO3, 0.03 NaI Neat 53 
4 0.02 Cl, 1.0 K2CO3, 0.03 NaI Neat 4 
5 0.02 Br, 1.0 - - 2-butanone NR 
6 0.02 Br, 1.0 K2CO3, 0.03 - 2-butanone 25* 
21* 7 0.02 Br, 1.0 K2CO3, 0.04 NaI 2-butanone 
*Starting material was not completely consumed.  
 
Amide 34 was subjected to the Knoevenagel reaction with aldehyde 9 under the 
optimised conditions (Chapter 2.8) but none of the desired alkene product (Z)-7 was 
formed. It was observed that 9 underwent substantial N-deprotection to 4 during the 








3.2.3 Bis-silyl protection of 34 
Two protecting groups were considered for the hydroxyl groups of 34. Acetyl protection 
was investigated first, with bis-acetylation being achieved using acetic anhydride in 
pyridine. While the protection reaction was successful (72% yield), the subsequent 
Knoevenagel condensation with the bis-acetyl-protected diol was unsuccessful, 
producing only intractable mixtures containing many coloured products. 
Bis-silylation of 34 with TBDMSCl to form 8 was examined next. Standard conditions 
using imidazole as a nucleophilic base/catalyst were explored in both DMF and CH2Cl2. 
Faster and more complete reactions were observed in CH2Cl2 (2 h, 86% yield c.f. 6 h, 
72% yield in DMF). The reaction was successfully scaled up, with an 85% yield of 8 
from 5 g of starting material 34. 
 
Table 3.3. Bis-silyl protection of 34 with TBDMSCl to form 8. 
 
Entry 34, g 
TBDMSCl 
g, mol eq. 
Imidazole 
g, mol eq. Solvent Time, h 
8 
yield, % 
1 5.00 7.50, 3.6 8.10, 8.6 CH2Cl2 2.0 85 
2 1.40 2.05, 3.5 2.34, 8.8 CH2Cl2 2.0 86 





3.2.4 Knoevenagel Condensations with 8 
With the efficient formation of TBDMS-protected amide 8 established on multigram 
scale, attention was next turned to the Knoevenagel condensation reaction between 8 
and pyrrole aldehyde 9. Solvents, bases, reaction times and techniques that had been 
tested previously on the aniline derivative 23 (Chapter 2.8) were used to guide the 
choice of conditions to explore. Several different reactions were examined but the 
standard conditions that had been previously optimised using K2CO3, 18-crown-6 in 
THF at 65 
o
C, and with the pyrrole aldehyde 9 added last after the reaction had reached 
65 
o
C, were again found to be the best for this Knoevenagel reaction. The highest yields 
obtained of (Z)-7 and (E)-7 were 41% and 22%, respectively (Table 3.4, Entry 5). 
The condensation reaction had to be carefully monitored as with the aniline amide 23 
(See Chapter 2.6). N-aryloxindole 41 was formed as predicted, but stopping the reaction 
after 12 h limited its production such that it could only be isolated in trace amounts.  
 
Table 3.4. Optimisation of Knoevenagel reaction to produce (Z)-7 and (E)-7 from 8.  
 
Entry 8, g 
9 
g, mol eq. 
K2CO3 
g, mol eq. 
18-Crown-6 





1 1.13 0.35, 1.0 0.40, 1.5 0.53, 1.0 16 20, 10 
2 2.00 0.60, 1.0 0.94, 2.0 0.97, 1.1 14 33, 28 
3 2.98 1.10, 1.2 1.39, 2.0 1.01, 0.8 14 20, 11 




5 1.15 0.47, 1.3 0.37, 1.35 0.67, 1.3 12 41, 22 
6 1.08 0.57, 1.7 0.88, 3.5 0.64, 1.3 12 16, 15 
7 0.77 0.23, 1.0 0.29, 1.6 0.42, 1.2 12 28, 20 
8 0.41 0.22, 1.7 0.29, 3.0 0.39, 2.1 12 15, 10 
 
3.2.5 Isomerisation Reactions with (E)-7 
A series of isomerisation reactions were investigated with (E)-7 in an attempt to 
increase the yield of (Z)-7 but encouraging results were not obtained. The trans-alkene 
(E)-7 could be partially isomerised using catalytic H2SO4 in THF, producing a 19% 
yield of the desired (Z)-7 with 62% recovery of (E)-7. Base-promoted isomerisation 
using TEA or DIPEA was not successful, instead producing the oxindole derivative 41 
as the major product. 
 
3.2.6 Desilylation of (Z)-7 
The next step in the synthesis of 1 involved deprotection of the two TBS ethers of (Z)-7. 
Desilylation reactions are often carried out using TBAF, a fluoride source that is soluble 
in organic solvents. Initial attempts using TBAF in THF at room temperature or at 0 
o
C 
were unsuccessful, resulting in mixtures of coloured products and decomposed starting 
material. It was suspected that the basicity of the fluoride ions might be causing 
problems. 
Glacial acetic acid (1:5 v/v) was subsequently added to the TBAF/THF solutions to 
buffer the fluoride ion. These conditions resulted in clean conversions at room 
temperature to the bis-ethanolamine product (Z)-42 in 85% yield after column 





Scheme 3.3. Desilylation of (Z)-7 afforded (Z)-42 in 85% yield. 
 
3.2.7 Bis-Chlorination of (Z)-42 to Produce Target Codrug (Z)-1 
Several alternative groups could be considered for inclusion in the mustard arms of the 
codrug (Z)-1. Literature examples include use of chlorides, bromides or mesylates as 
leaving groups, or combinations of these. For example, evofosfamide utilises a 
bromophosphoramidite mustard,
171
 busulfan a dimesyl mustard
198




A two-step process involving mesylation followed by halogen displacement was 
pursued in the first instance. Mesylation was achieved under standard conditions (MsCl, 
TEA in CH2Cl2), affording 86% isolated yield of the dimesyl product (Z)-43 (500 mg 
scale). The compound proved to be unstable, however, and underwent polymerisation to 
a black tar, even when dried and stored at -20 
o
C under Ar. In subsequent halogenations 
attempts, mesylation reactions were quickly diluted in CH2Cl2 after completion, washed 
with saturated NaHCO3 and brine and evaporated to dryness. The crude product was 
purified on a short (~7 cm) silica gel column using EtOAc as eluent and the freshly 
prepared bis-mesylate was dried under vacuum before being taken up in minimal DMF 
and treated with an excess of LiCl or LiBr. The reactions were stirred at 75 
o
C until the 
starting material was consumed (as observed by TLC analysis, 1:1 EtOAc:pet. spirit) 




When halogenation reactions were performed on (Z)-43 with lithium bromide, the 
desired dibrominated product was not detected. Using LiCl in DMF, however, the target 
compound (Z)-1 was formed in 92% yield. Gratifyingly, it proved to be an air stable 
compound at room temperature. (E)-1 was also isolated from the chlorination reactions, 
although it proved to be less stable than (Z)-1. Both (Z)-1 and (E)-1 were able to be 




Scheme 3.4. Two-step procedure for the formation of (Z)-1 from (Z)-42 via mesylation 
followed by chlorination. Reagents and conditions: a. MsCl, TEA, CH2Cl2, 86%; b. 
LiCl (excess), DMF, 75 
o
C, 92%.  
 
3.3 Proof-of-Concept Reduction Reactions 
For the codrug (Z)-1 to provide dual-action tumour killing in vivo it is necessary for the 
nitro group to spontaneously cyclise onto the amide carbonyl following bioreduction to 
the aniline, releasing SU5416 2 and the phenylenediamine mustard (Figure 1.20). To 
probe this process, chemical reductions of the nitro group were investigated under three 
different conditions, including: (a) 10.0 mol eq. Fe
0
 in 2:3:2 glacial acetic 
acid:EtOH:water with ultrasonication,
199




Zn in 1:1 DMF:water,
200
 and (c) 2.0 mol eq. NaBH4 with 10% w/w Pd/C in 2:1 
MeOH:water. 
201
 These reactions were chosen for their mild conditions and because 
they were tolerant of alkenes, esters and amides. 
If the proof-of-concept reductions were successful,  nitro reduction to the amine (or 
hydroxylamine) would need to occur and be followed by spontaneous cyclisation, 
yielding SU5416 2 (or N-hydroxy-SU5416 2-OH), which is also a potent inhibitor of 
VEGFR-2.
202
 The reactions were monitored by TLC analysis and quenched 
immediately after the starting material had been consumed by filtering the reactions 
through celite. Reactions were conducted on 20 mg scale and the isolated yields of both 
2 and 2-OH were determined after purification by column chromatography. Yields of 
the phenylenediamine mustard were not obtained due to the compound’s instability. 
Ethyl ester (Z)-10 was investigated as a model substrate for the reduction reactions by 
Pichit Sudta earlier in the Kelso Lab. 2 was identified as the major product under each 
of the three conditions. Fe
0
 reduction yielded 81% of 2,  FeCl3/Zn reduction produced 
70% of 2, along with 21% of 2-OH, while NaBH4 / Pd/C produced 72% of 2 and no 2-
OH (Figure 3.1). 
Reductions were also investigated with the anilide derivative (Z)-29, which contained 
an aryl amide moiety like (Z)-1 (reactions were performed by me as part of my PhD). 
Under the three reduction conditions, (Z)-29 formed the desired cyclised products, 
although the ratios of 2 and 2-OH were different to those observed with (Z)-10. Fe
0
 
reduction yielded 32% of 2 and 35% of 2-OH, FeCl3/Zn reduction produced 58% of 2 
and 15% of 2-OH, while NaBH4 / Pd/C produced 20% yield of 2 and 56% of 2-OH 
(Figure 3.1). Overall, the yield of cyclised products was similar to (Z)-10, but the 




After results with (Z)-29 confirmed that spontaneous cyclisation could occur for aryl 
amides, the same reduction reactions were conducted with (Z)-1. Excitingly, all three 
reactions produced the desired cyclised SU5416 products, with the Fe
0
 reaction yielding 
51% of 2 and 28% of 2-OH,  the FeCl3/Zn reduction 50% of 2 and 24% of 2-OH, with 
NaBH4 / Pd/C 59% of 2 was obtained along with 21% of 2-OH (Figure 3.1, (Z)-1). 
These successful reductive cyclisations with (Z)-1 provided chemical proof-of-concept 
for the potential dual-activity of the compound in vivo, supporting further investigations 

















Figure 3.1. Summary of proof-of-concept chemical reduction reactions carried out with 
(Z)-10, (Z)-29 and (Z)-1. Isolated yields of SU5416 cyclised products 2 and 2-OH are 
shown. Reduction conditions: a. Fe/CH3COOH (blue), b. Zn/FeCl3 (red), c. Pd-
C/NaBH4 (green).  
 
3.4 Conclusions and Future Directions 
Work in this Chapter led to the successful synthesis of a prototype anti-tumour hypoxia-
activated codrug (Z)-1. A summary of the successful synthesis is provided in Scheme 
3.5. Overall, the route developed is satisfactory for producing useful quantities of (Z)-1, 
where the overall yield of 12% would be expected to give ~3 g of pure (Z)-1 over 7 




While the yields of steps (a) and (b) were moderate (71% and 70%, respectively), they 
were consistent on a multigram scale and the reactions were operationally simple. 
Recrystallisation from EtOH was successful for both 36 and 34 and no further 
purification was required. The aryl amine alkylation (b) was one shortcoming in the 
synthesis, taking at least 4 days to complete. Each of the other 6 steps was completed in 
less than 15 hours.  Alternative reaction conditions, such as use of microwave heating, 
use of other sources of ethanolamine such as oxirane
203
 or ethylene carbonate
204
 or the 
use of a Buchwald-Hartwig aryl cross coupling reaction
205
 to produce the key aryl 
amine moiety from a p-halo derivative of amide (Z)-29 could be explored. TBDMS 
protection in Step (c) was a facile reaction, with recrystallisation from pet. spirit 
yielding 86% of pure 8 after only 2.0 hours. 
The Knoevenagel reaction (d) was the lowest yielding step, producing 41% of (Z)-7 
when performed on 0.5 g scale. Unfortunately, isomerisation of pure (E)-7 to (Z)-7 was 
not high yielding, although further explorations are certainly recommended. (Z)-7 was 
also difficult to purify, requiring careful column chromatography to isolate it from the 
many streaking reactants and side products. Forming the alkene earlier in the synthesis 
using Route 1 would have been preferred, but problems with the acid (Z)-5 precluded 
this. New chemistry, which forms a higher yield of the desired isomer (Z)-7 from 8 
would improve the final yield of (Z)-1 significantly. 
Steps (e) to (g) all proceeded well, providing 67% yield of pure (Z)-1 over 3 steps from 
(Z)-7 with little isomerisation. Gratifyingly, (Z)-1 was an air stable solid at room 
temperature. While column chromatography steps were utilised here after each step 
simple extractions may be sufficient to advance the material through before a final 





Scheme 3.5. Summary of the successful synthesis of (Z)-1. Reagents and conditions; a. 
p-phenylenediamine, HBTU, DIPEA, CH2Cl2, rt, 4 h, 71%; b. 2-bromoethanol, K2CO3, 
50 
o
C, 5 days, 70%; c. TBDMSCl, imidazole, CH2Cl2, rt, 2 h, 86%; d. 9, K2CO3, 18-
crown-6, THF, 65 
o
C, 12 h, (Z)-7 41%, [+ (E)-7 22%]; e. 5:1 1.0M TBAF (in 
THF):AcOH, 0 
o
C to rt, 4 h, 85%; f. MsCl, TEA, CH2Cl2, 0 
o
C to rt, 1 h, 86%; g. LiCl 
(excess), DMF, 75 
o
C, (Z)-1 92%. 
 
(Z)-1 was shown to produce SU5416 2 and N-hydroxy-SU5416 2-OH upon chemical 
reduction under standard aryl nitro reduction conditions. This was a key milestone in 




success suggests that (Z)-1 has potential for hypoxia-selective activation in vivo and 
these investigations are the logical next step. The development of evofosfamide 
provides a blueprint of experiments for further study here.
167,171
 The first experiments 
on (Z)-1 should confirm selective activation in cell culture by hypoxic tumour cells. A 
simple protocol would be to perform two cell viability studies with (Z)-1 present, one 
under normoxic conditions and another with initial incubation under a low 
concentration of O2 to activate the scaffold.
171
 Hypoxia-selectivity could be further 
quantified by performing these studies with increasing O2 gas concentration, which 
should lower activation of (Z)-1.
167
 These experiments would give a hypoxic-cell 
selectivity index which could be used to guide further studies on the scaffold. 
Other experiments on (Z)-1 would explore its metabolic and plasma stability. These 
properties could easily be determined with commercially available human/mouse liver 
microsomes (hLM/mLM) and standard plasma stability assays. Metabolites identified 
could be used to guide modifications to the structure of (Z)-1 to reduce metabolism. 
Extensive SAR obtained during the development of sunitinib would provide guidance 
for predicting the effects of modifications to the aryl NO2 portion of (Z)-1.
206,207
 
The compound could also be modified to incorporate alternative alcohol or amine 
containing cytotoxins via ester or amide linkages. The Kelso Lab is currently targeting 
codrug 45, incorporating the antimetabolite 5-fluorodeoxyuridine (Floxuridine) as a 



























Chapter 4  
Synthesis and Evaluation of 2-Aryl-3H-













3H-Pyrrolizin-3-one 14 was the major product formed during attempted coupling 
reactions between (Z)-5 or (E)-5 and several amines and alcohols (Chapter 2.3). 
Couplings with HBTU/HATU and DIPEA, DCC/EDCI with or without DMAP in a 
variety of solvents all produced 14 and failed to yield any of the coupled amides/esters.  
It was proposed that heightened acidity of the pyrrole N-H, arising from its 
intramolecular H-bond to the carbonyl oxygen, was promoting deprotonation in the 
presence of DIPEA or carbodiimide coupling reagents and the resulting pyrrolate anion 
was cyclising onto the activated acid (Chapter 2.3; Figure 4.1(a)). Electron donation 
from the pyrrole nitrogen into the electron withdrawing 2-nitrophenyl and carboxylate 
moieties could increase single bond character of the alkenic double bond of (E)-5, 
promoting bond rotation and isomerisation from (E)-5 to (Z)-5, thus facilitating its 
transformation to 14 under coupling conditions (Chapter 2.4.2; Figure 4.1(b)). Trace 
quantities of 14 were usually observed during Knoevenagel condensations of 2-








Figure 4.1. (a) Mechanism of formation of 3H-pyrrolizin-3-one 14 from (Z)-5 under 
amide/ester coupling conditions. (b) Explanation for facile isomerisation of (E)-5 to (Z)-
5, which allowed formation of 14 from (E)-5. 
 
Few 3H-pyrrolizin-3-ones have been described in the literature and there is little known 
about their chemistry or biological activity. A SciFinder Scholar structure search on the 
3H-pyrrolizin-3-one core returned 277 references (11/06/15). Many of these described 
tricyclic pyrrolo-indolones, pyrrolo-isoindolones, tetracyclic isoindolo-indolones and 
other polycyclic heterocycles, rather than simple 3H-pyrrolizin-3-ones.
208,209
 Several of 







Figure 4.2. 3H-pyrrolizin-3-one-containing structures returned from a SciFinder 
Scholar search. 
 
McNab et al reported the synthesis of an acetoxymethyl-3H-pyrrolizin-3-one in 2 steps. 
The first involved reacting 3-acetoxymethyl-pyrrole-2-carboxaldehyde 46 with 
Meldrum’s acid to form condensation product 47. Flash vacuum pyrolysis (FVP) of 47 
at 600 
o
C then produced the 3H-pyrrolizin-3-one 48 (Scheme 4.1).
211–213
 FVP requires 
specialised glassware, high vacuum and high temperatures to carry out reactions. 





Scheme 4.1. Synthesis of (3-oxo-3H-pyrrolizin-7-yl)methyl acetate 48.
213
 Reagents and 








4.2 Development of a Divergent Synthesis of 3H-Pyrrolizin-3-ones 
Discovery of the novel class of angiogenesis inhibitors in Chapter 2 demonstrated that 
the indolin-2-one ring system of sunitinib and SU5416 was not essential for activity.
217
 
3H-pyrrolizin-3-ones carrying a pendant aryl ring at the 2-position retain many of the 
structural features of SU5416 and it was hypothesised that they may also exhibit anti-
angiogenic properties. This hypothesis led to exploration of the structure activity 
relationships of the class as angiogenesis inhibitors.  
The synthetic route that had serendipitously led to formation of 3H-pyrrolizin-3-one 14 
was a four-step process that involved: (1) esterification of 2-nitrophenylacetic acid 11 
with allyl alcohol to form 12, (2) Knoevenagel condensation between 12 and pyrrole 
aldehyde 9 to form (Z)-13 (with significant formation of (E)-13), (3) de-allylation of the 
cis-product (Z)-13 with Pd(PPh3)4 and (4) ring closing acylation of the pyrrole nitrogen 
under amide coupling conditions. Steps 2-4 required column chromatography to isolate 
the pure products. This route was considered too long and inefficient for a structure-
activity exploration of the anti-angiogenic properties of 2-aryl-3H-pyrrolizin-3-ones. A 
shorter, more divergent approach capable of providing rapid access to multiple 2-aryl-
3H-pyrrolizin-3-one analogues was desired. 
It was proposed that divergent access to the scaffold might be achievable through a one-
pot procedure from pyrrole aldehyde 4 and the many commercially available ring-
substituted phenylacetic acids. It had already been established that the K
+
 salt of 
aldehyde 4, generated using KH, was cleanly acylated with chloroformates (Chapter 
2.2). We hypothesised that this salt would also react with phenylacetic acids, which had 
been pre-activated with amide coupling reagents. A procedure was conceived wherein a 






salt of 4 generated in a separate flask. Mixing of the two flasks would trigger a cascade 
of reactions, starting with pyrrole-N-acylation, to give intermediate 49 (Scheme 4.2). 
Abstraction of a benzylic proton under the basic reaction conditions (excess KH) would 
then trigger an intramolecular Knoevenagel condensation, leading to formation of 3H-
pyrrolizin-3-ones. 
 
Scheme 4.2. Proposed one-step divergent synthesis of 2-aryl-3H-pyrrolizin-3-ones 
carrying substituents on the phenyl ring. LG = Leaving Group. 
 
The procedure was initially explored using unsubstituted phenylacetic acid 50, activated 
as the acid chloride, HOBt ester or carbodiimide derivative in CH2Cl2. The potassium 
salt of 4 was generated using 1.1 mol eq. of KH in THF. Reactions using carbodiimide 
coupling reagent DCC with 10% w/w 4-(dimethylamino)pyridine (DMAP) produced 






Bu reduced the yield to 18% (Table 4.1 entries 1 and 2).  Use of the carbodiimide 
reagent EDCI produced 51 in 17% yield (Table 4.1, Entry 3). 
Activation of 50 to the HOBt ester with HBTU/DIPEA showed more promise (37% 
yield, Table 4.1, Entry 4) and was explored further. Substitution of HBTU with HATU 
reduced the yield to 23%. The HOBt ester was formed using standard amide coupling 
conditions, where 2 mol eq. of DIPEA and 1 mol eq. of HBTU were used and stirred at 
RT in CH2Cl2. The potassium salt of pyrrole 4 was formed separately using 1.1 mol eq. 
of KH at 0 
o
C in THF. Rapid addition of the HOBt ester solution to the pyrrolate 
solution led to formation of the desired product 51. It was noted that slower addition or 
reverse addition resulted in slower reactions and lower yields.  
Exploration of the number of mol eq. of KH present in the reaction was studied in the 
Kelso lab by a German exchange student Claudia Ries in 2012. She identified that 2.0 
mol eq produced the highest yield of 51 (48%, Table 4.1, Entry 6). Under these 
conditions, 1.0 mol eq. of KH was generating the potassium salt of 4 and the second 1.0 
mol eq. was presumably acting to trigger the Knoevenagel condensation after mixing 
the two flasks and following pyrrole N-acylation. Changing from 2.0 mol eq. of KH to 
2.0 mol eq. of potassium hexamethyldisilazane (KHMDS) or KO
t
Bu under the 
conditions identified by Claudia reduced the yield to 38% in both cases (Table 4.1, 
Entries 7 and 8). Use of phenylacetyl chloride in place of the activated ester of 50 
resulted in a 32% yield of 51. The yield, however, was not reproducible and the 
reactions were much less convenient to carry out.  
It appeared that the yield was approaching a maximum of only 50%. One reason for this 
may have been the presence of the conjugate acid of DIPEA (formed during HOBt ester 




H2 gas through deprotonation of DIPEA.H
+
. This would leave less than 1.0 mol eq. of 
hydride available for the intramolecular Knoevenagel reaction, thereby reducing the 
yield. 
Table 4.1. Reactions and conditions explored for the one-pot synthesis of 3H-
pyrrolizin-3-one 51.  
 








 Yield 51 (%) 
1 DCC DMAP (0.1) KH (1.1) 24 
2 DCC DMAP (0.1) KO
t
Bu (1.1) 18 
3 EDCI DMAP (0.1) KH (1.1) 17 
4 HBTU DIPEA (2.0) KH (1.1) 37 
5 HATU DIPEA (2.0) KH (1.1) 23 
6 HBTU DIPEA (2.0) KH (2.0) 48 
7 HBTU DIPEA (2.0) KHMDS (2.0) 38 
8 HBTU DIPEA (2.0) KO
t
Bu (2.0) 38 
* Reactions were carried out using 1.0 mol eq. of phenylacetic acid 50 with 1.1 mol eq. 
of amide coupling reagent at RT and Base 1 and 1.0 mol eq. of pyrrole aldehyde 4 with 




 relative to 4 
+
 relative to 4 
 
The highest yield obtained for 51 was 48% using 1.1 mol eq. HBTU and 2.0 mol eq. 
DIPEA to activate 1.0 mol eq. phenylacetic acid 50 to the HOBt ester in Flask 1, and 




Flask 2, before pouring Flask 1 into Flask 2 in one portion. Yield improvements may be 
possible through use of an alternative activation process in Flask 1 that does not 
produce DIPEA.H
+
 (e.g. use of hydride as base), although this was not explored.  
Nevertheless, the reaction was suitable for the synthesis of small quantities of pure 2-
aryl-3H-pyrrolizin-3-ones for the SAR study. Accordingly, analogues carrying 
substituents at the phenyl ortho, meta and para positions were pursued using this 
chemistry with pyrrole aldehyde 4 and commercially acquired, ring-substituted 
phenylacetic acids. 
 
4.3. Synthesis of 2-Aryl-3H-Pyrrolizin-3-one Analogues 
Mono-substituted fluorophenyl (52-54), chlorophenyl (55-57), bromophenyl (58-60), 
tolyl (61-63), methoxyphenyl (64-66), and nitrophenyl acetic acids (11, 67-68) were 
acquired from Sigma Aldrich and submitted to the optimised procedure (Table 4.2). The 
reactions and product purification proceeded smoothly in most cases. The reactions 
were generally complete in less than 4 hours, after which they were evaporated to 
dryness, taken up in Et2O and washed with saturated sodium bicarbonate and brine, 
before being dried over anhydrous MgSO4 and concentrated. The crude products were 
purified by silica gel column chromatography using mixtures of pet. spirit and acetone 
as eluents. Visualisation of the products was possible during column chromatography 
due to their deep red or maroon colour, simplifying the procedure. 
The reactions were performed on 200-500 mg scale and the yields obtained were 
between 4% and 48%. Phenylacetic acids with larger ortho-substituents provided the 
lowest yields of 2-aryl-3H-pyrrolizin-3-ones (e.g. o-bromophenyl 75 13%, o-




may have been due to steric hindrance hampering the Knoevenagel reaction at the 
neighbouring benzylic position. Meta-substituted products were obtained in the highest 
yields (e.g. m-fluorophenyl 70 37%, m-chlorophenyl 72 35% and m-bromophenyl 76 
44%; Table 4.2). Para-substituted products were also produced in reasonable yields 
(e.g. p-fluorophenyl 71, p-chlorophenyl 74 and p-bromophenyl 77 were synthesised in 
38%, 30% and 34% yields, respectively; Table 4.2). 
Electron-withdrawing substituents that increased acidity at the benzyl position resulted 
in lower yields (e.g. 28% and 4% yield for o-nitro 14 and p-nitro 85, respectively). 
Electron donating substituents appeared to favour the reaction. o-Methoxyphenyl 
derivative 81 was the second highest yielding ortho-substituted 3H-pyrrolizin-3-one at 
45% (Table 4.2. Entry 14). One possible explanation for these results is that activated 
acids with more acidic benzylic protons favoured neutralisation of the potassium 













Table 4.2. Synthesis of 2-aryl-3H-pyrrolizin-3-ones. 
 
Entry Phenylacetic acid R1 R2 R3 Product Yield, % 
1 50 H 
F 
H 
H H 51 48 
2 52 H H 69 37 
3 53 F H 70 37 
















H F 71 38 
5 55 H H 72 16 
6 56 Cl H 73 35 
7 57 H Cl 74 30 
8 58 H H 75 13 
9 59 Br H 76 44 
10 60 H Br 77 34 
11 61 H H 78 21 
12 62 Me H 79 41 
13 63 H Me 80 37 
14 64 H H 81 33 
15 65 OMe H 82 45 
16 66 H OMe 83 30 
17 11 H H 14 28 
18 67 NO2 H 84 15 









4.4 Biological Assessment of Mono-Substituted 2-Aryl-3H-pyrrolizin-3-ones 
 4.4.1 HUVEC Tube Formation Assay 
Anti-angiogenesis activity of the nineteen 3H-pyrrolizin-3-ones was examined using a 
semi-quantitative, cell-based endothelial tube formation assay with human umbilical 
vein endothelial cells (HUVECs).
218
 HUVECs extracted from umbilical veins are 
commonly used for models of angiogenesis as they are easy to culture and sensitive to 
growth factors, such as EGF and FGF. Matrix-cultured HUVECs differentiate in 
response to growth factors, becoming elongated and motile and able to self-organise 
into capillary-like structures over a period of 2-12 hours. This process is disrupted by 
small molecule RTK inhibitors of angiogenesis, making it a convenient model for 
measurements of angiogenesis inhibition.
219
 Representative time-lapse images showing 
various stages of pro-angiogenic tube formation by EA.hy926 cells (HUVEC/A549 
hybrid cell line) are shown in Figure 4.3.
218
 
Quantification of angiogenesis and the inhibitory effects of compounds uses the method 
reported by Aranda et al.
218
 An image of the cells is captured and the cells are tallied 
and categorised as ellipsoid (i.e. undifferentiated, Figure 4.3. Image 1), sprouting (i.e. 
differentiating, Figure 4.3, Image 2) or connected to other cells (Figure 4.3, Images 3 
and 4). The total number of closed polyhedra (Figure 4.3, Images 5 and 6) are also 
counted, along with ‘complex meshes’, which are polyhedra containing walls more than 
2 cells thick (Figure 4.3, Images 7 and 8).  
The numerator of an equation is calculated by summing the number of sprouting  cells 
and the number of connected cells multiplied by a factor of 2 and the number of 
polygons multiplied by a factor of 3. The denominator of the equation is the total 
number of cells, including undifferentiated cells.
218




to account for ‘complex meshes’, which represent extensive angiogenesis. A score of 0 
is added for no complex meshes, 1 for at least one polyhedra with walls of 2-4 cells 
thick or 2 for at least one polyhedra with walls of 4+ cells thick.  
Assays were conducted with adherent HUVEC cells (C-003-5C, Life Technologies), 
cultured according to the manufacturer’s specifications in 75 cm
3
 flasks and utilised 
between passages 2-4. Tube formation was monitored in Geltrex matrix (Life 
Technologies) according to manufacturer’s specifications in standard flat-bottomed 
plates using a 24 well format. The cells were seeded at 3.5–4.5× 10
4
 cells per Geltrex-
coated well and incubated for 2 hours at 37 
o
C in 5% CO2/air. Compounds were 
solubilised in DMSO to form stock solutions at 100 µM. Aliquots were added to each 
well to give a final concentration of 10 µM with 1% DMSO. After 8 hours, the media 
was removed and replaced with sterile PBS buffer prior to imaging by light microscopy. 
Three to six images were taken and scored for each well over two independent assays, 
giving a total of 6-10 counts for each compound. 1% DMSO was used as a negative 
control (vehicle) and 10 µM sunitinib as a positive control (inhibition). Angiogenesis 
was indicated by the angiogenesis score relative to the negative control (vehicle) i.e. a 















                  
                                                   
                
 
Figure 4.3. (a) Representative images of EA.hy926 cells during the angiogenic tube 
formation process.
218




The assay showed that the original ortho-NO2-substituted analogue 14 was the most 
potent angiogenesis inhibitor and that most other substitutions were not well-tolerated. 
Compound 14 produced a score that was 29.7% ± 4.1 of the angiogenesis score 
observed with vehicle at 10 µM and 74.0% ± 12.6 of the vehicle score at 1 µM. The 
next most potent compounds were the unsubstituted phenyl derivative 51 (68.4% ± 6.6 
of vehicle) and 2-fluorophenyl 69 (67.2% ± 6.2 of vehicle). The o-methoxyphenyl 81, 
o-bromophenyl 75 and o-tolyl 78 analogues produced modest reductions in 
angiogenesis. All other derivatives were essentially inactive. The positive control 










Figure 4.4. (a). Inhibition angiogenesis in an endothelial tube formation assay by 2-
aryl-3H-pyrrolizin-3-one derivatives and controls. Compounds were present at 10 µM. 
Data for 14, the most potent compound, is shown in red and is also provided at 1 µM. 
(b) Representative images showing degree of angiogenesis evident with the 2-
fluorophenyl analogue 69 (left) and the more potent inhibitor 14 (right, both compounds 





4.4.2. Rat Aortic Ring Angiogenesis Assay 
The two most potent angiogenesis inhibitors 2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14 
and 2-phenyl-3H-pyrrolizin-3-one 51 were submitted to the more physiologically 
relevant (though more expensive and labour intensive) rat aortic ring angiogenesis assay 
to confirm their angiogenesis inhibition activities (see Chapter 2.7 for assay details).  
Compound 14 showed a similar inhibitory potency to the SU5416 in the assay, 
producing 4% F.O.V. occupancy at 10 µg/mL (c.f. 10% for SU5416 at 10 µg/mL). 
Compound 14 also showed a dose-dependent response, producing 1% F.O.V. 
occupancy at 100 µg/mL. The unsubstituted phenyl derivative 51 potently inhibited 
angiogenesis at 10 µg/mL (12% F.O.V. occupancy) but solubility issues similar to those 
of SU5416 2 (see Chapter 2.7) appeared to interfere with its activity at the higher 
concentration of 100 µg/mL (21% F.O.V. occupancy). These results corroborated those 
observed in the endothelial tube formation assay, confirming that 14 and 51 are new 
anti-angiogenic leads. 
 




4.5 Conclusions and Future Directions 
The chemistry and biological activity of the serendipitously discovered 2-aryl-3H-
pyrrolizin-3-one 14 and related analogues was investigated in this chapter. The crystal 
structure of 14 was determined by X-ray analysis, revealing a preferred orientation 
where the carbonyl oxygen makes a favourable interaction with the NO2 nitrogen 
(Chapter 2.3). The 2-nitrophenyl-3H-pyrrolizin-3-one 14 was shown to be a potent 
inhibitor of angiogenesis in both the endothelial tube formation assay (29.7% of vehicle 
angiogenesis at 10 µM) and the rat aortic ring angiogenesis assay (4% F.O.V. 
occupancy at 10 µg/mL).  
A divergent synthesis of analogues of 14 was developed using commercially available 
mono-substituted phenylacetic acids and pyrrole aldehyde 4. While usable quantities of 
all analogues were obtained there is much scope for improving the yields. Eighteen 
analogues of 14 were synthesised and tested for anti-angiogenic properties in the 
endothelial tube formation assay. Compound 14, the ortho-fluoro compound 69 and 
unsubstituted phenyl derivative 51 showed the strongest inhibition of angiogenesis, 
while the other analogues were essentially inactive. Based on the results from this assay, 
compounds 14 and 51 were advanced to the more sophisticated and physiologically 
relevant rat aortic ring angiogenesis assay to confirm their anti-angiogenic properties. 
Both compounds showed strong inhibitory effects in this assay, confirming that 2-aryl-
3H-pyrrolizin-3-ones represent a new class of angiogenesis inhibitors.  
There are several biochemical pathways that affect angiogenesis. Screening 14 and 51 
against a panel of angiogenesis-modulating RTKs would shine light on the specific 




inhibited receptors would be vital for supporting lead optimisation studies. Key 
receptors to test against would be the VEGFR and EGFR families of RTKs. 
Very little is known about the chemistry of 2-aryl-3H-pyrrolizin-3-ones like 14 and 51. 
Derivatisation at the β-alkene position could be interesting for continuing angiogenesis 
inhibitor development since modifications at the phenyl ring appeared to be poorly 
tolerated. Work from the McNab lab identified reactivity at this position, suggesting it 
may be possible to introduce nucleophiles directly onto 14 and 51.
215
 Introducing a 






























Reagents and solvents were used without further purification unless otherwise stated. 
Dichloromethane (CH2Cl2), dimethylformamide (DMF), toluene and diethyl ether 
(Et2O) were used directly from a PureSolv Solvent purification system. THF was 
purified by drying over KOH before distillation from sodium benzophenone ketyl. 
Compounds were weighed using a Sartorius Extend 220g or OHaus Adventurer 
balance. Solvents were removed under reduced pressure (in vacuo) at rt - 40 
o
C using a 
Heidolph or Büchi rotary evaporator with Vacuubrand pumps. Solvent residues were 
removed in vacuo using a Javac Vector RD-90 double stage high vacuum pump. 
Analytical thin layer chromatography (TLC) analysis was performed using Merck 0.2 
mm silica gel 60 F254 coated aluminium plates. Compounds were visualised on TLC 
plates under UV light (254 nm). Column chromatography was performed on Merck 
silica gel 60 (230-400 mesh). Low resolution electrospray (ESI) mass spectra were 
obtained using a Shimadzu LCMS-2010EV spectrometer. ESI High Resolution Mass 
Spectra (HRMS) were obtained on a Xevo QToF mass spectrometer with 
perfluorokerosene as internal standard. Fourier-Transform Infrared (FTIR) spectra were 




C and two-dimensional (2D) NMR experiments were performed using a Varian Inova 
500 MHz or Varian Premium Shielded 500 MHz spectrometer at 25 
o
C. Chemical shifts 
are reported as δ (ppm) relative to internal TMS (
1
H) or solvent (
13
C) unless stated 
otherwise. The abbreviations s = singlet, d = doublet, t = triplet, q = quartet, dd = 







5.2 Compound Characterisation 
 (E)-2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-((4-(dimethylamino)phenyl)imino)-3H-indole 1-
oxide 15 
To a solution of (E)-5 (201 mg, 0.70 mmol) in CH2Cl2 (10 mL) was added HATU (372 
mg, 0.98 mmol). The solution was stirred at room temperature for 5 minutes before 
adding N,N-dimethyl-p-phenylenediamine (DMPD, 95.3 mg, 0.70 mmol) in one 
portion. The reaction was then stirred at room temperature and monitored by TLC 
analysis (3:7 EtOAc:pet. spirit). After 3 h, the mixture was extracted with EtOAc (3 x 
25 mL) and the combined organic phase washed with brine (2 x 25 mL), dried over 
anhydrous MgSO4 and concentrated. The residue was purified by column 
chromatography (100% pet. spirit to 8:2 pet. spirit:EtOAc) to give 15 (100 mg, 40% 
yield) as a dark purple solid. Use of the same procedure with (Z)-5 resulted in similar 





H NMR (CDCl3, 500 MHz): δ 2.33 (s, 3H, 
H1), 2.51 (s, 3H, H2), 3.04 (s, 6H, H5), 5.96 (d, 1H, J = 3.0 
Hz, H3), 6.80 (d, 2H, J = 8.5 Hz, H6), 7.05 (d, 2H, J = 9.0 Hz, 
H7), 7.08 (t, 1H, J = 7.5, H9), 7.12 (d, 1H, J = 7.5, H8), 7.45 (t, 
1H, J = 7.5 Hz, H10), 7.63 (d, 1H, J = 7.5 Hz, H11), 11.86 (s 
(br), 1H, H4). 
13
C NMR (CDCl3, 126 MHz): δ 13.5 (C1), 16.5 (C2), 40.7 (C5), 112.6 
(C6), 112.7 (C15), 112.9 (C11), 113.7 (C3), 117.0 (C18), 119.0 (C13), 121.5 (C7), 123.7 
(C8), 128.0 (C9), 128.5 (C19), 131.8 (C10), 132.3 (C20), 139.3 (C17), 147.9 (C12), 149.2 
(C16), 154.8 (C14). HRMS-ESI: m/z calcd for C22H23N4O [M+H
+
] 359.1872; observed 
359.1868. FTIR: neat (cm
-1





(E)-3-((4-aminophenyl)imino)-2-(3,5-dimethyl-1H-pyrrol-2-yl)-3H-indole 1-oxide 16 
Use of p-phenylenediamine in place of N,N-dimethyl-p-
phenylenediamine in the procedure described for producing 
15 afforded 16 (56% yield) as a dark amorphous solid. 
1
H 
NMR* (CDCl3, 500 MHz): δ 2.32 (s, 3H, H1), 2.51 (s, 3H, 
H2), 3.70 (v. br, 2H, H5), 5.95 (s, 1H, H3), 6.76 (d, 2H, J = 8.5 
Hz, H6), 6.90 (d, 2H, J = 8.5 Hz, H7), 6.95 (d, 1H, J = 7.5 Hz, H8), 7.05 (t, 1H, J = 7.5 
Hz, H9), 7.43 (t, 1H, J = 7.5 Hz, H10), 7.60 (d, 1H, J = 7.5 Hz, H11), 11.79 (br s, 1H, H4). 
13
C NMR (CDCl3, 126 MHz): δ 13.4 (C1), 16.4 (C2), 113.0 (C11), 113.8 (C3), 115.6 (C6), 
117.0 (C18), 118.8 (C13), 120.69 (C7), 124.1 (C8), 127.7 (C9), 128.8 (C19), 132.0 (C10), 
132.6 (C20), 134.1 (C17), 141.4 (C16), 144.7 (C15), 148.0 (C12), 156.1 (C14). HRMS-ESI: 
m/z calcd for C20H19N4O [M+H
+
] 331.1553; observed 331.1551. * NMR peaks were 
taken from an impure sample due to the compound’s instability. Melting point and 
coherent FTIR data could not be obtained due to the compound’s instability. 
 
2-(3,5-dimethyl-1H-pyrrol-2-yl)-3-oxo-3H-indole 1-oxide 17 
To a solution of 0.05 g 15 or 16 (0.14 mmol or 0.15 mmol, respectively) in THF (2 mL) 
was added 2 mL of 1 M HCl. The reaction was stirred at rt and monitored by TLC 
analysis (7:3 pet. spirit:EtOAc). After 30 minutes, the mixture was extracted with 
EtOAc (2 x 25 mL). The combined organic phase was washed with saturated NaHCO3 
(2 x 30 mL) and brine (2 x 30 mL), dried anhydrous MgSO4 and concentrated to give 17 





H NMR (CDCl3, 500 MHz): δ 2.32 (s, 3H, H1), 2.50 (s, 3H, H2), 5.97 




11.64 (br s, 1H, H4). 
13
C NMR (CDCl3, 126 MHz): δ 13.5 
(C1), 15.0 (C2), 112.8 (C8), 114.4 (C3), 117.1 (C13), 121.9 
(C5), 122.4 (C10), 129.0 (C6), 129.3 (C14), 129.7 (C12), 133.6 
(C15), 135.2 (C7), 148.8 (C9), 185.3 (C11). HRMS-ESI: m/z calcd for C14H13N2O2 
[M+H
+
] 241.0972; observed 241.0972. FTIR: neat (cm
-1
) 3281, 2918, 1727, 1576, 1522, 
1461, 1458, 1370, 1329, 1265, 1208, 1117, 1065. 
 
(E)-3,5-dimethyl-2-(2-nitrostyryl)-1H-pyrrole 18 
Compound 18 was isolated as a trace product from the reactions used to produce 16 and 
by rt storage of (Z)-5 in CDCl3 over 2 weeks.  
M.P. and FTIR not recorded due to scarcity and lack of purity 
of product. 
1
H NMR (CDCl3, 500 MHz): δ 2.16 (s, 3H, H1), 
2.29 (s, 3H, H2), 5.79 (s, 1H, H3), 6.97 (d, 1H, J = 16.1 Hz, 
H5), 7.04 (d, 1H, J = 16.1 Hz, H6), 7.27 (t, 1H, J = 7.5 Hz, H9), 
7.53 (t, 1H, J = 7.5 Hz, H8), 7.74 (d, 1H, J = 8.0 Hz, H7), 7.90 (d, 1H, J = 8.0 Hz, H10).
 
13
C NMR (CDCl3, 126 MHz): δ 11.1 (C1), 13.2 (C2), 110.3 (C3), 113.0 (C6), 122.2 (C5), 
123.3 (C13), 123.9 (C15), 125.0 (C10), 125.6 (C14), 126.2 (C9), 126.7 (C7), 131.1 (C12), 





(Z)- and (E)-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)-N-phenylacrylamide 
(Z)-29 and (E)-29 
To a dry round-bottom flask under N2 was added 2-(2-nitrophenyl)-N-phenylacetamide 




crown-6 (1.139 g, 4.31 mmol) and dry THF (20 mL). After stirring at 70 
o
C for 1 h a 
brown to dark blue solution appeared. 1-methoxycarbonyl-5-dimethyl-1H-pyrrole-2-
carboxaldehyde 9 (0.820 g, 4.52 mmol. Prepared as per Sudta, et al.)
217
 dissolved in dry 
THF (8 mL) was added dropwise over 15 minutes and the mixture stirred at 70 
o
C for a 
further 10 h. The reaction was quenched with water (30 mL) and evaporated to dryness. 
The residues were taken up in EtOAc (50 mL) and washed with saturated NaHCO3 (2 x 
50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 and concentrated. The 
crude product was purified by silica gel column chromatography (100% pet. spirit to 8:2 
pet. spirit:acetone) to provide (Z)-29 (0.591 g, 38% yield) as an orange-red solid, (E)-29 
(0.405, 26% yield) as a red oil and trace quantities of N-phenyl-SU5416 33 (typically 2-
5% yield). 





(CDCl3, 500 MHz): δ 2.12 (s, 3H, H1), 2.32 (s, 3H, H2), 5.86 
(s, 1H, H3), 6.56 (s, 1H, H5), 6.87 (br s, 1H, H9), 7.12 (t, 1H, 
J = 7.5 Hz, H6), 7.32 (t, 2H, J = 7.5 Hz, H7), 7.37 (t, 2H, J = 
7.5 Hz, H8), 7.56 (t, 1H, J = 8.0 Hz, H12), 7.60 (d, 1H, J = 
8.0 Hz, H10), 7.71 (t, 1H, J = 8.0 Hz, H11), 8.03 (d, 1H, J = 8.0 Hz, H13), 12.00 (br s, 
1H, H4). 
13
C NMR (CDCl3, 126 MHz): δ 11.4 (C1), 13.6 (C2), 111.1 (C3), 115.6 (C16), 
121.4 (C8), 124.1 (C18), 124.9 (C6, C13), 129.0 (C7), 129.1 (C12), 130.1 (C19), 133.48 
(C11), 133.52 (C10), 133.8 (C20), 135.8 (C15), 137.4 (C21), 149.7 (C14), 166.2 (C17). 
HRMS-ESI: m/z calcd for C21H20N3O3 [M+H
+
] 362.1499; observed 362.1501. FTIR: 
neat (cm
-1
) 3400, 1650, 1595, 1592, 1518, 1498, 1436, 1362, 1352, 1318, 1229, 1188, 






(E)-29. Red oil. 
1
H NMR* (CDCl3, 500 MHz): δ 1.92 (s, 3H, 
H1), 2.13 (s, 3H, H2), 5.70 (s, 1H, H3), 6.47 (br s, 1H, H9), 
7.04 (t, 1H, J = 7.0 Hz, H6), 7.14 (br s, 1H, H4), 7.24 (t, 2H, 
J = 7.5 Hz, H7), 7.43 (d, 2H, J = 8.0 Hz, H8), 7.57 (d, 1H, J 
= 7.5 Hz, H10), 7.68 (s, 1H, H5), 7.75 (t, 1H, J = 7.5 Hz, 
H11), 7.66 (m, 1H, H12), 8.13 (d, 1H, J = 8.0 Hz, H13). 
13
C 
NMR (CDCl3, 126 MHz): δ 11.2 (C1), 13.1 (C2), 110.6 (C3), 118.9 (C16), 120.4 (C8), 
123.3 (C19), 124.1 (C6), 125.1 (C5), 125.4 (C13), 128.7 (C7), 129.6 (C20), 130.3 (C12), 
131.5 (C15), 133.5 (C21), 133.8 (C10), 134.3 (C11), 138.0 (C18), 149.4 (C14), 165.0 (C17). 
HRMS-ESI: m/z calcd for C21H20N3O3 [M+H
+
] 362.1499; observed 362.1503. *Peaks 
obtained from impure sample. 
33. Yellow oil. 
1
H NMR (CDCl3, 500 MHz): δ 2.33 (s, 3H, 
H2), 2.36 (s, 3H, H1), 5.98 (s, 1H, H3), 6.83 (m, 1H , H12), 
7.11 (m, 2H, H10/H11), 7.43 (t, 1H, J = 7.5 Hz, H6), 7.45 (d, 
2H, J = 7.0 Hz, H8), 7.50 (s, 1H, H5), 7.57 (m, 3H, H7/H9), 
13.06 (br s, 1H, H4). 
13
C NMR (CDCl3, 126 MHz): δ 11.7 
(C1), 13.9 (C2), 109.0 (C12), 111.2 (C15), 112.8 (C3), 117.1 
(C9), 122.0 (C10), 123.7 (C5), 125.4 (C11), 125.6 (C14), 127.1 (C8), 127.1 (C18), 127.9 
(C6), 129.6 (C7), 132.8 (C19), 135.1 (C17), 137.2 (C20), 139.7 (C13), 168.0 (C16). HRMS-
ESI: m/z calcd for C21H19N2O [M+H
+







(Z)- and (E)-N-benzyl-3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide (Z)-
30 and (E)-30. 
Protocol as per 29, using 2-(2-nitrophenyl)-N-benzylacetamide 24 in place of 23.  




H NMR (CDCl3, 500 MHz): δ 2.09 (s, 3H, H1), 2.31 (s, 
3H, H2), 4.50 (d, 2H, J = 6.0 Hz, H9), 5.50 (br s, 1H, H10), 
5.83 (s, 1H, H3), 6.48 (s, 1H, H5), 7.20 (d, 2H, J = 8.0 Hz, 
H8), 7.22 (m, 1H, J = 7.0 Hz, H6), 7.28 (t, 2H, J = 7.5 Hz, 
H7), 7.47 (m, 1H, J = 8.0 Hz. H13), 7.49 (m, 1H, J = 6.5 Hz, H11), 7.61 (t, 1H, J = 7.5 
Hz, H12), 7.94 (d, 1H, J = 8.5 Hz, H14), 12.21 (br s, 1H, H4). 
13
C NMR (CDCl3, 126 
MHz): δ 11.3 (C1), 13.6 (C2), 43.9 (C9), 110.7 (C3), 115.8 (C17), 124.0 (C20), 124.7 
(C14), 127.33 (C8), 127.34 (C6), 128.3 (C5), 128.6 (C7), 128.9 (C13), 129.2 (C21), 133.1 
(C22), 133.3 (C12), 133.4 (C11), 136.0 (C16), 138.0 (C19), 149.5 (C15), 167.6 (C18). 
HRMS-ESI: m/z calcd for C22H22N3O3 [M+H
+
] 376.1656; observed 376.1667. FTIR: 
neat (cm
-1
) 3435, 1643, 1570, 1543, 1507, 1453, 1362, 1341, 1316, 1237, 1217, 1150. 
 
(E)-30. < 5%, red amorphous solid (impure). 
1
H NMR 
(CDCl3, 500 MHz): δ 1.92 (s, 3H, H1), 2.15 (s, 3H, H2), 
4.46 (d, 2H, J = 6.0 Hz, H9), 5.50 (br s, 1H, H10), 5.69 (s, 
1H, H3), 6.36 (br s, 1H, H4), 7.20-7.33 (m, 5H, H8-10), 
7.54 (d, 1H, J = 7.0 Hz, H11), 7.67 (m, 2H, H5,13), 7.74 (t, 
1H, J = 7.5 Hz, H12), 8.14 (d, 1H, J = 8.5 Hz, H14). Note: owing to impurities, the 
chemical shift of the pyrrolic N-H signal could not be assigned unambiguously. 
13
C 
NMR (CDCl3, 126 MHz): δ 11.3 (C2), 13.1 (C1), 43.9 (C9), 110.4 (C3), 118.6 (C17), 




(C16), 132.9 (C22), 133.4 (C12), 133.8 (C11), 138.0 (C19), 149.7 (C15), 166.7 (C18). 
Melting point and coherent FTIR not obtained due to impurity. HRMS-ESI: m/z calcd 
for C22H22N3O3 [M+H
+
] 376.1656; observed 376.1677. 
 
N,N-bis(2-hydroxyethyl)-4-nitroaniline 37 
p-Fluoronitrobenzene (1.250 g, 8.86 mmol) and freshly 
distilled diethanolamine (0.767 g,  7.30 mmol) were added 
to a roundbottom flask under N2. The reaction was stirred at 
100 
o
C for 12 h, until consumption of starting material was observed by TLC analysis 
(EtOAc). The crude reaction mixture was diluted in EtOAc (50 mL) and washed with 
saturated NaHCO3 (3 x 50 mL) and brine (3 x 50 mL). The organic layer was 
concentrated in vacuo and then recrystallised from MeOH/water to give 37 (1.27 g, 77% 






TBDMSCl (80.0 mg, 0.53 mmol) and imidazole (78.4 mg, 1.15 mmol) were added to a 
roundbottom flask and stirred for 5 min in CH2Cl2 (5 mL). To the stirring solution was 
then added a solution containing N,N-bis(2-hydroxyethyl)-4-nitroaniline 37 (50.0 mg, 
0.22 mmol)  CH2Cl2 (5 mL) over 5 minutes. The reaction was stirred for 20 h, 
monitored by TLC analysis (EtOAc). The reaction was diluted with CH2Cl2 (20 mL) 
and cooled to -18 
o
C for 1 h. The precipitate was filtered off and the filtrated collected 
and added to a separating funnel. The organic phase was washed with saturated 




and the residue purified by silica gel column 
chromatography (1:1 EtOAc:pet. spirit) to give 38 (72.8 
mg, 72% yield) as a dark yellow crystalline product. 






2-nitrophenylacetic acid (5.065 g, 28.0 mmol), p-phenylenediamine (3.333 g, 30.8 
mmol) and HBTU (11.694 g, 30.8 mmol) were stirred in a roundbottom flask with 
CH2Cl2 (50 mL) under N2 at 0
o
 C. DIPEA (10.7 mL, 61.4 mmol) was then added 
dropwise over 5 minutes to the stirring solution and the reaction allowed to warm to rt 
and stirred for 4 h with monitoring by TLC (EtOAc). The reaction was diluted with 
CH2Cl2 (100 mL), added to a separating funnel and extracted with 1 M hydrochloric 
acid (3 x 50 mL). The combined aqueous acidic phase was washed with CH2Cl2 (3 x 50 
mL), removing a white precipitate. The combined acidic aqueous phase was neutralised 
using 1 M sodium hydroxide resulting in an off-white precipitate. The solid was filtered, 
washed with cold water and dried in vacuo afford 36 (5.70 g, 75% yield) as an off-white 
solid. Product purity could be increased by recrystallisation from hot EtOH. While 
compound 36 is commercially available (e.g. Aurora Building Blocks), no 





H NMR (d6-DMSO, 500 MHz): δ 4.03 
(s, 2H, H5), 4.82 (s, 2H, H1), 6.48 (d, 2H, J = 9.0 Hz, H2), 
7.16 (d, 2H, J = 9.0 Hz, H3), 7.53 (m, 2H, H6,8), 7.68 (t, 






C NMR (d6-DMSO, 126 MHz):  δ 40.7 (C5), 113.8 (C2), 120.9 (C3), 124.5 
(C9), 128.2 (C8,13), 130.9 (C11), 133.4 (C6), 133.5 (C7), 144.8 (C14), 149.2 (C10), 166.4 
(C12). HRMS-ESI: m/z calcd for C14H14N3O3 [M+H
+
] 272.1031; observed 272.1035. 
FTIR: neat (cm
-1
) 3344, 1684, 1517, 1424, 1410, 1357, 1307, 1275, 1237, 1175. 
 
N-(4-(bis(2-hydroxyethyl)amino)phenyl)-2-(2-nitrophenyl)acetamide 34 
N-(4-aminophenyl)-2-(2-nitrophenyl)acetamide 36 (1.902 g, 7.01 mmol) was added to a 
roundbottom flask along with anhydrous K2CO3 (1.750 g, 12.7 mmol) under N2. 2-
bromoethanol (15 mL) was added and the reaction mixture stirred at 50 
o
C for 5 days, or 
until complete consumption of starting material was observed by TLC analysis 
(EtOAc). The reaction mixture was concentrated and the residue taken up in EtOAc (50 
mL). The organic phase was washed with brine (3 x 50 mL), dried over anhydrous 
MgSO4 and evaporated to dryness. The crude residue was recrystallised from hot EtOH 





H NMR (d6-DMSO, 500 
MHz): δ 3.35 (t, 4H, J = 6.5 Hz, H3), 3.50 (q, 4H, 
J = 6.5 Hz, H2), 4.04 (s, 2H, H7), 4.69 (t, 2H, J = 
5.5 Hz, H1), 6.60 (d, 2H, J = 9.0 Hz, H4), 7.29 (d, 
2H, J = 9.0 Hz, H5), 7.53 (m, 2H, H8,9), 7.68 (t, 1H, J = 7.5 Hz, H10), 8.02 (d, 1H, J = 
8.0 Hz, H11), 9.82 (s, 1H, H6). 
13
C NMR (d6-DMSO, 126 MHz):  δ 40.0 (C7), 53.7 (C3), 
58.5 (C2), 111.6 (C4), 121.2 (C5), 124.8 (C11), 128.1 (C15), 128.5 (C10), 131.2 (C13), 
133.7 (C8), 133.8 (C9), 144.7 (C16), 149.5 (C12), 166.8 (C14). HRMS-ESI: m/z calcd for 
C18H22N3O5 [M+H
+
] 360.1554; observed 360.1559. FTIR: neat (cm
-1
) 3276, 1653, 






To to a roundbottom flask was added N-(4-(bis(2-hydroxyethyl)amino)phenyl)-2-(2-
nitrophenyl)acetamide 34 (1.400 g, 3.90 mmol), TBDMSCl (2.046 g, 13.6 mmol) and 
imidazole (2.3369 g, 34.3 mmol), along with CH2Cl2 (30 mL). The reaction was stirred 
at rt for 2 h or until complete consumption of starting material was observed by TLC 
analysis (7:3 pet. spirit:EtOAc). The reaction was diluted with CH2Cl2 (50 mL) and 
cooled to -18 
o
C for 2 h. The precipitated solids were removed by gravity filtration and 
the filtrate added to a separating funnel. The organic phase was washed with saturated 
NaHCO3 (5 x 50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 and 
concentrated. The crude residue was recrystallised from pet. spirit (-18 
o
C, overnight) to 






H NMR (CDCl3 500 
MHz): δ 0.02 (s, 12H, H2), 0.88 (s, 18H, 
H1), 3.46 (t, 4H, J = 6.5 Hz, H4), 3.71 (t, 
4H, J = 6.5 Hz, H3), 3.96 (s, 2H, H8), 
6.60 (d, 2H, J = 9.0 Hz, H5), 7.27 (d, 2H, 
J = 9.0 Hz, H6), 7.45 (t, 1H, J = 7.5 Hz, H11), 7.56 (br s, 1H, H7), 7.57 (d, 1H, J = 7.5 
Hz, H9), 7.61 (t, 1H, J = 7.5 Hz, H10), 8.04 (d, 1H, J = 8.0 Hz, H12). 
13
C NMR (CDCl3, 
126 MHz): -5.4 (C2), 18.2 (C18), 25.9 (C1), 41.6 (C8), 53.7 (C4), 60.3 (C3), 111.6 (C5), 
122.1 (C6), 125.1 (C12), 126.5 (C16), 128.4 (C11), 130.4 (C14), 133.4 (C9), 133.6 (C10), 
145.3 (C17), 148.9 (C13), 166.7 (C15). HRMS-ESI: m/z calcd for C30H50N3O5Si2 [M+H
+
] 
588.3284; observed 588.3289. FTIR: neat (cm
-1
) 2950, 1682, 1653, 1528, 1517, 1343, 





dimethyl-1H-pyrrol-2-yl)-2-(2-nitrophenyl)acrylamide (Z)-7 and (E)-7 
N-(4-(bis(2-((tert-butyldimethylsilyl)oxy)ethyl)amino)phenyl)-2-(2-
nitrophenyl)acetamide 8 (1.150 g, 1.96 mmol), oven-dried anhydrous K2CO3 (0.366 g, 
2.65 mmol) and 18-crown-6 (0.6657 g, 2.52 mmol) were added to a three-necked 
roundbottom flask and dissolved in 15 mL of THF under N2. The reaction was stirred at 
65 
o
C for 1 h giving a brown to light blue coloured solution. 1-methoxycarbonyl-5-
dimethyl-1H-pyrrole-2-carboxaldehyde 9 (0.4650 g, 2.57 mmol) in dry THF (10 mL) 
was then added dropwise over 15 minutes to the stirring solution. The reaction was 
heated at 65 
o
C for a further 12 h. After quenching with water, the reaction was 
extracted with EtOAc (2 x 50 mL) and the combined organic phase washed with 
saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over anhydrous MgSO4 
and concentrated. The crude residue was purified by silica gel column chromatography 
(100% pet. spirit to 8:2 pet. spirit:EtOAc) affording (Z)-7 (0.56 g, 41% yield) as a red 
amorphous solid and (E)-7 (0.30 g, 22% yield) as a red oil, along with trace amounts of 
the N-arylindolin-2-one 41. 




H NMR (CDCl3, 500 
MHz): δ 0.03 (s, 12H, H5), 0.88 (s, 18H, H4), 
2.10 (s, 3H, H2), 2.28 (s, 3H, H1), 3.46 (t, 4H, J 
= 6.5 Hz, H7), 3.71 (t, 4H, J = 6.5 Hz, H6), 5.82 
(s, 1H, H3), 6.51 (s, 1H, H12), 6.61 (d, 2H, J = 
9.0 Hz, H8), 6.66 (s, 1H, H10), 7.13 (d, 2H, J = 
9.0 Hz, H9), 7.55 (t, 1H, J = 8.0 Hz, H15), 7.59 




12.08 (br s, 1H, H11). 
13
C NMR (CDCl3, 126 MHz): δ -5.4 (C5), 11.4 (C2), 13.6 (C1), 
18.3 (C23), 25.9 (C4), 53.7 (C7), 60.2 (C6), 110.8 (C3), 111.6 (C8), 116.2 (C19), 124.2 
(C24, C9), 124.8 (C16), 125.7 (C21), 128.6 (C12), 128.9 (C15), 129.4 (C25), 133.4 (C26), 
133.4 (C14), 133.5 (C13), 136.2 (C18), 145.9 (C22), 149.6 (C17), 166.3 (C20). HRMS-ESI: 
m/z calcd for C37H57N4O5Si2 [M+H
+
] 693.3862; observed 693.3861. FTIR: neat (cm
-1
) 
3313, 2928, 1654, 1612, 1595, 1514, 1379, 1360, 1322, 1289, 1250, 1095, 1054, 833, 
810. 
 
(E)-7. Red oil. 
1
H NMR  (CDCl3, 500 MHz): 
δ -0.02 (s, 12H, H5), 0.85 (s, 18H, H4), 2.22 
(s, 3H, H2), 2.26 (s, 3H, H1), 3.41 (t, 4H, J = 
6.4 Hz, H7), 3.67 (t, 4H, J = 6.4 Hz, H6), 3.90 
(br s, 1H, H10), 5.79 (s, 1H, H3), 6.53 (d, 2H, 
J = 9.0 Hz, H8), 7.23 (d, 2H, J = 9.0 Hz, H9), 
7.34 (t, 1H, J = 8.0 Hz, H15), 7.43 (d, 1H, J = 
7.0 Hz, H13), 7.49 (t, 1H, J = 7.0 Hz, H14), 7.95 (d, 1H, J = 8.0 Hz, H16), 8.03 (br s, 1H, 
H11). 
13
C NMR (CDCl3, 126 MHz): δ -5.5 (C5), 12.9 (C1,2), 18.1 (C23), 25.8 (C4), 53.6 
(C7), 60.2 (C6), 111.5 (C8), 111.9 (C3), 122.0 (C9,12), 124.8 (C16), 126.7 (C19), 126.8 
(C21), 128.1 (C15), 128.6 (C25), 130.5 (C26), 131.3 (C24), 133.3 (C13,14), 138.8 (C18), 
145.0 (C22), 148.8 (C17), 167.0 (C20). HRMS-ESI: m/z calcd for C37H57N4O5Si2 [M+H
+
] 








pyrrol-2-yl)methylene)indolin-2-one 41.  
1
H NMR (CDCl3, 500 MHz): δ 0.07 (s, 12H, H5), 0.91 
(s, 18H, H4), 2.31 (s, 3H, H1), 2.34 (s, 12H, H2), 3.56 
(t, 4H, J = 6.5 Hz, H7), 3.80 (t, 4H, J = 6.5 Hz, H6), 
5.96 (s, 1H, H3), 6.77 (d, 1H, J = 7.0 Hz, H15), 6.81 (d, 
2H, J = 9.0 Hz, H8), 7.08 (m, 2H, H13,H14), 7.24 (d, 
2H, J = 9.0 Hz, H9), 7.45 (s, 1H, H11), 7.54 (d, 1H, J = 
7.0 Hz, H12), 13.21 (br s, 1H, H10). 
13
C NMR (CDCl3, 
126 MHz): δ -5.3 (C5), 11.6 (C2), 13.9 (C1), 18.3 (C22), 25.9 (C4), 53.6 (C7), 60.3 (C6), 
109.1 (C15), 111.7 (C18), 112.0 (C8), 112.5 (C3), 117.0 (C12), 121.7 (C13), 122.8 (C20), 
123.3 (C11), 125.4 (C14), 125.5 (C17), 127.1 (C24), 128.0 (C9), 132.2 (C23), 136.7 (C25), 
140.7 (C16), 147.7 (C21), 168.5 (C19). HRMS-ESI: m/z calcd for C37H56N3O3Si2 [M+H
+
] 
646.3855; observed 646.3860. FTIR: neat (cm
-1
) 2928, 1666, 1610, 1596, 1564, 1518, 




To a solution of (Z)-7 (0.500 g, 0.721 mmol) in THF (5 mL) at 0 
o
C was added 5:1 1 M 
TBAF (in THF):glacial acetic acid (3 mL) dropwise over 1 minute. The reaction was 
stirred at 0 
o
C for 4 h or until complete consumption of starting material was observed 
by TLC analysis (1:1 pet. spirit:EtOAc). The reaction was quenched with saturated 
NaHCO3 (10 mL) and extracted with EtOAc (2 x 40 mL) and the combined organic 
phase washed with saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over 










H NMR (CDCl3, 500 MHz): δ 
2.10 (s, 3H, H2), 2.26 (s, 3H, H1), 3.50 (t, 4H, J = 
6.0 Hz, H5), 3.78 (t, 4H, J = 6.0 Hz, H4), 5.82 (s, 
1H, H3), 6.54 (s, 1H, H10), 6.61 (d, 2H, J = 8.5 Hz, 
H6), 6.74 (s, 1H, H8), 7.12 (d, 2H, J = 8.5 Hz, H7), 
7.53 (t, 1H, J = 8.0 Hz, H13), 7.58 (d, 1H, J = 7.5 
Hz, H11), 7.68 (t, 1H, J = 7.5 Hz, H12), 8.00 (d, 1H, J = 8.5, H14). 
13
C NMR (CDCl3, 126 
MHz): δ 11.4 (C2), 13.6 (C1), 55.2 (C5), 60.5 (C4), 110.9 (C3), 112.8 (C6), 116.0 (C17), 
124.1 (C21), 124.2 (C7), 124.9 (C14), 126.6 (C19), 128.8 (C10), 129.0 (C13), 129.6 (C22), 
133.4 (C23), 133.5 (C11/12), 136.1 (C16), 145.8 (C20), 149.4 (C15), 166.5 (C18). HRMS-
ESI: m/z calcd for C25H29N4O5 [M+H
+
] 465.2132; observed 465.2138. FTIR: neat (cm
-
1
) 3274, 2868, 1641, 1513, 1341, 1321, 1262, 1235, 1202, 1179, 1151, 1041, 1001. 
 
(Z)-((4-(3-(3,5-dimethyl-1H-pyrrol-2-yl)-2-(2-
nitrophenyl)acrylamido)phenyl)azanediyl) bis(ethane-2,1-diyl) dimethanesulfonate (Z)-
43 and (Z)- and (E)-N-(4-(bis(2-chloroethyl)amino)phenyl)-3-(3,5-dimethyl-1H-pyrrol-
2-yl)-2-(2-nitrophenyl)acrylamide (Z)-1 and (E)-1  
Diol (Z)-42 (0.350 g, 0.75 mmol) was stirred in CH2Cl2 (10 mL) at 0 
o
C under N2 and 
triethylamine (0.30 mL, 2.15 mmol) was added, followed by mesyl chloride (0.15 mL, 
1.94 mmol). The reaction was stirred at 0 
o
C for 1 h or until complete consumption of 
starting material by TLC analysis (EtOAc). The reaction was diluted with CH2Cl2 (40 




washed with saturated NaHCO3 (2 x 50 mL) and brine (2 x 50 mL), dried over 
anhydrous MgSO4 and concentrated. The crude residue was purified by column 
chromatography (EtOAc) to afford (Z)-43 (0.40 g, 86% yield) as an unstable red oil.  
(Z)-43. 
1
H NMR (CDCl3, 500 MHz): δ 2.10 (s, 
3H, H2), 2.22 (s, 3H, H1), 2.94 (s, 6H, H4), 
3.70 (br s, 4H, H6), 4.30 (br s, 4H, H5), 5.83 (s, 
1H, H3), 6.56 (s, 1H, H11), 6.68 (d, 2H, J = 8.5 
Hz, H7), 6.67 (br s, 1H, J = 4.0 Hz, H9), 7.21 
(d, 2H, J = 8.0 Hz, H8), 7.55 (t, 1H, J = 7.0 Hz, 
H14), 7.59 (d, 1H, J = 7.0 Hz, H12), 7.70 (t, 1H, 
J = 7.0 Hz, H13), 8.01 (d, 1H, J = 7.0 Hz, H15), 12.01 (br s, 1H, H10). 
13
C NMR (CDCl3, 
126 MHz): δ 11.2 (C2), 13.4 (C1), 37.1 (C4), 50.8 (C6), 66.6 (C5), 110.8 (C3), 112.9 (C7), 
116.1 (C18), 123.9 (C22), 124.0 (C8), 124.8 (C15), 128.0 (C20), 128.7 (C11), 129.0 (C14), 
129.5 (C23), 133.2 (C24), 133.4 (C12), 133.6 (C13), 135.7 (C17), 143.7 (C21), 149.1 (C16), 
166.2 (C19). HRMS-ESI: m/z calcd for C27H33N4O9S2 [M+H
+
] 621.1683; observed 
621.1689.  
 
Dimesylate (Z)-43 was immediately taken into DMF (8 mL) and excess lithium chloride 
(~0.2 g) added. The solution was stirred at 75 
o
C for 45 minutes until complete 
consumption of starting material by TLC analysis (1:1 pet. spirit:EtOAc). The reaction 
was concentrated and taken up in EtOAc (50 mL), washed with water (3 x 50 mL), 
dried over anhydrous MgSO4 and concentrated. The crude residue was purified by silica 
gel column chromatography (100% pet. spirit to 8:2 pet. spirit:EtOAc) to afford (Z)-1 
(0.30 g, 92% yield) as an orange crystalline product. Trace amounts of (E)-1 (0.01 g, 








H NMR (CDCl3, 500 
MHz): δ 2.11 (s, 3H, H2), 2.28 (s, 3H, H1), 3.60 (t, 
4H, J = 7.0 Hz, H5), 3.70 (t, 4H, J = 7.0 Hz, H4), 
5.83 (s, 1H, H3), 6.55 (s, 1H, H10), 6.64 (d, 2H, J = 
9.0 Hz, H6), 6.69 (br s, 1H, H8), 7.21 (d, 2H, J = 8.5 
Hz, H7), 7.56 (t, 1H, J = 8.0 Hz, H13), 7.60 (d, 1H, J 
= 7.5 Hz, H11), 7.70 (t, 1H, J = 7.5 Hz, H12), 8.02 (d, 1H, J = 8.0 Hz, H14), 12.03 (br s, 
1H, H9). 
13
C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 13.6 (C1), 40.4 (C5), 53.6 (C4), 
110.9 (C3), 112.4 (C6), 115.8 (C17), 124.1 (C21), 124.5 (C7), 124.9 (C14), 127.6 (C19), 
129.0 (C10, C13), 129.8 (C22), 133.5 (C11, C12), 133.6 (C23),  136.1 (C16), 143.8 (C20), 





501.1455; observed 501.1455. FTIR: neat (cm
-1
) 3402, 2921, 2852, 1647, 1521, 1513, 
1460, 1353, 1322, 1235, 1178, 1150, 747. 
 




H NMR (CDCl3, 500 
MHz): δ 1.93 (s, 3H, H1), 2.16 (s, 3H, H2), 3.58 (t, 
4H, J = 7.0 Hz, H4), 3.67 (t, 4H, J = 7.0 Hz, H5), 
5.71 (s, 1H, H3), 6.43 (br s, 1H H9), 6.60 (d, 2H, J 
= 8.0 Hz, H6), 6.91 (s, 1H, H8), 7.30 (d, 2H, J = 
8.0 Hz, H7), 7.59 (d, 1H, J = 7.5 Hz, H11), 7.67 (s, 
1H, H10), 7.70 (t, 1H, J = 7.5 Hz, H13), 7.78 (t, 1H, J = 8.0 Hz, H12), 8.16 (d, 1H, J = 8.0 
Hz, H14). 
13
C NMR (CDCl3, 126 MHz): δ 11.3 (C2), 13.1 (C1), 40.5 (C4), 53.6 (C5), 
110.5 (C3), 112.5 (C6), 119.0 (C17), 122.7 (C7), 123.4 (C22), 124.9 (C10), 125.4 (C14), 
128.9 (C21), 129.3 (C19), 130.2 (C13), 131.8 (C16), 133.2 (C23), 133.9 (C11), 134.2 (C12), 








] 501.1455; observed 501.1453. FTIR: neat (cm
-1
) 3309, 2912, 1653, 1525, 1517, 
1346, 1249, 1216, 807, 636. 
 
5.2.1 2-Aryl-3H-pyrrolizin-3-ones 
5.2.1.1 General Procedure 
An oven-dried 50 mL round-bottom flask containing a magnetic stirrer bar was sealed 
with a septum, charged with Ar and tared. KH (~0.5 g, 30% mineral oil dispersion) was 
then added to the flask and mineral oil was removed by washing with pet. spirit (2 x 30 
mL) using a syringe under N2 flow. The flask containing dry KH was charged with Ar 
and weighed to obtain an accurate mass of KH. Dry THF (10 mL) was added to the 
flask containing KH (0.15 g, 3.7 mmoles, under Ar) and the mixture cooled to 0 
o
C. 3,5-
dimethyl-1H-pyrrole-2-carbaldehyde 4 (0.23 g, 1.9 mmoles) was dissolved in dry THF 
(5 mL) under Ar and slowly cannulated into the stirring KH solution (caution: flask 
requires outlet needle to release evolving H2 gas). The mixture was left to stir for 5 
minutes at 0 
o
C. Phenylacetic acid derivative (1.9 mmoles) was added to a separate 50 
mL round-bottom flask under Ar along with HBTU (0.71 g, 1.9 mmoles) and dry 
CH2Cl2 (10 mL) under Ar. DIPEA (0.65 mL, 3.7 mmoles) was added dropwise to the 
solution and stirred for 5 minutes until the HBTU completely dissolved. The HBTU 
solution was cooled to 0 
o
C before addition in a single portion to the pyrrole 
carboxaldehyde solution at 0 
o
C. The reaction was allowed to warm slowly to room 
temperature. A dark red colour was observed in each reaction indicating formation of 
the desired product. The reaction was quenched with ice-cold water after 2 h and 
extracted with Et2O (2 x 50 mL). The combined organic phase was washed with 




MgSO4 and concentrated. The crude residue was purified by silica gel column 
chromatography using a gradient from 100% pet. spirit to 1:9 acetone:pet. spirit) to 
afford the 2-aryl-3H-pyrrolizin-3-one product as a dark red solid. 
 
5.2.1.2 Compound Chatacterisation 
5,7-dimethyl-2-(2-nitrophenyl)-3H-pyrrolizin-3-one 14 




H NMR (CDCl3, 500 MHz): δ 
2.03 (s, 3H, H2), 2.29 (s, 3H, H1), 5.57 (s, 1H, H3), 7.14 (s, 1H, 
H4), 7.45 (t, 1H, J = 8.5 Hz, H7), 7.47 (d, 1H, J = 8.5 Hz, H5), 
7.59 (t, 1H, J = 8.5 Hz, H6), 7.95 (d, 1H, J = 8.5 Hz, H8). 
13
C 
NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.2 (C3), 
124.6 (C8), 126.3 (C10), 126.6 (C11, C14), 128.8 (C6), 130.7 (C4), 130.8 (C5), 132.1 (C13), 
132.8 (C7), 135.8 (C15), 148.6 (C9), 163.7 (C12). ESI-HRMS: m/z calculated for 
C17H16N2O4 [M + H]
+
 269.0926; observed 269.0898. FTIR: neat (cm
-1
) 2921, 2360, 
1727, 1603, 1560, 1523, 1395, 1354, 1288, 1248, 1209, 1128. 
 
5,7-dimethyl-2-phenyl-3H-pyrrolizin-3-one 51 




H NMR (CDCl3, 500 MHz): δ 2.01 
(s, 3H, H2), 2.33 (s, 3H, H1), 5.55 (s, 1H, H3), 7.22 (s, 1H, H4), 
7.27 (t, 1H, J = 7.5 Hz, H7), 7.36 (t, 2H, J = 8.0 Hz, H6), 7.77 
(d, 2H, J = 8.0 Hz, H5). 
13
C NMR (CDCl3, 126 MHz): δ 11.4 
(C2), 12.4 (C1), 115.9 (C3), 124.6 (C11), 126.0 (C6), 127.6 (C7), 128.2 (C4), 128.5 (C5), 




for C15H14NO [M + H]
+
 224.1068; observed 224.1075. FTIR: neat (cm
-1
) 2919, 1719, 
1700, 1598, 1527, 1445, 1360, 1293, 1269, 1207, 1131. 
 
2-(2-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 69 




H NMR (CDCl3, 500 MHz): δ 1.99 
(s, 3H, H2), 2.31 (s, 3H, H1), 5.53 (s, 1H, H3), 7.06 (dd, 1H, J = 
12.0, 8.0 Hz, H8), 7.14 (m, 1H, H6), 7.19 (m, 1H, H7), 7.43 (d, 
1H, J = 2.5 Hz, H4), 8.15 (m, 1H, H5). 
13
C NMR (CDCl3, 126 
MHz): δ 11.3 (C2), 12.3 (C1), 115.5 (C8, 
2
JC-F = 22.6 Hz), 116.1 
(C3), 120.1 (C10, 
2
JC-F = 11.6 Hz), 123.1 (C11, 
3
JC-F = 2.5 Hz), 124.03 (C6, 
4
JC-F = 3.4 
Hz), 125.6 (C13), 128.4 (C7, 
3
JC-F = 8.7 Hz), 129.0 (C5, 
3
JC-F = 2.9 Hz), 132.29 (C14), 
132.6 (C4), 135.0 (C15), 160.4 (C9, 
1
JC-F = 249.9 Hz), 165.4 (C12). ESI-HRMS: m/z 
calculated for C15H13FNO [M + H]
+
 242.0981; observed 242.0981. FTIR: neat (cm
-1
) 
2922, 1734, 1716, 1530, 1486, 1397, 1368, 1302, 1260.54, 1211, 1136, 770. 
 
2-(3-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 70 




H NMR (CDCl3, 500 MHz): δ 2.01 
(s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 6.95 (m, 1H, H7), 
7.23  (s, 1H, H4), 7.30 (dd, 1H, J = 14.0 Hz, 7.5 Hz, H6), 7.53 
(d, 1H, J = 11.0 Hz, H8) , 7.54 (d, 1H, 6.5 Hz, H5). 
13
C NMR 
(CDCl3, 126 MHz): δ11.4 (C2), 12.4 (C1), 112.8 (C8, 
2
JC-F = 
23.0 Hz), 114.3 (C7, 
2
JC-F = 21.6 Hz), 116.1 (C3), 121.49 (C5, 
4
JC-F = 2,9 Hz), 125.7 
(C14), 128.5 (C11, 
4
JC-F = 2.8 Hz), 129.0 (C4), 129.9 (C6, 
3
JC-F = 8.7 Hz), 131.7 (C14), 
134.1 (C10, 
3
JC-F = 8.7 Hz), 135.2 (C15), 161.9 (C9, 
1




HRMS: m/z calculated for C15H13FNO [M + H]
+
 242.0981; observed 242.0979. FTIR: 
neat (cm
-1
) 2916, 1707, 1601, 1582, 1530, 1437, 1397, 1366, 1298, 1265, 1215, 1138, 
1134, 910, 874, 809, 782. 
 
2-(4-fluorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 71 




H NMR (CDCl3, 500 MHz): δ 
2.00 (s, 3H, H2), 2.31 (s, 3H, H1), 5.54 (s, 1H, H3), 7.04 (t, 
2H, J = 8.5 Hz, H6), 7.15 (s, 1H, H4), 7.75 (dd, 2H, J = 8.5, 
5.5 Hz, H5). 
13
C NMR (CDCl3, 126 MHz): δ11.4 (C2), 12.4 
(C1), 115.5 (C6, 
2
JC-F = 21.5 Hz), 115.9 (C3), 124.8 (C11), 127.7 (C4), 127.8 (C5), 128.2 
(C9), 129.0 (C8), 131.9 (C12), 134.7 (C13), 161.3/163.2 (C7, 
1
JC-F = 247.8 Hz), 165.5 
(C10). ESI-HRMS: m/z calculated for C15H13NOF [M + H]
+
 242.0981; observed 
242.0981. FTIR: neat (cm
-1
) 2917, 1711, 1608, 1557, 1531, 1499, 1450, 1394, 1364, 
1299, 1267, 1225, 1158, 1139, 1133, 1095, 828. 
 
2-(2-chlorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 72 




H NMR (CDCl3, 500 MHz): δ 2.03 
(s, 3H, H2), 2.33 (s, 3H, H1), 5.57 (s, 1H, H3), 7.21 (m, 1H, H6), 
7.28 (m, 1H, H7), 7.42 (dd, 1H,  J = 7.5, 1.0 Hz, H5), 7.43 (s, 
1H, H4), 7.62 (dd, 1H, J = 8.0, 1.5 Hz, H8). 
13
C NMR (CDCl3, 
126 MHz): δ 11.4 (C2), 12.3 (C1), 116.0 (C3), 125.6 (C13), 126.6 (C7), 127.5 (C14), 128.6 
(C6), 130.2 (C5), 130.2 (C9), 131.0 (C8), 131.9 (C10), 132.8 (C11), 133.6 (C4), 135.1 
(C15), 165.3 (C12). ESI-HRMS: m/z calculated for C15H13(
35
Cl)NO [M + H]
+
 258.0686; 
observed 258.0681. FTIR: neat (cm
-1









H NMR (CDCl3, 500 MHz): δ 2.01 
(s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 7.23 (t, 1H, J = 
8.5 Hz, H7), 7.23 (s, 1H, H4), 7.27 (t, 1H, J = 8.0 Hz, H6), 7.66 
(d, 1H, J = 8.0 Hz, H5), 7.78 (t, 1H, J = 1.5 Hz, H8). 
13
C NMR 
(CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.1 (C3), 123.96 (C5), 123.97 (C11), 125.7 
(C13), 125.9 (C8), 127.4 (C7), 128.3 (C14), 129.0 (C4), 129.7 (C6), 133.7 (C10), 134.5 
(C9), 135.2 (C15), 156.1 (C12). ESI-HRMS: m/z calculated for C15H13NO(
35
Cl) [M + H]
+
 
258.0680; observed 258.0695. FTIR: neat (cm
-1
) 2913, 1716, 1589, 1530, 1477, 1379, 
1364, 1137, 1093, 782, 722, 683. 
 
2-(4-chlorophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 74 




H NMR (CDCl3, 500 MHz): δ 
2.01 (s, 3H, H2), 2.32 (s, 3H, H1), 5.55 (s, 1H, H3), 7.20 (s, 
1H, H4), 7.32 (d, 1H, J = 7.5 Hz, H6), 7.72 (d, 1H, J = 7.5 Hz, 
H5). 
13
C NMR (CDCl3, 126 MHz): δ11.4 (C2), 12.4 (C1), 
116.1 (C3), 125.3 (C11), 127.2 (C5), 128.3 (C4), 128.7 (C6), 128.7 (C9), 130.5 (C8), 131.9 
(C12), 133.3 (C7), 135.0 (C13), 165.4 (C10). ESI-HRMS: m/z calculated for 
C15H13(
35
Cl)NO [M + H]
+
 258.0680; observed 258.0681. FTIR: neat (cm
-1
) 2932, 1721, 













H NMR (CDCl3, 500 MHz): δ 
2.02 (s, 3H, H2), 2.32 (s, 3H, H1), 5.57 (s, 1H, H3), 7.14 (m, 1H, 
H7), 7.32 (m, 1H, H6), 7.50 (dd, 1H, J = 8.0, 1.5 Hz, H5), 7.62 
(dd, 1H, J = 8.0, 1.0 Hz, H8). 
13
C NMR (CDCl3, 126 MHz): δ 
11.4 (C2), 12.3 (C1), 115.9 (C3), 122.8 (C9), 125.6 (C14), 127.1 (C6), 128.9 (C7), 129.5 
(C11), 131.2 (C5), 131.7 (C15), 132.2 (C10), 133.4 (C8), 133.5 (C4), 135.1 (C13), 165.0 
(C12). ESI-HRMS: m/z calculated for C15H13(
79
Br)NO [M + H]
+
 302.0175; observed 
302.0177. FTIR: neat (cm
-1
) 3100, 2917, 1720, 1610, 1556, 1533, 1467, 1426, 1365, 
1252, 1132, 768, 733, 629. 
 
2-(3-bromophenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 76 




H NMR (CDCl3, 500 MHz): δ 
2.01 (s, 3H, H2), 2.32 (s, 3H, H1), 5.56 (s, 1H, H3), 7.21 (t, 1H, 
J = 8.0 Hz, H6), 7.24 (s, 1H, H4), 7.37 (d, 1H, J = 8.0 Hz, H7), 
7.72 (d, 1H, J = 8.0 Hz, H5), 7.93 (s, 1H, H8). 
13
C NMR 
(CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 116.2 (C3), 122.7 (C10), 124.4 (C7), 125.8 
(C15), 128.2 (C11), 128.8 (C8), 129.1 (C4), 130.0 (C6), 130.3 (C5), 131.8 (C13), 134.0 
(C9), 135.2 (C14), 165.1 (C12). ESI-HRMS: m/z calculated for C15H13(
79
Br)NO [M + H]
+
 
302.0175; observed 302.0172. FTIR: neat (cm
-1
) 2932, 2367, 1712, 1663, 1587, 1530, 












H NMR (CDCl3, 500 MHz): δ 
2.00 (s, 3H, H2), 2.31 (s, 3H, H1), 5.55 (s, 1H, H3), 7.22 (s, 
1H, H4), 7.47 (d, 2H, J = 8.5 Hz, H6), 7.65 (d, 2H, J = 8.5 
Hz, H5). 
13
C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4 
(C1), 116.1 (C3), 121.5 (C9), 125.4 (C11), 127.5 (C5), 128.4 (C4), 128.7 (C7), 130.9 (C8), 
131.6 (C6), 131.7 (C13), 135.1 (C12), 165.3 (C10). ESI-HRMS: m/z calculated for 
C15H13(
79
Br)NO [M + H]
+
 302.0175; observed 302.0176. FTIR: neat (cm
-1
) 2923, 2363, 
1719, 1608, 1527, 1457, 1362, 1262, 1207, 1130, 1028, 881, 817, 803, 788. 
 
5,7-dimethyl-2-o-tolyl-3H-pyrrolizin-3-one 78 




H NMR (CDCl3, 500 MHz): δ 2.00 
(s, 3H, H2), 2.31 (s, 3H, H1), 2.38 (s, 3H, H5), 5.54 (s, 1H, H3), 
6.97 (s, 1H, H4), 7.21 (m, 3H, H7,8,9), 7.35 (d, 1H, H6). 
13
C 
NMR (CDCl3, 126 MHz): δ 11.3 (C2), 12.3 (C1), 20.9 (C5), 
115.6 (C3), 124.2 (C14), 125.6 (C7/8/9), 127.9 (C7/8/9), 129.7 (C6), 130.5 (C7/8/9), 131.3, 
131.7, 131.8 (C4), 132.2, 134.7, 136.4, 165.5 (C13). ESI-HRMS: m/z calculated for 
C16H16NO [M + H]
+
 238.1232; observed 238.1220. FTIR: neat (cm
-1
) 3308, 2925, 1707, 
1375, 1231, 1138, 1081, 1033, 968, 923, 790. 
 
5,7-dimethyl-2-m-tolyl-3H-pyrrolizin-3-one 79 




H NMR (CDCl3, 500 MHz): δ 2.00 
(s, 3H, H2), 2.32 (s, 3H, H1), 2.36 (s, 3H, H5), 5.54 (s, 1H, H3), 




7.5 Hz, H7), 7.56 (d, 1H, J = 8.0 Hz, H6), 7.60 (s, 1H, H9). 
13
C NMR (CDCl3, 126 
MHz): δ 11.4 (C2), 12.4 (C1), 21.5 (C5), 115.8 (C3), 123.1 (C6), 124.4 (C14), 126.7 (C9), 
128.1 (C4), 128.39/128.41 (C7, C8), 130.1 (C12), 131.9 (C11), 132.0 (C15), 134.6 (C16), 
138.0 (C10), 165.7 (C13). ESI-HRMS: m/z calculated for C16H16NO [M + H]
+
 238.1232; 
observed 238.1225. FTIR: neat (cm
-1
) 2915, 1707, 1600, 1533, 1442, 1368, 1276, 1172, 
1091, 918, 862, 783, 776, 690. 
 
5,7-dimethyl-2-p-tolyl-3H-pyrrolizin-3-one 80 




H NMR (CDCl3, 500 MHz): δ 
1.98 (s, 3H, H2), 2.30 (s, 3H, H1), 2.34 (s, 3H, H5), 5.51 (s, 
1H, H3), 7.13 (s, 1H, H4), 7.16 (d, 2H, J = 8.0 Hz, H7), 7.66 
(d, 2H, J = 8.0 Hz, H6). 
13
C NMR (CDCl3, 126 MHz): δ 
11.3 (C2), 12.3 (C1), 21.2 (C5), 115.7 (C3), 124.1 (C12), 125.9 (C6), 127.2 (C4), 129.1 
(C7), 129.2 (C9), 130.0 (C10), 132.1 (C13), 134.4 (C14), 137.4 (C8), 165.7 (C11). ESI-
HRMS: m/z calculated for C16H16NO [M + H]
+
 238.1232; observed 238.1229. FTIR: 
neat (cm
-1
) 2915, 1723, 1711, 1615, 1531, 1451, 1365, 1297, 1266, 1135, 966, 811. 
 
2-(2-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 81 




H NMR (CDCl3, 500 MHz): δ 2.01 
(s, 3H, H2), 2.31 (s, 3H, H1), 3.89 (s, 3H, H5), 5.53 (s, 1H, H3), 
6.99 (t, 1H, J = 7.5 Hz, H7), 6.92 (d, 1H, J = 8.5 Hz, H9), 7.23 
(m, 1H, H8), 7.55 (s, 1H, H4), 8.05 (dd, 1H, J = 7.5, 1.0 Hz, H6). 
13
C NMR (CDCl3, 126 MHz): δ 11.3 (C2), 12.3 (C1), 55.4 (C5), 110.7 (C9), 115.8 (C3), 




132.6 (C14), 134.4 (C16), 157.4 (C10), 166.3 (C13). ESI-HRMS: m/z calculated for 
C16H16NO2 [M + H]
+
 254.1181; observed 254.1169. FTIR: neat (cm
-1
) 2919, 2363, 
1712, 1605, 1529, 1492, 1433, 1369, 1287, 1246, 1184, 1121, 1061, 1022. 
 
2-(3-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 82 




H NMR (CDCl3, 500 MHz): δ 2.01 
(s, 3H, H2), 2.32 (s, 3H, H1), 3.83 (s, 3H, H5), 5.54 (s, 1H, H3), 
6.82 (dd, 1H, J = 8.0 / 2.5 Hz, H8), 7.21 (s, 1H, H4), 7.26 (t, 1H, 
J = 8.0 Hz, H7), 7.33 (d, 1H, J = 8.0 Hz, H6), 7.40 (s, 1H, H9). 
13
C NMR (CDCl3, 126 MHz): δ 11.4 (C2), 12.4 (C1), 55.2 (C5), 
111.1 (C9), 113.7 (C8), 115.9 (C3), 118.4 (C6), 124.8 (C14), 128.4 (C4), 129.4 (C7), 129.7 
(C12), 131.9 (C15), 133.3 (C16), 134.8 (C11), 159.7 (C10), 165.6 (C13). ESI-HRMS: m/z 
calculated for C16H16NO2 [M + H]
+
 254.1181; observed 254.1181. FTIR: neat (cm
-1
) 
2936, 1712, 1597, 1579, 1531, 1484, 1429, 1396, 1365, 1295, 1278, 1261, 1171, 1037.  
 
2-(4-methoxyphenyl)-5,7-dimethyl-3H-pyrrolizin-3-one 83 




H NMR (CDCl3, 500 MHz): δ 
1.98 (s, 3H, H2), 2.30 (s, 3H, H1), 3.82 (s, 3H, H5), 5.51 (s, 
1H, H3), 6.89 (d, 2H, J = 9.0, H7), 7.07, (s, 1H, H4), 7.72 
(d, 2H, J = 9.0, H7). 
13
C NMR (CDCl3, 126 MHz): δ 22.3 
(C2), 12.3 (C1), 55.2 (C5), 113.9 (C7), 115.7 (C3), 123.7 (C12), 124.8 (C9), 126.1 (C4), 
127.3 (C6), 129.8 (C10), 132.2 (C13), 134.2 (C14), 159.2 (C8), 165.9 (C11). ESI-HRMS: 
m/z calculated for C16H16NO2 [M + H]
+
 254.1181; observed 254.1190. FTIR: neat (cm
-
1









H NMR (CDCl3, 500 MHz): δ 
2.05 (s, 3H, H2), 2.34 (s, 3H, H1), 5.60 (s, 1H, H3), 7.39 (s, 1H, 
H4), 7.52 (t, 1H, J = 8.0 Hz, H6), 8.09 (dd, 1H, J = 7.5, 1.5 Hz, 
H7), 8.17 (d, 1H, J = 7.5 Hz, H5), 8.60 (t, 1H, J = 1.5 Hz, H8). 
13
C NMR (CDCl3, 126 MHz): δ 11.5 (C2), 12.4 (C1), 116.5 (C3), 
120.5 (C8), 121.8 (C7), 127.07/127.09 (C11, C14), 129.4 (C6), 130.2 (C4), 131.5 (C5), 
131.6 (C15), 133.6 (C10), 135.9 (C13), 148.5 (C9), 164.8 (C12). ESI-HRMS: m/z 
calculated for C17H16N2O4 [M + H]
+
 269.0926; observed 269.0932. FTIR: neat (cm
-1
) 
2920, 1712, 1598, 1516, 1397, 1347, 1295, 1258, 1212, 1140, 1137, 1100. 
 
5,7-dimethyl-2-(4-nitrophenyl)-3H-pyrrolizin-3-one 85 




H NMR (CDCl3, 500 MHz): δ 
2.06 (s, 3H, H2), 2.35 (s, 3H, H1), 5.62 (s, 1H, H3), 7.43 (s, 
1H, H4), 7.96 (d, 2H, J = 8.5 Hz, H5), 8.21 (d, 2H, J = 8.5 
Hz, H6). 
13
C NMR (CDCl3, 126 MHz): δ 11.6 (C2), 12.5 
(C1), 116.8 (C3), 123.9 (C6), 126.0 (C5), 126.9 (C9), 128.0 (C11), 131.3 (C4), 131.8 (C12), 
136.4 (C13), 138.4 (C8), 146.3 (C7), 164.7 (C10). ESI-HRMS: m/z calculated for 
C17H16N2O4 [M + H]
+
 269.0926; observed 269.0931. FTIR: neat (cm
-1
) 3160, 2920, 









5.3 Proof of Concept Chemical Reduction Reactions 
Reduction with Fe(0) in CH3COOH 
Compound (Z)-1 (17.5 mg, 0.035 mmol) was dissolved in a 
mixture of 1:1:1 glacial acetic acid:EtOH:water (3 mL). 
Reduced iron powder (23.1 mg, 0.41 mmol) was added and the 
reaction subjected to ultrasonic irradiation for 1 h at 30
 
C or 
until complete consumption of starting material by TLC 
analysis (7:3 pet. spirit:acetone). The reaction mixture was 
filtered through a celite plug and washed with EtOH (10 mL). 
The filtrate was concentrated and taken into Et2O (25 mL). The 
organic layer was washed with saturated NaHCO3 (20 mL) and brine (20 mL), dried 
over anhydrous MgSO4 and concentrated. The crude residue was purified by silica gel 
column chromatography (100% pet. spirit to 85:15 pet. spirit:acetone) to afford SU5416 
2 (4.2 mg, 50% yield) as a yellow solid and 2-OH (2.5 mg, 28%) as a dark orange solid. 
A similar procedure using (Z)-10 (50.8 mg, 0.161 mmol) also afforded SU5416 2 (30.9 
mg, 81.4%).  
 
Reduction with FeCl3.6H2O/Zn (dust) 
A mixture of ferric chloride hexahydrate (60.2 mg, 0.22 mmol), zinc dust (53.1 mg, 
0.81 mmol) and (Z)-1 (18.0 mg, 0.036 mmol) was stirred at room temperature in 1:1 
DMF:water (2 mL). After 3 h or complete consumption of starting material by TLC 
analysis (7:3 pet. spirit:acetone), the reaction mixture was diluted with Et2O (30 mL) 
and filtered through celite. The filtrate was added to a separating funnel and washed 




residues were purified by silica gel column chromatography (100% pet. spirit to 85:15 
pet. spirit:acetone) to afford SU5416 2 (4.3 mg, 50%) as a yellow solid, along with 2-
OH (2.2 mg, 24%) as a dark orange solid. A similar procedure using (Z)-10 (53.3 mg, 
0.169 mmol) also afforded SU5416 2 (26.5 mg, 70%) and 2-OH (8.6 mg, 20%). 
 
Reduction with NaBH4/Pd-C 
To a stirred suspension of (Z)-1 (16.8 mg, 0.034 mmol) and Pd-C (10 mg) in 2:1 
MeOH:H2O (2.5 mL), NaBH4 (13.1 mg, 0.35 mmol) was added. The reaction mixture 
was stirred at rt for 30 mins before the catalyst was removed through a celite plug. The 
plug was washed with MeOH and the filtrates concentrated. The crude product was 
taken into Et2O (25 mL), washed with brine (2 x 25 mL), dried over anhydrous MgSO4 
and concentrated. The crude residue was purified by column chromatography using a 
gradient from 100% pet. spirit to 85:15 pet. spirit:acetone to give SU5416 2 (4.7 mg, 
58%) as a yellow solid along with 2-OH (1.8 mg, 21%) as a dark orange solid. A similar 
procedure using (Z)-10 (52 mg, 0.17 mmol) afforded 2 (27 mg, 72%). 
 
5.4 Rat Aortic Ring Angiogenesis Assay 
Compounds were tested for angiogenesis inhibition by Anna Bezos in Professor Chris 
Parish’s lab at the John Curtin School of Medical Research (ANU). Experiments were 
carried out in 48-well culture plates using the previously reported assay conditions with 
some modifications.
192
 Briefly, thoracic aortas from female Fischer 344 rats were 
excised and the 2.5 cm long vessels placed in Hank’s buffered salt solution (HBSS) 
media containing 2.5 µg/mL amphotericin B and cross-sectioned at 1 mm intervals. In 




was added to each well, followed by 0.5 mL per well of 3 mg/mL bovine fibrinogen in 
Medium 199. The thrombin and fibrinogen were mixed rapidly and one aortic section 
was quickly placed in the centre of the well before clot formation. Fibrin gel formation 
usually occurred within 0.5 min, leaving the vessel fragment suspended in the gel.  
On gel formation, 0.5 mL of Medium 199 supplemented with 20% foetal calf serum 
(FCS), 0.1% 6-aminohexanoic acid, L-glutamine, and antibiotics (gentamicin sulfate 
and amphotericin B) and test compound were added to each well. Six replicate cultures 
were examined for each concentration of compound. Vessels were cultured at 37 
o
C in 
5% CO2 in a humidified environment for 7 days, with the medium being changed on 
Day 4. On Day 5, the percentage of the field of view occupied by vessel outgrowths 
(F.O.V. occupancy %) was used as a quantitative measure of angiogenesis (inhibition) 
relative to control (no compound added). 
 
5.5 HUVEC Tube Formation Assay 
The endothelial tube formation assay was performed in accordance with the vendor’s 
recommendations.
219
 Briefly, adherent human umbilical vein endothelial cells (C-003-




 in standard T75 flasks and 
incubated at 37 ºC and 5% CO2 in a humidified cell culture incubator with Medium 200 
supplemented with low serum growth supplement (LSGS, Life Technologies). Media 
was refreshed every 36 hours and cultures were passaged at 80% confluency (5-6 days). 
HUVECs were used for assays between passages 2-4. 
Geltrex was thawed overnight at 4 
o
C and 50-100 µL was added to coat the base of 24-
well culture plates and the plates incubated at 37 
o
C for 1 hour to set the gel. Cells were 
seeded at 4 x 10
3




hours at 37 
o
C to allow adherence. Compounds were added to give a final concentration 
of 10 uM in LSGS-supplemented Medium 200 containing 1% DMSO. Cells were 
incubated at 37 
o
C for a further 5 hours before the media was carefully aspirated and 
replaced with PBS for visualisation by optical microscopy. 
A series of 3-5 images of each well were taken using a microscope camera at 20x 
magnification and used for the analysis. Experiments were performed twice with 
individual cultures of HUVECs, giving 6-10 images for each compound. Angiogenesis 
analysis was performed according to Aranda et al.
218
 Briefly, total cell count, sprouting 
(i.e. differentiating, elongated) cells, connected cells, enclosed polygons and complex 
polygons (those with 2-3 cells thick edges and those with 4+) were counted and each 
image was scored according to the following equation: 
                  
                                                   
                
 
Where 0 is no complex polygons, 1 is at least one polygon with walls 2-3 cells thick and 
2 is at least one polygon with walls 4+ cells thick. 1% DMSO in LSGS-supplemented 
Medium 200 was used as a positive control (vehicle) and 10 µM sunitinib malate was 
used as a negative control. Experiments containing test compounds were scored as a 






















6.1 Appendix 1  
6.1.1 Crystallographic data 
(a) Compound (Z)-5.  
C15H14N2O4, Mr = 286.29, T = 150 K; monoclinic, space group P21/n, Z = 4; a = 
13.8996 (1) Å, b = 7.3274 (1) Å, c = 14.6266 (1) Å; β = 113.1054 (9)°; V = 1370.19 (2) 
Å
3
; Dx = 1.388 g.cm
-3
; 20464 reflections measured (θ = 4-72°) merged to 2692 unique 
data; R = 0.033 (for 2610 data with I > 2ơ(I)), Rw = 0.089 (all data); S = 1.01.  
(b) Compound 14.  
C15H12N2O3, Mr = 268.27, T = 150 K; triclinic, space group P1, Z = 2; a = 7.9103 (7) Å, 
b = 8.2020 (4) Å, c = 10.8545 (9) Å; α = 79.807 (6)°; β = 69.688 (8)°; γ = 87.445 (6)°; 
V = 649.92 (9) Å
3
; Dx = 1.371 g.cm
-3
; 9934 reflections measured (θ = 4-72°) merged to 
2534 unique data; R = 0.059 (for 2263 data with I > 2ơ(I)), Rw = 0.178 (all data); S = 
1.01.  
 (c) Compound (Z)-13.  
C18H18N2O4, Mr = 326.35, T = 200 K; monoclinic, space group P21/c, Z = 4; a = 
12.5669 (4) Å, b = 7.9086 (3) Å, c = 17.6200 (4) Å;  β = 103.730 (2)°; V = 1701.15 (6) 
Å
3
;  Dx = 1.274 g.cm
-3
; 32664 reflections measured (2θ = 5-55°) merged to 3903 unique 
data; R = 0.053 (for 2656 data with I > 2ơ(I)), Rw = 0.147 (all data); S = 0.95. 
(d) Compound (E)-13.  
C18H18N2O4, Mr = 326.35, T = 298(2) K; triclinic, space group P-1, Z = 2; a = 8.4326 
(4) Å, b = 10.2147 (4) Å , c = 11.0598 (6) Å; α = 72.485 (3)°, β = 76.605 (2)°, γ = 
71.312 (3)°; V = 850.89 (7) Å
3
; Dx = 1.274 g.cm
-3
; 7615 reflections measured (2θ = 4-
54.2°) merged to 3674 unique data R = 0.064 (for 2849 data with I > 2ơ(I)), Rw = 0.187 




(e) Compound 15.  
C22H22N4O, Mr = 358.44, T = 150 K; monoclinic, space group P21/n, Z = 4; a = 10.7644 





; 8260 reflections measured (θ = 5-72°) merged to 3501 unique data; R = 
0.036 (for 3202 data with I > 2ơ(I)), Rw = 0.097 (all data); S = 0.99.  
(f) Compound 17.  
C14H12N2O2, Mr = 240.26, T = 150 K; orthorhombic, space group Pca21, Z = 8; a = 
26.7517 (16) Å, b = 5.4982 (5) Å, c = 15.7489 (16) Å; V = 2316.4 (3) Å
3
; Dx = 1.378 
g.cm
-3
; 8621 reflections measured (θ = 3-69°) merged to 2285 unique data; R = 0.080 
(for 1797 data with I > 2ơ(I)), Rw = 0.183 (all data); S = 1.04.  
 
 6.1.2 Crystal Structure Determination 
Images of (Z)-13 and (E)-13 were measured on Nonius Kappa CCD diffractometers 
(Mo Kα radiation, graphite monochromator, λ 0.71073Å) and data were extracted using 
the DENZO package.
221
 Images of (Z)-5, 14, 15 and 17 were measured on Agilent 
SuperNova diffractometers (Cu Kα radiation, graphite or mirror monochromators, λ 
1.54180 Å) and data were extracted using the CrysAlis PRO package.
222
 
For (Z)-13, (Z)-5, 14, 15 and 17 structure solution was by direct methods (SIR92)
223
 and 
the structure was refined using the CRYSTALS program package.
224
 For (E)-13, 
structure solution was by direct methods (SIR97)
225
 and the structure was refined using 
the SHELXL-97 program package.
226
 Atomic coordinates, bond lengths and angles, and 
displacement parameters of (Z)-13 and (E)-13 have been deposited at the Cambridge 










Appendix 2. NMR spectra of compound 15. (a) 
1
H NMR spectrum of 15; (b) 
13
C NMR 
spectrum of 15. Assignments were derived from 2D NMR experiments, including 























1. Australian Institute of Health and Welfare. Cancer in Australia: an overview, 
2012. (2012). 
2. Australian Institute of Health and Welfare. Australian Cancer Incidence and 
Mortality (ACIM) books: All cancers combined. (2014). at 
<http://www.aihw.gov.au/acim-books> 
3. Zaenker, K. S. & Entschladen, F. Paving Roads for New Drugs in Oncology. 
Recent Pat. Anticancer. Drug Discov. 4, 137–145 (2009). 
4. Amit, I. et al. A module of negative feedback regulators defines growth factor 
signaling. Nat. Genet. 39, 503–12 (2007). 
5. Hanahan, D. & Weinberg, R. a. Hallmarks of cancer: the next generation. Cell 
144, 646–74 (2011). 
6. Cancer Management: A Multidisciplinary Approach. (UBM Medica, 2011). 
7. DeVita, V. T. & Chu, E. A history of cancer chemotherapy. Cancer Res. 68, 
8643–53 (2008). 
8. Midgley, R. & Kerr, D. J. Adjuvant chemotherapy for stage II colorectal cancer: 
the time is right! Nat Clin Pr. Oncol 2, 364–369 (2005). 
9. Neoptolemos, J. P. Adjuvant therapy in pancreatic cancer: historical and current 
perspectives. Ann. Oncol. 14, 675–692 (2003). 
10. Kent, E. C. & Hussain, M. H. Neoadjuvant Therapy for Prostate Cancer: An 
Oncologist’s Perspective. Rev. Urol. 5 Suppl 3, S28–37 (2003). 
11. Thompson, a M. & Moulder-Thompson, S. L. Neoadjuvant treatment of breast 
cancer. Ann. Oncol. 23 Suppl 1, x231–6 (2012). 
12. Archer, V. R., Billingham, L. J. & Cullen, M. H. Palliative chemotherapy: no 
longer a contradiction in terms. Oncologist 4, 470–7 (1999). 
13. Malayeri, R., Pirker, R. & Huber, H. New Drugs in the Palliative Chemotherapy 
of Advanced Non-Small-Cell Lung Cancer. Oncol. Res. Treat. 24, 416–421 
(2001). 
14. Wöhrer, S. S., Raderer, M. & Hejna, M. Palliative chemotherapy for advanced 
gastric cancer. Ann. Oncol. 15 , 1585–1595 (2004). 
15. Löwenberg, B. et al. On the value of intensive remission-induction chemotherapy 
in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase 
III study of the European Organization for Research and Treatment of Cancer 
Leukemia Group. J. Clin. Oncol. 7 , 1268–1274 (1989). 
16. Stone, R. M. Consolidation chemotherapy for adults with AML in first remission: 




17. Larson, R. a et al. A five-drug remission induction regimen with intensive 
consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia 
group B study 8811. Blood 85, 2025–37 (1995). 
18. Sanz, M., Mart  n, G. & Coco, F. Choice of chemotherapy in induction, 
consolidation and maintenance in acute promyelocytic leukaemia. Best Pract. 
Res. Clin. … 16, 433–451 (2003). 
19. Grossi, F. et al. Sequential, alternating, and maintenance/consolidation 
chemotherapy in advanced non-small cell lung cancer: a review of the literature. 
Oncologist 12, 451–64 (2007). 
20. Tallman, M. S. et al. Pretransplantation consolidation chemotherapy decreases 
leukemia relapse after autologous blood and bone marrow transplants for acute 
myelogenous leukemia in first remission. Biol. Blood Marrow Transplant. 12, 
204–16 (2006). 
21. American Cancer Society. Non-hodgkin lymphoma. at 
<http://www.cancer.org/acs/groups/cid/documents/webcontent/003126-pdf.pdf> 
22. Widakowich, C., de Castro, G., de Azambuja, E., Dinh, P. & Awada, A. Review: 
side effects of approved molecular targeted therapies in solid cancers. Oncologist 
12, 1443–55 (2007). 
23. U.S. Food and Drug Administration. Hematology/Oncology (Cancer) Approvals 
& Safety Notifications. at 
<http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm279174.htm> 
24. Dobbelstein, M. & Moll, U. Targeting tumour-supportive cellular machineries in 
anticancer drug development. Nat. Rev. Drug Discov. 13, 179–96 (2014). 
25. Ramaswamy, S. Rational Design of Cancer-Drug Combinations. N. Engl. J. Med. 
357, 299–300 (2007). 
26. Zimmermann, G. R., Lehár, J. & Keith, C. T. Multi-target therapeutics: when the 
whole is greater than the sum of the parts. Drug Discov. Today 12, 34–42 (2007). 
27. Eastman, A. The formation, isolation and characterization of DNA adducts 
produced by anticancer platinum complexes. Pharmacol. Ther. 34, 155–166 
(1987). 
28. Siddik, Z. H. Cisplatin: mode of cytotoxic action and molecular basis of 
resistance. Oncogene 22, 7265–79 (2003). 
29. An alkylating agent for multiple myeloma: Melphalan (alkeran). JAMA 191, 
547–549 (1965). 
30. Adamietz, I. A., Schober, C., Schulte, R. W. M., Peest, D. & Renner, K. 





31. Longley, D. B., Harkin, D. P. & Johnston, P. G. 5-Fluorouracil: Mechanisms of 
Action and Clinical Strategies. Nat. Rev. Cancer 3, 330–8 (2003). 
32. Santi, D. V, McHenry, C. S. & Sommer, H. Mechanism of interaction of 
thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13, 471–481 
(1974). 
33. American Cancer Society. Fluorouracil. at 
<http://www.cancer.gov/cancertopics/druginfo/fluorouracil> 
34. Wang, L.-M., Courtland White, J. & Capizzi, R. The effect of ara-C-induced 
inhibition of DNA synthesis on its cellular pharmacology. Cancer Chemother. 
Pharmacol. 25, 418–424 (1990). 
35. Major, P. P., Egan, E. M., Herrick, D. J. & Kufe, D. W. Effect of ara-C 
incorporation on deoxyribonucleic acid synthesis in cells. Biochem. Pharmacol. 
31, 2937–2940 (1982). 
36. Hryniuk, W. The mechanism of action of methotrexate in cultured L5178Y 
leukemia cells. Cancer Res. 35, 1085–1092 (1975). 
37. Heinemann, V., Hertel, L. W., Grindey, G. B. & Plunkett, W. Comparison of the 
Cellular Pharmacokinetics and Toxicity of 2 ′ , 2 ′ -Difluorodeoxycytidine and 1- 
β -d-Arabinofuranosylcytosine. Cancer Res. 48, 4024–4031 (1988). 
38. Pereira, S., Fernandes, P. A. & Ramos, M. J. Mechanism for ribonucleotide 
reductase inactivation by the anticancer drug gemcitabine. J. Comput. Chem. 25, 
1286–94 (2004). 
39. Cerqueira, N. M. F. S. a, Fernandes, P. a & Ramos, M. J. Understanding 
ribonucleotide reductase inactivation by gemcitabine. Chemistry 13, 8507–15 
(2007). 
40. Bergman, A. M. et al. In vivo induction of resistance to gemcitabine results in 
increased expression of ribonucleotide reductase subunit M1 as the major 
determinant. Cancer Res. 65, 9510–6 (2005). 
41. Burris, H. A. et al. Improvements in survival and clinical benefit with 
gemcitabine as first-line therapy for patients with advanced pancreas cancer: a 
randomized trial. J. Clin. Oncol. 15 , 2403–2413 (1997). 
42. Sandler, a & Ettinger, D. S. Gemcitabine: single-agent and combination therapy 
in non-small cell lung cancer. Oncologist 4, 241–51 (1999). 
43. Hussain, S. A. & James, N. D. The systemic treatment of advanced and 
metastatic bladder cancer. Lancet Oncol. 4, 489–497 (2003). 
44. Tacar, O., Sriamornsak, P. & Dass, C. R. Doxorubicin: an update on anticancer 
molecular action, toxicity and novel drug delivery systems. J. Pharm. 




45. Wolters Kluwer Health Inc. Doxorubicin. at 
<http://www.drugs.com/pro/doxorubicin.html> 
46. Frederick, C. A. et al. Structural comparison of anticancer drug-DNA complexes: 
adriamycin and daunomycin. Biochemistry 29, 2538–49 (1990). 
47. Chan, K.-S., Koh, C.-G. & Li, H.-Y. Mitosis-targeted anti-cancer therapies: 
where they stand. Cell Death Dis. 3, e411 (2012). 
48. Jordan, M. & Wilson, L. Microtubules as a target for anticancer drugs. Nat. Rev. 
Cancer 4, 253–265 (2004). 
49. Xi, G. et al. Autophagy inhibition promotes paclitaxel-induced apoptosis in 
cancer cells. Cancer Lett. 307, 141–8 (2011). 
50. Himes, R., Kersey, R., Heller-Bettinger, I. & Samson, F. Action of the vinca 
alkaloids vincristine, vinblastine, and desacetyl vinblastine amide on 
microtubules in vitro. Cancer Res. 3798–3802 (1976). 
51. Rowinsky, E. K. & Donehower, R. C. Paclitaxel (Taxol). N. Engl. J. Med. 332, 
1004–1014 (1995). 
52. Rowinksy, E. in Holland-Frei Cancer Med. 6th Ed. (2003). 
53. Gourdie, T. a et al. DNA-directed alkylating agents. 1. Structure-activity 
relationships for acridine-linked aniline mustards: consequences of varying the 
reactivity of the mustard. J. Med. Chem. 33, 1177–86 (1990). 
54. Yamagata, M. & Tannock, I. F. The chronic administration of drugs that inhibit 
the regulation of intracellular pH: in vitro and anti-tumour effects. Br. J. Cancer 
73, 1328–34 (1996). 
55. Houtgraaf, J. H., Versmissen, J. & van der Giessen, W. J. A concise review of 
DNA damage checkpoints and repair in mammalian cells. Cardiovasc. Revasc. 
Med. 7, 165–72 (2004). 
56. Sancar, A., Lindsey-Boltz, L. A., Unsal-Kaçmaz, K. & Linn, S. Molecular 
mechanisms of mammalian DNA repair and the DNA damage checkpoints. 
Annu. Rev. Biochem. 73, 39–85 (2004). 
57. Levine, a J. P53, the Cellular Gatekeeper for Growth and Division. Cell 88, 323–
31 (1997). 
58. Soussi, T., Ishioka, C., Claustres, M. & Béroud, C. Locus-specific mutation 
databases: pitfalls and good practice based on the p53 experience. Nat. Rev. 
Cancer 6, 83–90 (2006). 
59. Wang, Z. & Sun, Y. Targeting p53 for Novel Anticancer Therapy. Transl. Oncol. 




60. Vazquez, A., Bond, E. E., Levine, A. J. & Bond, G. L. The genetics of the p53 
pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discov. 7, 979–87 (2008). 
61. Wilson, J. M. Gendicine: the first commercial gene therapy product. Hum. Gene 
Ther. 16, 1014–5 (2005). 
62. Gabrilovich, D. INGN 201 (Advexin®): adenoviral p53 gene therapy for cancer. 
Expert Opin. Biol. Ther. 6, 823–832 (2006). 
63. De Lange, T. Shelterin: the protein complex that shapes and safeguards human 
telomeres. Genes Dev. 19, 2100–10 (2005). 
64. Diotti, R. & Loayza, D. Shelterin complex and associated factors at human 
telomeres. Nucleus 2, 119–35 (2011). 
65. Grandin, N. & Charbonneau, M. Protection against chromosome degradation at 
the telomeres. Biochimie 90, 41–59 (2008). 
66. Hayflick, L. The limited in vitro lifetime of human diploid cell strains. Exp. Cell 
Res. 37, 614–636 (1965). 
67. Shay, J. W. & Bacchetti, S. A survey of telomerase activity in human cancer. 
Eur. J. Cancer 33, 787–791 (2014). 
68. Bryan, T. M., Englezou, a, Gupta, J., Bacchetti, S. & Reddel, R. R. Telomere 
elongation in immortal human cells without detectable telomerase activity. 
EMBO J. 14, 4240–8 (1995). 
69. De Cian, A. et al. Targeting telomeres and telomerase. Biochimie 90, 131–55 
(2008). 
70. Strahl, C. & Blackburn, E. H. Effects of reverse transcriptase inhibitors on 
telomere length and telomerase activity in two immortalized human cell lines. 
Mol. Cell. Biol. 16, 53–65 (1996). 
71. Datta, A. et al. Persistent inhibition of telomerase reprograms adult T-cell 
leukemia to p53-dependent senescence. Blood 108, 1021–9 (2006). 
72. Röth, A., Harley, C. B. & Baerlocher, G. M. Imetelstat (GRN163L)--telomerase-
based cancer therapy. Recent results cancer Res. 184, 221–34 (2010). 
73. Li, S., Nosrati, M. & Kashani-Sabet, M. Knockdown of telomerase RNA using 
hammerhead ribozymes and RNA interference. Methods Mol. Biol. 405, 113–31 
(2007). 
74. Chen, C., Wang, Q., Liu, J., Hao, Y. & Tan, Z. Contribution of Telomere G-
Quadruplex Stabilization to the Inhibition of Telomerase-Mediated Telomere 




75. Chambers, A. F. The metastatic process: basic research and clinical implications. 
Oncol. Res. 11, 161–8 (1999). 
76. Kim, J. & Dang, C. V. Cancer’s molecular sweet tooth and the Warburg effect. 
Cancer Res. 66, 8927–30 (2006). 
77. Swietach, P., Vaughan-Jones, R. D. & Harris, A. L. Regulation of tumor pH and 
the role of carbonic anhydrase 9. Cancer Metastasis Rev. 26, 299–310 (2007). 
78. Colen, C. B. et al. Metabolic Targeting of Lactate Efflux by Malignant Glioma 
Inhibits Invasiveness and Induces Necrosis : An In Vivo Study 1. 13, 620–632 
(2011). 
79. Estrella, V. et al. Acidity generated by the tumor microenvironment drives local 
invasion. Cancer Res. 73, 1524–35 (2013). 
80. Kennedy, K. & Dewhirst, M. Tumor metabolism of lactate: the influence and 
therapeutic potential for MCT and CD147 regulation. Futur. Oncol. 6, 1–32 
(2010). 
81. Danø, K. et al. Plasminogen activation and cancer. Thromb. Haemost. 676–681 
(2005). doi:10.1160/TH05-01-0054 
82. Mohamed, M. M. & Sloane, B. F. Cysteine cathepsins: multifunctional enzymes 
in cancer. Nat. Rev. Cancer 6, 764–75 (2006). 
83. Coussens, L. M. & Werb, Z. Matrix metalloproteinases and the development of 
cancer. Chem. Biol. 3, 895–904 (1996). 
84. Umeda, T., Eguchi, Y., Okino, K., Kodama, M. & Hattori, T. Cellular 
localization of urokinase-type plasminogen activator, its inhibitors, and their 
mRNAs in breast cancer tissues. J. Pathol. 183, 388–97 (1997). 
85. Overall, C. M. & López-Otín, C. Strategies for MMP inhibition in cancer: 
innovations for the post-trial era. Nat. Rev. Cancer 2, 657–72 (2002). 
86. Goldstein, L. J. Experience in Phase I Trials and an Upcoming Phase II Study 
with uPA Inhibitors in Metastatic Breast Cancer. Breast Care (Basel). 3, 25–28 
(2008). 
87. Ertongur, S. et al. Inhibition of the invasion capacity of carcinoma cells by WX-
UK1, a novel synthetic inhibitor of the urokinase-type plasminogen activator 
system. Int. J. Cancer 110, 815–24 (2004). 
88. Witsch, E., Sela, M. & Yarden, Y. Roles for growth factors in cancer 
progression. Physiology (Bethesda). 25, 85–101 (2010). 
89. Lemmon, M. A. & Schlessinger, J. Cell signaling by receptor tyrosine kinases. 




90. Xu, Y., Richert, N., Ito, S., Merlino, G. T. & Pastan, I. R. A. Characterization of 
epidermal growth factor receptor gene expression in malignant and normal 
human cell lines Biochemistry : 81, 7308–7312 (1984). 
91. Yarden, Y. The EGFR family and its ligands in human cancer : signalling 
mechanisms and therapeutic opportunities. 37, 3–8 (2001). 
92. Attisano, L. & Wrana, J. L. Signal transduction by the TGF-beta superfamily. 
Science 296, 1646–7 (2002). 
93. Elliott, R. L. & Blobe, G. C. Role of transforming growth factor Beta in human 
cancer. J. Clin. Oncol. 23, 2078–93 (2005). 
94. Li, H., Xu, D., Li, J., Berndt, M. C. & Liu, J.-P. Transforming growth factor beta 
suppresses human telomerase reverse transcriptase (hTERT) by Smad3 
interactions with c-Myc and the hTERT gene. J. Biol. Chem. 281, 25588–600 
(2006). 
95. Hudis, C. A. Trastuzumab--mechanism of action and use in clinical practice. N. 
Engl. J. Med. 357, 39–51 (2007). 
96. Higa, G. M. & Abraham, J. Lapatinib in the treatment of breast cancer. Expert 
Rev. Anticancer Ther. 7, 1183–92 (2007). 
97. Jordan, V. C. Tamoxifen (ICI46,474) as a targeted therapy to treat and prevent 
breast cancer. Br. J. Pharmacol. 147 Suppl, S269–76 (2006). 
98. Fradet, Y. Bicalutamide (Casodex) in the treatment of prostate cancer. Expert 
Rev. Anticancer Ther. 4, 37–48 (2004). 
99. Griffioen, a W. & Molema, G. Angiogenesis: potentials for pharmacologic 
intervention in the treatment of cancer, cardiovascular diseases, and chronic 
inflammation. Pharmacol. Rev. 52, 237–68 (2000). 
100. Fox, S. B., Gasparini, G. & Harris, a L. Angiogenesis: pathological, prognostic, 
and growth-factor pathways and their link to trial design and anticancer drugs. 
Lancet Oncol. 2, 278–89 (2001). 
101. Kesisis, G., Broxterman, H. & Giaccone, G. Angiogenesis inhibitors. Drug 
selectivity and target specificity. Curr. Pharm. Des. 13, 2795–2809 (2007). 
102. Vaupel, P. & Harrison, L. Tumor hypoxia: causative factors, compensatory 
mechanisms, and cellular response. Oncologist 9 Suppl 5, 4–9 (2004). 
103. Vaupel, P. & Mayer, A. Hypoxia in cancer: significance and impact on clinical 
outcome. Cancer Metastasis Rev. 26, 225–39 (2007). 
104. Unruh, A. et al. The hypoxia-inducible factor-1 alpha is a negative factor for 




105. Sullivan, R. & Graham, C. H. Hypoxia-driven selection of the metastatic 
phenotype. Cancer Metastasis Rev. 26, 319–31 (2007). 
106. Kim, J., Gao, P. & Dang, C. V. Effects of hypoxia on tumor metabolism. Cancer 
Metastasis Rev. 26, 291–8 (2007). 
107. Liao, D. & Johnson, R. S. Hypoxia: a key regulator of angiogenesis in cancer. 
Cancer Metastasis Rev. 26, 281–90 (2007). 
108. Denny, W. The role of hypoxia-activated prodrugs in cancer therapy. Lancet 
Oncol. 1, 25–29 (2000). 
109. Semenza, G. L. & Wang, G. L. A nuclear factor induced by hypoxia via de novo 
protein synthesis binds to the human erythropoietin gene enhancer at a site 
required for transcriptional activation. Mol. Cell. Biol. 12, 5447–54 (1992). 
110. Wang, G. L., Jiang, B. H., Rue, E. a & Semenza, G. L. Hypoxia-inducible factor 
1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. 
Proc. Natl. Acad. Sci. U. S. A. 92, 5510–4 (1995). 
111. Semenza, G. L. Hydroxylation of HIF-1: oxygen sensing at the molecular level. 
Physiology (Bethesda). 19, 176–82 (2004). 
112. Iyer, N. V et al. Cellular and developmental control of O2 homeostasis by 
hypoxia-inducible factor 1 alpha. Genes Dev. 12, 149–62 (1998). 
113. Lukashev, D., Ohta, a & Sitkovsky, M. Hypoxia-dependent anti-inflammatory 
pathways in protection of cancerous tissues. Cancer Metastasis Rev. 26, 273–9 
(2007). 
114. Zhong, H. et al. Overexpression of hypoxia-inducible factor 1alpha in common 
human cancers and their metastases. Cancer Res. 59, 5830–5 (1999). 
115. Melillo, G. Targeting hypoxia cell signaling for cancer therapy. Cancer 
Metastasis Rev. 26, 341–52 (2007). 
116. Harada, H. et al. The Akt/mTOR pathway assures the synthesis of HIF-1alpha 
protein in a glucose- and reoxygenation-dependent manner in irradiated tumors. 
J. Biol. Chem. 284, 5332–42 (2009). 
117. Agani, F. & Jiang, B.-H. Oxygen-independent regulation of HIF-1: novel 
involvement of PI3K/AKT/mTOR pathway in cancer. Curr. Cancer Drug 
Targets 13, 245–51 (2013). 
118. Kilic-Eren, M., Boylu, T. & Tabor, V. Targeting PI3K/Akt represses Hypoxia 
inducible factor-1α activation and sensitizes Rhabdomyosarcoma and Ewing’s 
sarcoma cells for apoptosis. Cancer Cell Int. 13, 36 (2013). 
119. Mottet, D. et al. Regulation of hypoxia-inducible factor-1alpha protein level 




synthase kinase 3beta pathway in HepG2 cells. J. Biol. Chem. 278, 31277–85 
(2003). 
120. Hassan, B., Akcakanat, A., Holder, A. M. & Meric-Bernstam, F. Targeting the 
PI3-kinase/Akt/mTOR signaling pathway. Surg. Oncol. Clin. N. Am. 22, 641–64 
(2013). 
121. Rubio-Viqueira, B. & Hidalgo, M. Targeting mTOR for cancer treatment. Curr. 
Opin. Investig. Drugs 7, 501–12 (2006). 
122. Yancopoulos, G. D. et al. Vascular-specific growth factors and blood vessel 
formation. Nature 407, 242–8 (2000). 
123. Gschwind, A., Fischer, O. M. & Ullrich, A. The discovery of receptor tyrosine 
kinases: targets for cancer therapy. Nat. Rev. Cancer 4, 361–70 (2004). 
124. Ferrara, N. Role of vascular endothelial growth factor in the regulation of 
angiogenesis. Kidney Int. 56, 794–814 (1999). 
125. Jeltsch, M., Leppänen, V.-M., Saharinen, P. & Alitalo, K. Receptor tyrosine 
kinase-mediated angiogenesis. Cold Spring Harb. Perspect. Biol. 5, (2013). 
126. Morabito, A., De Maio, E., Di Maio, M., Normanno, N. & Perrone, F. Tyrosine 
kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: 
current status and future directions. Oncologist 11, 753–64 (2006). 
127. Gotink, K. J. & Verheul, H. M. W. Anti-angiogenic tyrosine kinase inhibitors: 
what is their mechanism of action? Angiogenesis 13, 1–14 (2010). 
128. Pazdur, R. FDA Approval for Bevacizumab. at 
<http://www.cancer.gov/cancertopics/druginfo/fda-bevacizumab> 
129. Goldman, J. M. & Melo, J. V. Chronic myeloid leukemia--advances in biology 
and new approaches to treatment. N. Engl. J. Med. 349, 1451–64 (2003). 
130. Novartis. Gleevec Prescribing Information. (2008). at 
<http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021588s024lbl.pdf> 
131. U.S. Food and Drug Administration. FDA approves additional medical indication 
for Sprycel. (2010). at 
<http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm231409.
htm> 
132. Chow, L. Q. M. & Eckhardt, S. G. Sunitinib: from rational design to clinical 
efficacy. J. Clin. Oncol. 25, 884–96 (2007). 
133. Roskoski, R. Sunitinib: a VEGF and PDGF receptor protein kinase and 




134. Muñoz, C. et al. Study of differences in the VEGFR2 inhibitory activities 
between semaxanib and SU5205 using 3D-QSAR, docking, and molecular 
dynamics simulations. J. Mol. Graph. Model. 32, 39–48 (2012). 
135. Pfizer. Sutent Prescribing Information. (2014). at 
<http://labeling.pfizer.com/ShowLabeling.aspx?id=607> 
136. Schenone, S., Bondavalli, F. & Botta, M. Antiangiogenic agents: an update on 
small molecule VEGFR inhibitors. Curr. Med. Chem. 14, 2495–516 (2007). 
137. De Angelis, C. Side effects related to systemic cancer treatment: are we changing 
the Promethean experience with molecularly targeted therapies? Curr. Oncol. 15, 
198–9 (2008). 
138. Singh, Y., Palombo, M. & Sinko, P. Recent trends in targeted anticancer prodrug 
and conjugate design. Curr. Med. Chem. 15, 1802–1826 (2008). 
139. Denny, W. Prodrug strategies in cancer therapy. Eur. J. Med. Chem. 36, 577–595 
(2001). 
140. Huttunen, K. M., Raunio, H. & Rautio, J. Prodrugs - from serendipity to rational 
design. Pharmacol. Rev. 63, 750–71 (2011). 
141. Hwang, J. J. & Marshall, J. L. Capecitabine: fulfilling the promise of oral 
chemotherapy. Expert Opin. Pharmacother. 3, 733–43 (2002). 
142. Takiuchi, H. & Ajani, J. A. Uracil-tegafur in gastric carcinoma: a comprehensive 
review. J. Clin. Oncol. 16, 2877–85 (1998). 
143. Boddy, A. V & Yule, S. M. Metabolism and pharmacokinetics of 
oxazaphosphorines. Clin. Pharmacokinet. 38, 291–304 (2000). 
144. National Cancer Institute. Cyclophosphamide. (2013). at 
<http://www.cancer.gov/cancertopics/druginfo/cyclophosphamide> 
145. Guise, C. P. et al. Bioreductive prodrugs as cancer therapeutics: targeting tumor 
hypoxia. Chin. J. Cancer 33, 80–6 (2014). 
146. Rooseboom, M., Commandeur, J. A. N. N. M. & Vermeulen, N. P. E. Enzyme-
Catalyzed Activation of Anticancer Prodrugs. 56, 53–102 (2004). 
147. Carter, P. Improving the efficacy of antibody-based cancer therapies. Nat. Rev. 
Cancer 1, 118–29 (2001). 
148. Schrama, D., Reisfeld, R. A. & Becker, J. C. Antibody targeted drugs as cancer 
therapeutics. Nat. Rev. Drug Discov. 5, 147–59 (2006). 





150. Lopus, M., Oroudjev, E. & Wilson, L. Maytansine and cellular metabolites of 
antibody-maytansinoid conjugates strongly suppress microtubule dynamics by 
binding to microtubules. Mol. cancer … 9, 2689–2699 (2010). 
151. Francisco, J. A. et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E 
conjugate with potent and selective antitumor activity. Blood 102, 1458–65 
(2003). 
152. Horie, R., Higashihara, M. & Watanabe, T. Hodgkin’s lymphoma and CD30 
signal transduction. Int. J. Hematol. 77, 37–47 (2003). 
153. Tarkowski, M. Expression and a role of CD30 in regulation of T-cell activity. 
Curr. Opin. Hematol. 10, 267–71 (2003). 
154. Poncet, J. The dolastatins, a family of promising antineoplastic agents. Curr. 
Pharm. Des. 5, 139–62 (1999). 
155. Vaklavas, C. & Forero-Torres, A. Safety and efficacy of brentuximab vedotin in 
patients with Hodgkin lymphoma or systemic anaplastic large cell lymphoma. 
Ther. Adv. Hematol. 3, 209–25 (2012). 
156. Chari, R. V et al. Immunoconjugates containing novel maytansinoids: promising 
anticancer drugs. Cancer Res. 52, 127–31 (1992). 
157. Niculescu-Duvaz, I. Trastuzumab emtansine, an antibody-drug conjugate for the 
treatment of HER2+ metastatic breast cancer. Curr. Opin. Mol. Ther. 12, 350–60 
(2010). 
158. Gillies, R. J. & Gatenby, R. a. Hypoxia and adaptive landscapes in the evolution 
of carcinogenesis. Cancer Metastasis Rev. 26, 311–7 (2007). 
159. Chan, D. a & Giaccia, A. J. Hypoxia, gene expression, and metastasis. Cancer 
Metastasis Rev. 26, 333–9 (2007). 
160. Semenza, G. L. Hypoxia and cancer. Cancer Metastasis Rev. 26, 223–4 (2007). 
161. Bertout, J. a, Patel, S. a & Simon, M. C. The impact of O2 availability on human 
cancer. Nat. Rev. Cancer 8, 967–75 (2008). 
162. Chung, A. S., Lee, J. & Ferrara, N. Targeting the tumour vasculature: insights 
from physiological angiogenesis. Nat. Rev. Cancer 10, 505–14 (2010). 
163. Farnsworth, R. H., Lackmann, M., Achen, M. G. & Stacker, S. A. Vascular 
remodeling in cancer. Oncogene (2013). doi:10.1038/onc.2013.304 





165. Prekeges, J. L., Rasey, J. S., Grunbaum, Z. & Krohn, K. H. Reduction of 
fluoromisonidazole, a new imaging agent for hypoxia. Biochem. … 42, 2387–
2395 (1991). 
166. Jameson, M. B. et al. A phase i trial of PR-104, a nitrogen mustard prodrug 
activated by both hypoxia and aldo-keto reductase 1C3, in patients with solid 
tumors. Cancer Chemother. Pharmacol. 65, 791–801 (2010). 
167. Meng, F. et al. Molecular and cellular pharmacology of the hypoxia-activated 
prodrug TH-302. Mol. Cancer Ther. 11, 740–51 (2012). 
168. McCord, J. M. & Fridovich, I. Superoxide dismutase. An enzymic function for 
erythrocuprein (hemocuprein). J. Biol. Chem. 244, 6049–6055 (1969). 
169. Denny, W. A. W. Hypoxia-activated prodrugs in cancer therapy: progress to the 
clinic. Futur. Oncol. 6, 419–428 (2010). 
170. Palmer, B. D., Wilson, W. R., Pullen, S. M. & Denny, W. a. Hypoxia-selective 
antitumor agents. 3. Relationships between structure and cytotoxicity against 
cultured tumor cells for substituted N,N-bis(2-chloroethyl)anilines. J. Med. 
Chem. 33, 112–21 (1990). 
171. Duan, J.-X. et al. Potent and highly selective hypoxia-activated achiral 
phosphoramidate mustards as anticancer drugs. J. Med. Chem. 51, 2412–20 
(2008). 
172. Roe, F. J. C. Metronidazole: view of uses and toxicity. J. Antimicrob. Chemother. 
3, 205–212 (1977). 
173. Josephy, P. D., Palcic, B. & Skarsgard, L. D. In vitro metabolism of 
misonidazole. Br. J. Cancer 43, 443–50 (1981). 
174. Baillet, F., Housset, M., Dessard-Diana, B. & Boisserie, G. Positive clinical 
experience with misonidazole in brachytherapy and external radiotherapy. Int. J. 
Radiat. Oncol. Biol. Phys. 16, 1073–5 (1989). 
175. Dische, S. Chemical sensitizers for hypoxic cells: a decade of experience in 
clinical radiotherapy. Radiother. Oncol. 3, 97–115 (1985). 
176. Atwell, G. J., Sykes, B. M., O’Connor, C. J. & Denny, W. A. Relationships 
between structure and kinetics of cyclization of 2-aminoaryl amides: potential 
prodrugs of cyclization-activated aromatic mustards. J. Med. Chem. 37, 371–380 
(1994). 
177. Blanche, E. a., Maskell, L., Colucci, M. a., Whatmore, J. L. & Moody, C. J. 
Synthesis of potential prodrug systems for reductive activation. Prodrugs for anti-
angiogenic isoflavones and VEGF receptor tyrosine kinase inhibitory oxindoles. 




178. Das, N., Dhanawat, M., Dash, B., Nagarwal, R. C. & Shrivastava, S. K. Codrug: 
An efficient approach for drug optimization. Eur. J. Pharm. Sci. 41, 571–588 
(2010). 
179. Similä, S., Keinänen, S. & Kouvalainen, K. Oral antipyretic therapy: evaluation 
of benorylate, an ester of acetylsalicylic acid and paracetamol. Eur. J. Pediatr. 
121, 15–20 (1975). 
180. Singleton, J. W. et al. A trial of sulfasalazine as adjunctive therapy in Crohn’s 
disease. Gastroenterology 77, 887–97 (1979). 
181. Williams, C., Panaccione, R., Ghosh, S. & Rioux, K. Optimizing clinical use of 
mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap. Adv. 
Gastroenterol. 4, 237–48 (2011). 
182. Friedel, H. A., Campoli-Richards, D. M. & Goa, K. L. Sultamicillin. A review of 
its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 
37, 491–522 (1989). 
183. Mendel, D. B. et al. In Vivo Antitumor Activity of SU11248 , a Novel Tyrosine 
Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-
derived Growth Factor Receptors : Determination of a Pharmacokinetic / 
Pharmacodynamic Relationship In Vivo Antitumor Activ. (2003). 
184. Sun, L. et al. Synthesis and biological evaluations of 3-substituted indolin-2-
ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward 
particular receptor tyrosine kinases. J. Med. Chem. 41, 2588–603 (1998). 
185. Dubey, L. Side reactions of onium coupling reagents BOP and HBTU in the 
synthesis of silica polymer supports. Ukr. Bioorganica Acta 1, 13–19 (2005). 
186. Reybier, K. et al. Electrochemical behavior of indolone-N-oxides: relationship to 
structure and antiplasmodial activity. Bioelectrochemistry 88, 57–64 (2012). 
187. Nepveu, F. et al. Synthesis and antiplasmodial activity of new indolone N-oxide 
derivatives. J. Med. Chem. 53, 699–714 (2010). 
188. Ibrahim, H. et al. Antibacterial, antifungal and antileishmanial activities of 
indolone-N-oxide derivatives. J. Antibiot. (Tokyo). 65, 499–504 (2012). 
189. Trager, W. & Jensen, J. Human malaria parasites in continuous culture. Science 
(80-. ). 193, 673–675 (1976). 
190. Desjardins, R. E., Canfield, C. J., Haynes, J. D. & Chulay, J. D. Quantitative 
assessment of antimalarial activity in vitro by a semiautomated microdilution 
technique. Antimicrob. Agents Chemother. 16, 710–718 (1979). 
191. O’Brien, J., Wilson, I., Orton, T. & Pognan, F. Investigation of the Alamar Blue 
(resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. 




192. Brown, K. J. et al. A novel in vitro assay for human angiogenesis. Lab. Invest. 
75, 539–555 (1996). 
193. Medigen Biotechnology Corporation. A Phase III Study of PI-88 in the Adjuvant 
Treatment of Subjects With Hepatitis Virus Related Hepatocellular Carcinoma 
After Surgical Resection (PATRON). Clinicaltrials.gov at 
<http://clinicaltrials.gov/show/NCT01402908> 
194. Lee, M. S. & Kim, S. Y. Synthesis of Poly(arylene ether)s Containing 
Triphenylamine Units via Nitro Displacement Reaction. Macromolecules 38, 
5844–5845 (2005). 
195. Huang, A., Liu, F., Zhan, C., Liu, Y. & Ma, C. One-pot synthesis of pyrrolo[1,2-
a]quinoxalines. Org. Biomol. Chem. 9, 7351–7 (2011). 
196. Ferlin, M. G., Dalla Via, L. & Gia, O. M. Synthesis and antiproliferative activity 
of some new DNA-targeted alkylating pyrroloquinolines. Bioorg. Med. Chem. 
12, 771–7 (2004). 
197. Hay, M. P., Anderson, R. F., Ferry, D. M., Wilson, W. R. & Denny, W. a. 
Synthesis and evaluation of nitroheterocyclic carbamate prodrugs for use with 
nitroreductase-mediated gene-directed enzyme prodrug therapy. J. Med. Chem. 
46, 5533–45 (2003). 
198. Porwanski, S. et al. Bis-β-cyclodextrinyl- and bis-cellobiosyl-diazacrowns: 
synthesis and molecular complexation behaviors toward Busulfan anticancer 
agent and two basic aminoacids. Tetrahedron 65, 6196–6203 (2009). 
199. Gamble, A. B., Garner, J., Gordon, C. P., O’Conner, S. M. J. & Keller, P. A. Aryl 
Nitro Reduction with Iron Powder or Stannous Chloride under Ultrasonic 
Irradiation. Synth. Commun. 37, 2777–2786 (2007). 
200. Desai, D. G., Swami, S. S. & Hapase, S. B. Rapid and Inexpensive Method for 
Reduction of Nitroarenes to Anilines. Synth. Commun. 29, 1033–1036 (1999). 
201. Pogorelić, I. et al. Rapid, efficient and selective reduction of aromatic nitro 
compounds with sodium borohydride and Raney nickel. J. Mol. Catal. A Chem. 
274, 202–207 (2007). 
202. Bouérat, L. et al. Indolin-2-ones with high in vivo efficacy in a model for 
multiple sclerosis. J. Med. Chem. 48, 5412–5414 (2005). 
203. Schmidt, F. et al. Glucuronide prodrugs of hydroxy compounds for antibody 
directed enzyme prodrug therapy (adept): A phenol nitrogen mustard carbamate. 
Bioorganic Med. Chem. Lett. 7, 1071–1076 (1997). 
204. Selva, M., Fabris, M., Lucchini, V., Perosa, A. & Noè, M. The reaction of 
primary aromatic amines with alkylene carbonates for the selective synthesis of 
bis-N-(2-hydroxy)alkylanilines: the catalytic effect of phosphonium-based ionic 




205. Lazareva, N. F., Albanov, A. I., Lazarev, I. M. & Pestunovich, V. A. 
N,N,N′,N′,N″-Pentamethyl-N″-[(trifluorosilyl)methyl] phosphoric triamide. First 
example of the existence of intramolecular P=O→Si coordination bond in the Si-
containing phosphoric triamides. Appl. Organomet. Chem. 21, 281–287 (2007). 
206. Sun, L. et al. Synthesis and biological evaluations of 3-substituted indolin-2-
ones: A novel class of tyrosine kinase inhibitors that exhibit selectivity toward 
particular receptor tyrosine kinases. J. Med. Chem. 41, 2588–2603 (1998). 
207. Sun, L. et al. Discovery of 5-[5-fluoro-2-oxo-1,2- dihydroindol-(3Z)-
ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylic acid (2-
diethylaminoethyl)amide, a novel tyrosine kinase inhibitor targeting vascular 
endothelial and platelet-derived growth factor receptor tyrosi. J. Med. Chem. 46, 
1116–1119 (2003). 
208. Morriello, G. J. et al. Fused bicyclic pyrrolizinones as new scaffolds for human 
NK1 antagonists. Bioorg. Med. Chem. 16, 2156–70 (2008). 
209. Morriello, G. J. et al. Substituted fused bicyclic pyrrolizinones as potent, orally 
bioavailable hNK1 antagonists. Bioorg. Med. Chem. Lett. 20, 2007–12 (2010). 
210. Park, Y. C., Gunasekera, S. P., Lopez, J. V, McCarthy, P. J. & Wright, A. E. 
Metabolites from the marine-derived fungus Chromocleista sp. isolated from a 
deep-water sediment sample collected in the Gulf of Mexico. J. Nat. Prod. 69, 
580–4 (2006). 
211. Despinoy, X. L. M. & McNab, H. Hydrogenation of pyrrolizin-3-ones; new 
routes to pyrrolizidines. Org. Biomol. Chem. 7, 4502–11 (2009). 
212. Pinho, T. M. V. D., Soares, M. I. L. & Paixa, A. N -Vinyl- and C -Vinylpyrroles 
from Azafulvenium Methides . Flash Vacuum Pyrolysis Route to 5-Oxo-5 H -
pyrrolizines and 1-Azabenzo [ f ] azulenes. 6629–6638 (2005). 
213. McNab, H. & Thornley, C. New chemistry of pyrrolizin-3-one: a concise route to 
3,8-didehydroheliotridin-5-one. J. Chem. Soc. Chem. Commun. 1570 (1993). 
doi:10.1039/c39930001570 
214. Clark, B. A. J., Despinoy, X. L. M., McNab, H., Sommerville, C. C. & 
Stevenson, E. Pyrolytic cyclisation reactions of 3-azolylpropenyl alcohols; 
unexpectedly facile thermal decomposition of 5H-pyrrolo[2,1-a]isoindole. J. 
Chem. Soc. Perkin Trans. 1 2049–2052 (1999). doi:10.1039/a904884g 
215. Mcnab, H. & Thornley, (the Late) Craig. Chemistry of pyrrolizinones. Part 1. 
Reactions of pyrrolizin-3-ones with electrophiles: synthesis of 3,8-
didehydroheliotridin-5-ones. J. Chem. Soc. Perkin Trans. 1 1, 3584–3591 (2000). 
216. McNab, H., Montgomery, J., Parsons, S. & Tredgett, D. G. Pyrrolizine-1,3-dione. 




217. Sudta, P. et al. Synthesis, Structural Characterisation, and Preliminary Evaluation 
of Non-Indolin-2-one-based Angiogenesis Inhibitors Related to Sunitinib 
(Sutent). Aust. J. Chem. 66, 864 (2013). 
218. Aranda, E. & Owen, G. I. A semi-quantitative assay to screen for angiogenic 
compounds and compounds with angiogenic potential using the EA.hy926 
endothelial cell line. Biol. Res. 42, 377–89 (2009). 
219. Invitrogen. Endothelial Tube Formation Assay (In Vitro Angiogenesis). at 
<http://tools.lifetechnologies.com/content/sfs/manuals/Endothelial_Cells_Tube_
Formation.pdf> 
220. Lo Meo, P., D’Anna, F., Riela, S., Gruttadauria, M. & Noto, R. Host–guest 
interactions involving cyclodextrins: useful complementary insights achieved by 
polarimetry. Tetrahedron 63, 9163–9171 (2007). 
221. Otwinowski, Z. & Minor, W. in Methods Enzymol. 307–326 (1997). 
doi:10.1016/S0076-6879(97)76066-X 
222. Agilent Technologies. CrysAlis PRO. (2013). 
223. Altomare, A. et al. SIR 92 – a program for automatic solution of crystal 
structures by direct methods. J. Appl. Crystallogr. 27, 435 (1994). 
224. Betteridge, P. W., Carruthers, J. R., Cooper, R. I., Prout, K. & Watkin, D. J. 
CRYSTALS version 12: software for guided crystal structure analysis. J. Appl. 
Crystallogr. 36, 1487–1487 (2003). 
225. Altomare, A. et al. SIR 97: a new tool for crystal structure determination and 
refinement. J. Appl. Crystallogr. 32, 115–119 (1999). 
226. Sheldrick, G. M. A short history of SHELX. Acta Crystallogr. Sect. A Found. 
Crystallogr. 64, 112–122 (2008).  
 
